<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1202256890
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2025
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Speranta
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        NERATINIB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        40
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        180
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        11389.90
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="THE ARAB PHARMACEUTICAL MANUFACTURING PSC" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            THE ARAB PHARMACEUTICAL MANUFACTURING PSC
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 441]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)	
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Speranta is</strong><br />Speranta<strong> </strong>contains the active substance &lsquo;neratinib&rsquo;. It belongs to a group of medicines called &lsquo;tyrosine kinase inhibitors&rsquo; used to block cancer cells and treat breast cancer.</p><p><strong>What Speranta is used for</strong><br />Speranta<strong> </strong>is used for patients who have early stage breast cancer which:</p><ul><li>Is hormone receptor positive (HR-positive) and human epidermal growth factor receptor 2-positive (HER2-positive), and</li><li>Has previously been treated with another medicine called &lsquo;trastuzumab&rsquo;.</li></ul><p>The &lsquo;HER2 receptor&rsquo; is a protein found on the surface of cells in the body. It helps control how a healthy breast cell grows. In HER2-positive breast cancer, the cancer cells have a large amount of HER2 receptors on their surface. This results in the cancer cells dividing and growing faster.</p><p>&lsquo;Hormone receptors&rsquo; are also proteins expressed inside the cells of some specific tissues. Estrogens and progesterone bind to these proteins and regulate cell activity. In HR-positive breast cancer, tumor cell division and growth can be enhanced by estrogens and/or progesterone.</p><p>Before Speranta<strong> </strong>is used, your cancer must have been tested to show it is HR-positive and HER2-positive. You must also have previously been treated with trastuzumab.</p><p><strong>How Speranta works</strong><br />Speranta<strong> </strong>works by blocking the HER2 receptors on the cancer cells. This helps to stop the cells from dividing and growing.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Speranta </strong></p><ul><li>If you are allergic to neratinib or any of the other ingredients of this medicine (listed in Section 6),</li><li>If you have a severe liver problem,</li><li>If you are taking rifampicin (a medicine for tuberculosis (TB)),</li><li>If you are taking carbamazepine or phenytoin (medicines for seizures),</li><li>If you are taking St. John&rsquo;s wort (herbal product for depression).</li></ul><p><strong>Warnings and precautions</strong><br />Talk to your doctor or pharmacist before taking Speranta.</p><p><strong>You need to take an anti-diarrhoea medicine when you start Speranta</strong><br />Speranta can cause diarrhoea early during treatment. You should take an anti-diarrhoea medicine so that your diarrhoea does not become severe, and to prevent you from getting dehydrated during treatment with Speranta.</p><p><strong>Tests and checks for liver problems</strong><br />Speranta can cause changes in liver function &ndash; these are shown in blood tests. Your doctor will do blood tests before and during your treatment with Speranta. Your doctor will stop your treatment with Speranta if your liver tests show severe problems.</p><p><strong>Children and adolescents</strong><br />Do not use in children under 18 years of age. The safety of neratinib and how effective it is has not been studied in this age group.</p><p><strong>Other medicines and Speranta</strong><br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This is because Speranta can affect the way some other medicines work. Also some other medicines can affect the way Speranta works.</p><p>In particular tell your doctor or pharmacist if you are taking any of the following medicines:</p><ul><li>Rifampicin - a medicine for tuberculosis</li><li>Carbamazepine, phenobarbital, or phenytoin - medicines for seizures</li><li>St John&rsquo;s wort - an herbal product for depression</li><li>Ketoconazole, voriconazole, itraconazole or fluconazole - medicines for fungal infections</li><li>Erythromycin or clarithromycin - medicines for bacterial infections</li><li>Protease inhibitors - antiviral medicines</li><li>Nefazodone &ndash; a medicine to treat depression</li><li>Diltiazem or verapamil - medicines for high blood pressure and chest pain</li><li>Dabigatran or digoxin - a medicine for heart problems</li><li>Rosuvastatin &ndash; a medicine to treat high cholesterolemia</li><li>Irinotecan &ndash; a medicine used in colorectal cancers</li><li>Sulfasalazine &ndash; an anti-inflammatory intestinal medicine</li><li>Medicines for stomach problems such as:<ul><li>Lansoprazole, omeprazole or similar medicines called &lsquo;proton pump inhibitors&rsquo; or PPIs are not recommended.</li><li>Ranitidine, cimetidine or similar medicines called &ldquo;H<sub>2</sub> receptor antagonists&rdquo;. Neratinib should be taken 10 hours after the H<sub>2</sub>-receptor antagonist dosing and at least 2 hours before the next dose of the H<sub>2</sub>-receptor antagonist</li><li>Antacid medicines - the dose of these medicines and Speranta should be separated by at least 3 hours.</li></ul></li></ul><p>If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist before taking Speranta.</p><p><strong>Speranta with food and drink</strong><br />Do not take grapefruit or pomegranate while you are taking Speranta &ndash; this includes eating them, drinking the juice or taking a supplement that might contain them. This is because these fruits may interact with Speranta and affect how the medicine works.</p><p><strong>&nbsp;Pregnancy and breast-feeding</strong><br /><em>Pregnancy</em><br />If you are pregnant, the doctor will assess the potential benefit to you and risk to the foetus before giving this medicine to you. If you become pregnant while taking this medicine, the doctor will assess the potential benefit to you and the risk to the foetus, of continuing this medicine.</p><p><em>Contraception</em><br />Women who can become pregnant must use an effective method of contraception, including a barrier method:</p><ul><li>While taking Speranta and</li><li>For one month after treatment has finished.</li></ul><p>Men must use an effective barrier method of contraception such as a condom:</p><ul><li>While taking Speranta and</li><li>For three months after treatment has finished.</li></ul><p><strong>Breast-feeding</strong><br />Talk to your doctor before taking neratinib if you are breast-feeding or plan to breast-feed because small amounts of this medicine may pass into your breast milk. Your doctor will discuss with you the benefits and risks of taking Speranta during this time.</p><p><strong>Driving and using machines</strong><br />Speranta has minor or moderate influence on the ability to drive and use machines. The side effects of Speranta (for example, dehydration and dizziness resulting from diarrhoea, fatigue, and fainting) may affect how tasks that require judgment, motor or cognitive skills are carried out.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p><strong>How much Speranta to take</strong><br />The recommended dose of Speranta is 6 tablets once a day (a total of 240 mg).</p><ul><li>Take the tablets with food. Do not crush or dissolve. Do not swallow the desiccant.</li><li>Take all the tablets with water, at about the same time each day, preferably in the morning.</li></ul><p>The course of treatment is one year.</p><p><strong>You need to take an anti-diarrhoea medicine when you start Speranta</strong><br />Speranta can cause diarrhoea early during treatment unless anti-diarrhoea medicine is taken to prevent or reduce diarrhoea. Diarrhoea usually happens early in treatment with Speranta and may be severe, causing you to get dehydrated.</p><ul><li>Start taking anti-diarrhoea medicine with the first dose of Speranta.</li><li>Your doctor will tell you how to take the anti-diarrhoea medicine.</li><li>Keep taking anti-diarrhoea medicine during the first one to two months of Speranta treatment. Your doctor will tell you if you need to keep taking anti-diarrhoea medicine after the first two months to control your diarrhoea.</li><li>Your doctor will also tell you if you need to change the dose of Speranta because of diarrhoea.</li></ul><p><strong>If you take more Speranta than you should</strong><br />If you take more Speranta than you should, contact a doctor or a hospital straight away. Take the medicine pack with you.</p><p>Some side effects associated with taking more Speranta than you should are: diarrhoea, nausea, vomiting and dehydration.</p><p><strong>If you forget to take Speranta</strong></p><ul><li>If you forget a dose, wait until the next day before you take the next dose.</li><li>Do not take a double dose to make up for a forgotten dose.</li></ul><p><strong>If you stop taking Speranta </strong></p><ul><li>Do not stop taking Speranta without talking to your doctor.</li></ul><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. The following side effects may happen with this medicine:</p><p><strong><em>Diarrhoea</em></strong><br />Neratinib can cause diarrhoea early during treatment unless anti-diarrhoeal medicines are taken to prevent or reduce diarrhoea. The diarrhoea may be severe, and you may get dehydrated. See Section 3 for more information about the anti-diarrhoea medicine you need to take at the same time as neratinib.</p><p><strong><em>Talk to your doctor if: </em></strong></p><ul><li>You are having diarrhoea that does not go away - they can advise how to control your diarrhoea.</li><li>You feel dizzy or weak from diarrhoea - alternatively go to the hospital immediately.</li></ul><p><strong><em>Liver problems</em></strong><br />Neratinib can cause changes in liver function - these are shown in blood tests. You may or may not have signs or symptoms of liver problems (e.g., yellow skin and/or eyes, dark urine, or light-colour stools). Your doctor will do blood tests before and during your treatment with neratinib. Your doctor will stop your treatment with neratinib if your liver tests show severe problems.</p><p><strong><em>Other side effects</em></strong><br />Tell your doctor or pharmacist if you notice any of the following side effects:</p><p><strong>Very common:</strong> may affect more than 1 in 10 people</p><ul><li>Diarrhoea</li><li>Stomach pain, feeling or being sick, low appetite</li><li>Dry or inflamed mouth, including blisters or mouth ulcers</li><li>Rash</li><li>Muscle spasms or cramps</li><li>Feeling very tired</li></ul><p><strong>Common:</strong> may affect up to 1 in 10 people</p><ul><li>Burning sensation during urination and frequent, and urgent need to urinate, (may be symptoms of urinary tract infection)</li><li>Dehydration</li><li>Fainting</li><li>Nosebleed</li><li>Mild stomach upset</li><li>Dry mouth</li><li>Changes in liver blood test results</li><li>Nail problems including nail splitting or colour change</li><li>Dry skin including cracked skin</li><li>Changes in kidney function test</li><li>Weight loss</li></ul><p><strong>Uncommon:</strong> may affect up to 1 in 100 people</p><ul><li>Kidney failure</li><li>Changes in liver blood test results (i.e., blood bilirubin increased)</li></ul><p>Tell your doctor or pharmacist if you notice any of the side effects above.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Store below 30&deg;C.</p><p>Store in the original package in order to protect from moisture.</p><p>Do not use this medicine after the expiry date which is stated on the package after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>Do not use this medicine if you notice any signs of damage to the packaging or if there are any signs of tampering (e.g., inner seal is broken).</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is neratinib maleate.</p><p>Each film-coated tablet of Speranta 40 mg Film-coated Tablets contains 48.31 mg neratinib maleate equivalent to 40 mg neratinib.</p><p>The other ingredients are mannitol, microcrystalline cellulose, colloidal anhydrous silica, povidone, crospovidone, magnesium stearate and Opadry red.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Speranta 40 mg Film-coated Tablets are red oval-shaped film-coated tablets, debossed with “N1” on one side in HDPE round bottles with desiccant bags and child resistant caps (CRCs). Do not swallow the desiccant bag.

Pack size: 180 Film-coated Tablets.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder and Batch releaser</strong><br />Jazeera Pharmaceutical Industries<br />Al-Kharj Road<br />P.O. Box 106229<br />Riyadh 11666, Saudi Arabia<br />Tel: + (966-11) 8107023, + (966-11) 2142472<br />Fax: + (966-11) 2078170<br />e-mail: SAPV@hikma.com</p><p><strong>Bulk manufacturer</strong><br />The Arab Pharmaceutical Manufacturing PSC<br />Sahab<br />Industrial City<br />P.O. Box 41<br />Amman 11512, Jordan<br />Tel: + (962-6) 4023916<br />Fax: + (962-6) 4023917</p><p><strong>Reporting of side effects</strong><br />If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects, you can also help provide more information on the safety of this medicine.</p><ul><li>Emirates Drug Establishment</li></ul><p>United Arab Emirates<br />Email: pv@ede.gov.ae<br />Tel: 80033784</p><ul><li>Saudi Arabia</li></ul><p>The National Pharmacovigilance Centre (NPC)<br />SFDA Call Center: 19999<br />E-mail: npc.drug@sfda.gov.sa<br />Website: https://ade.sfda.gov.sa</p><ul><li>Other GCC States</li></ul><p>Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 05/2023; version number Un1.0.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>ما هو سبيرانتا</strong><br />يحتوي سبيرانتا على المادة الفعالة &rsquo;نيراتينيب&lsquo;. وينتمي إلى مجموعة أدوية تسمى &rsquo;مثبطات كيناز التيروسين&lsquo; المستخدمة في منع نمو الخلايا السرطانية وعلاج سرطان الثدي.</p><p dir="RTL"><strong>ما هي دواعي استخدام سبيرانتا</strong><br />يُستخدم سبيرانتا لعلاج المرضى الذين يعانون من سرطان الثدي في مراحله المبكرة والذي يكون:</p><ul dir="rtl"><li>إيجابياً لمستقبلات الهرمونات وإيجابياً لبروتين مُستقبِل عامل النمو الأدمي البشري 2، و</li><li>سبق معالجته بدواء آخر يسمى &rsquo;تراستوزوماب&lsquo;.</li></ul><p dir="RTL">&rsquo;مستقبل عامل النمو الأدمي البشري 2&lsquo; هو بروتين يوجد على سطح الخلايا في الجسم. يساعد على التحكم في الطريقة التي تنمو بها خلية الثدي السليمة. في سرطان الثدي الإيجابي لبروتين مُستقبِل عامل النمو الأدمي البشري 2، توجد كمية كبيرة من مستقبلات عامل النمو الأدمي البشري 2 على سطح الخلايا السرطانية. يؤدي هذا الأمر إلى انقسام الخلايا السرطانية ونموها بشكل أسرع.</p><p dir="RTL">&rsquo;مستقبلات الهرمون&lsquo; هي أيضاً بروتينات تظهر داخل خلايا بعض الأنسجة المعينة. يرتبط هرمونا الإستروجين والبروجسترون بهذه البروتينات وينظمان نشاط الخلية. في سرطان الثدي إيجابي مستقبلات الهرمون، يمكن أن يعزز هرمونا الإستروجين و/أو البروجسترون انقسام الخلايا السرطانية ونموها.</p><p dir="RTL">قبل استخدام سبيرانتا، يجب اختبار السرطان لمعرفة إيجابية مستقبلات الهرمون وإيجابية مُستقبِل عامل النمو الأدمي البشري 2. يجب أيضاً أن يكون قد تم علاجك بتراستوزوماب سابقاً.</p><p dir="RTL"><strong>طريقة عمل سبيرانتا</strong><br />يعمل سبيرانتا من خلال حصر مستقبلات عامل النمو الأدمي البشري 2 الموجودة على الخلايا السرطانية. يساعد هذا الأمر على منع الخلايا من الانقسام والنمو.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول سبيرانتا</strong></p><ul dir="rtl"><li>إذا كنت تعانين من حساسية لنيراتينيب أو لأي من المواد الأخرى المستخدمة في تركيبة هذا الدواء (المذكورة في القسم 6)،</li><li>إذا كنت تعانين من مشكلة شديدة في الكبد،</li><li>إذا كنت تتناولين ريفامبيسين (دواء لمرض السل)،</li><li>إذا كنت تتناولين كاربامازيبين أو فينيتوين (أدوية لنوبات الصرع)،</li><li>إذا كنت تتناولين نبتة سانت جون (منتج عشبي للاكتئاب).</li></ul><p dir="RTL"><strong>الاحتياطات والتحذيرات</strong><br />تحدث مع طبيبك أو الصيدلي قبل تناول سبيرانتا.</p><p dir="RTL"><strong>تحتاج</strong><strong> </strong><strong>إلى تناول دواء مضاد للإسهال عند البدء في تناول سبيرانتا</strong><br />يمكن أن يسبب سبيرانتا إسهالاً في بداية فترة العلاج. يجب تناول دواء مضاد للإسهال حتى لا يصبح الإسهال شديداً، وللوقاية من الإصابة بالجفاف أثناء العلاج بسبيرانتا.</p><p dir="RTL"><strong>الاختبارات والفحوصات لمشاكل الكبد</strong><br />يمكن أن يسبب سبيرانتا تغيرات في وظائف الكبد - والتي تظهر في فحوصات الدم. سيجري طبيبك فحوصات الدم قبل وأثناء علاجك بسبيرانتا. سيوقف طبيبك علاجك بسبيرانتا إذا أظهرت فحوصات الكبد وجود مشاكل خطيرة.</p><p dir="RTL"><strong>الأطفال والمراهقون&nbsp;</strong><br />لا تستخدمه للأطفال الذين تقل أعمارهم عن 18 عاماً. لم تُجرَ أي دراسات بشأن سلامة نيراتينيب ومدى فاعليته في هذه الفئة العمرية.</p><p dir="RTL"><strong>الأدوية أخرى وسبيرانتا&nbsp;</strong><br />أخبر طبيبك أو الصيدلي إذا كنت تتناول، تناولت مؤخراً، أو قد تتناول أية أدوية أخرى. إذ قد يؤثر سبيرانتا على طريقة عمل بعض الأدوية الأخرى. كما أن بعض الأدوية الأخرى قد تؤثر على طريقة عمل سبيرانتا.</p><p dir="RTL">بشكل خاص، أخبر طبيبك أو الصيدلي إذا كنت تتناول أيّاً من الأدوية التالية:</p><ul dir="rtl"><li>ريفاميسين؛ دواء لعلاج السل</li><li>كاربامازيبين، فينوباربيتال أو فينيتوين- أدوية لعلاج نوبات الصرع</li><li>نبتة سانت جون- منتج عشبي لعلاج الاكتئاب</li><li>كيتوكونازول، فوريكونازول، إيتراكونازول- أدوية لعلاج العدوى الفطرية</li><li>إريثروميسين أو كلاريثروميسين- أدوية لعلاج العدوى البكتيرية</li><li>مثبطات إنزيم البروتياز- أدوية مضادة للفيروسات</li><li>نيفازودون- دواء لعلاج الاكتئاب</li><li>ديلتيازيم أو فيراباميل- أدوية لعلاج ارتفاع ضغط الدم وآلام الصدر</li><li>دابيغاتران أو ديجوكسين- دواء لعلاج مشاكل القلب</li><li>روسوفاستاتين- دواء لعلاج ارتفاع نسبة الكوليسترول في الدم</li><li>إيرينوتيكان- دواء يُستخدم في علاج سرطانات القولون والمستقيم</li><li>سلفاسالازين- دواء معوي مضاد للالتهابات</li><li>أدوية لعلاج مشاكل المعدة مثل:<ul><li>لا يُنصح باستخدام لانزوبرازول، أوميبرازول أو الأدوية المماثلة المسماة بمثبطات مضخة البروتون.</li><li>رانيتيدين، سيميتيدين أو الأدوية المماثلة والتي تسمى &quot;مضادات مستقبلات الهيستامين 2&quot;. يجب تناول نيراتينيب بعد 10 ساعات من تناول جرعة مضادات مستقبلات الهيستامين 2 وقبل ساعتين على الأقل من الجرعة التالية من مضادات مستقبلات الهيستامين 2</li><li>الأدوية المضادة للحموضة- يجب الفصل بين ميعاد جرعة هذه الأدوية وسبيرانتا بثلاث ساعات على الأقل.</li></ul></li></ul><p dir="RTL">استشر طبيبك أو الصيدلي قبل تناول سبيرانتا إذا كان أي مما سبق ينطبق عليك (أو إذا لم تكن متأكداً من ذلك).</p><p dir="RTL"><strong>سبيرانتا مع الطعام والشراب&nbsp;</strong><br />لا تتناولي الجريب فروت أو الرمان أثناء تناولك لسبيرانتا- ويشمل هذا الأمر تناولهما، شربهما كعصير أو تناول أي مكملات قد تحتوي عليهما. إذ أن هذه الفواكه قد تتفاعل مع سبيرانتا وتؤثر على طريقة عمل الدواء.</p><p dir="RTL"><strong>الحمل والرضاعة</strong><br /><em>الحمل</em><br />إذا كنتِ حاملاً، فسيُقدِّر الطبيب الفائدة المحتملة التي تعود عليك والخطر المحتمل على الجنين قبل وصف هذا الدواء لكِ. إذا أصبحت حاملاً أثناء فترة تناولك للدواء، فسيُقدِّر الطبيب الفائدة المحتملة التي تعود عليك والخطر المحتمل على الجنين قبل الاستمرار في تناول هذا الدواء.</p><p dir="RTL"><em>وسائل منع الحمل</em><br />يجب على النساء اللواتي قد يحملن أن يستخدمن وسيلة فعالة لمنع الحمل، والتي من ضمنها طريقة الحاجز:</p><ul dir="rtl"><li>أثناء تناولهن لسبيرانتا</li><li>ولمدة شهر بعد انتهاء العلاج.</li></ul><p dir="RTL">يجب على الرجال استخدام وسيلة فعالة لمنع الحمل مثل الواقي الذكري:</p><ul dir="rtl"><li>أثناء تناول سبيرانتا&nbsp;</li><li>ولمدة ثلاثة أشهر بعد انتهاء العلاج.</li></ul><p dir="RTL"><strong>الرضاعة</strong><br />تحدثي مع طبيبكِ قبل تناول نيراتينيب إذا كنتِ ترضعين طبيعياً أو تخططين للرضاعة الطبيعية إذ قد تنتقل كميات صغيرة من هذا الدواء إلى حليب الثدي. سيتناقش معكِ الطبيب في فوائد ومخاطر تناول سبيرانتا خلال هذه الفترة.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong><br />يُحدِث سبيرانتا تأثيراً طفيفاً أو متوسطاً على القدرة على القيادة واستخدام الآلات. قد تؤثر الآثار الجانبية لسبيرانتا (على سبيل المثال، الجفاف والدوخة الناتجة عن الإسهال، التعب والإغماء) على طريقة تنفيذ المهام التي تتطلب حضوراً ذهنياً، مهارات حركية أو معرفية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قم دائماً بتناول دوائك كما أخبرك طبيبك تماماً. تحقق من طبيبك أو الصيدلي إذا لم تكن متأكداً.</p><p dir="RTL"><strong>الجرعة المطلوبة من سبيرانتا</strong><br />الجرعة الموصى بها من سبيرانتا هي 6 أقراص مرة في اليوم (بإجمالي 240 ملغم).</p><ul dir="rtl"><li>تناول الأقراص مع الطعام. لا تسحقها أو تذبها. لا تبلع المادة الماصة للرطوبة.</li><li>تناول جميع الأقراص مع الماء كل يوم في نفس الوقت تقريباً، ويفضل تناولها في الصباح.</li></ul><p dir="RTL">تبلغ دورة العلاج سنة واحدة.</p><p dir="RTL"><strong>تحتاج إلى تناول دواء مضاد للإسهال عند البدء في تناول سبيرانتا&nbsp;</strong><br />يمكن أن يسبب سبيرانتا إسهالاً في بداية فترة العلاج إلا تم تناول أدوية مضادة للإسهال لمنعه أو تقليله. عادة ما يحدث إسهال في بداية فترة العلاج بسبيرانتا وقد يكون شديداً، مما يؤدي إلى إصابتك بالجفاف.</p><ul dir="rtl"><li>ابدأ بتناول الأدوية المضادة للإسهال مع الجرعة الأولى من سبيرانتا.</li><li>سيخبرك طبيبك بكيفية تناول الدواء المضاد للإسهال.</li><li>استمر في تناول الأدوية المضادة للإسهال خلال أول فترة تتراوح بين شهر وشهرين من العلاج بسبيرانتا. سيخبرك طبيبك إذا كنت بحاجة إلى الاستمرار في تناول الأدوية المضادة للإسهال بعد أول شهرين للسيطرة عليه.</li><li>سيخبرك طبيبك أيضاً إذا كنت بحاجة إلى تغيير جرعة سبيرانتا بسبب الإسهال.</li></ul><p dir="RTL"><strong>إذا تناولت سبيرانتا أكثر من اللازم&nbsp;</strong><br />إذا تناولت سبيرانتا أكثر من اللازم، فتواصل مع طبيبك أو مستشفى فوراً. وخذ عبوة الدواء معك.</p><p dir="RTL">بعض الآثار الجانبية المرتبطة بتناول سبيرانتا أكثر من اللازم هي: الإسهال، الغثيان، القيء، والجفاف.</p><p dir="RTL"><strong>إذا نسيت تناول سبيرانتا</strong></p><ul dir="rtl"><li>إذا نسيت تناول جرعة، فانتظر حتى اليوم التالي لتناول الجرعة التالية.</li><li>لا تتناول جرعة مضاعفة لتعويض الجرعة المنسية.</li></ul><p dir="RTL"><strong>إذا توقفت عن تناول سبيرانتا </strong></p><ul dir="rtl"><li>لا تتوقف عن تناول سبيرانتا قبل التحدث إلى طبيبك.</li></ul><p dir="RTL">إذا كانت لديك أي أسئلة إضافية حول استخدام هذا الدواء، فاستشر طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يسبب هذا الدواء آثاراً جانبيةً، إلا إنه ليس بالضرورة أن تحدث لدى جميع مستخدمي هذا الدواء. قد تحدث الآثار الجانبية التالية عند تناول هذا الدواء:</p><p dir="RTL"><strong><em>إسهال&nbsp;</em></strong><br />يمكن أن يسبب نيراتينيب الإسهال في بداية فترة العلاج إلا إذا تم تناول أدوية مضادة للإسهال لمنعه أو تقليله. قد يكون الإسهال شديداً وقد تصاب بالجفاف. انظر إلى القسم 3 للحصول على مزيد من المعلومات حول الأدوية المضادة للإسهال التي تحتاج إلى تناولها مع نيراتينيب في نفس الوقت.</p><p dir="RTL"><strong><em>تحدث مع طبيبك إذا: </em></strong></p><ul dir="rtl"><li>كنت تعاني من إسهال لا يتوقف - إذ يمكنه تقديم النصيحة بشأن كيفية السيطرة على الإسهال.</li><li>كنت تشعر بالدوخة أو الضعف بسبب الإسهال- ويمكن الذهاب إلى المستشفى فوراً.</li></ul><p dir="RTL"><strong><em>مشاكل في الكبد&nbsp;</em></strong><br />يمكن أن يسبب نيراتينيب تغيرات في وظائف الكبد- إذ تظهر في فحوصات الدم. قد تظهر عليك علامات أو أعراض مشاكل في الكبد وربما لا تظهر (على سبيل المثال، اصفرار في الجلد و/أو العينين، بول داكن، أو لون فاتح للبراز). سيجري طبيبك فحوصات الدم قبل وأثناء علاجك بنيراتينيب. سيوقف طبيبك علاجك بنيراتينيب إذا أظهرت اختبارات الكبد وجود مشاكل خطيرة.</p><p dir="RTL">&nbsp;<strong><em>الأعراض الجانبية الأخرى&nbsp;</em></strong><br />أخبري طبيبك أو الصيدلي إذا شعرت بأي من الآثار الجانبية التالية:</p><p dir="RTL"><strong>شائعة جداً:</strong> قد تؤثر على أكثر من شخص واحد من كل 10 أشخاص&nbsp;</p><ul dir="rtl"><li>إسهال</li><li>آلام في المعدة، غثيان أو قيئ، انخفاض في الشهية</li><li>جفاف الفم أو التهابه، ويتضمن ذلك ظهور بثور أو تقرحات في الفم</li><li>طفح جلدي</li><li>تشنجات أو تقلصات عضلية</li><li>شعور بالإرهاق الشديد</li></ul><p dir="RTL"><strong>شائعة:</strong> قد تؤثر على ما يصل إلى شخص واحد من كل 10 أشخاص</p><ul dir="rtl"><li>إحساس بالحرقان في أثناء التبول وحاجة متكررة وملحة للتبول (قد تكون أعراضاً على التهاب في المسالك البولية)</li><li>جفاف</li><li>إغماء</li><li>رعاف</li><li>اضطراب خفيف في المعدة</li><li>جفاف الفم</li><li>تغير في نتائج فحوصات الدم لوظائف الكبد</li><li>مشاكل في الأظافر، من ضمنها تشقق الأظافر أو تغير لونها</li><li>جفاف الجلد ومن ضمنها الجلد المتشقق</li><li>تغيرات في نتائج فحوصات وظائف الكلى</li><li>فقدان في الوزن</li></ul><p dir="RTL"><strong>غير شائعة:</strong> قد تؤثر على ما يصل إلى شخص واحد من بين كل 100 شخص</p><ul dir="rtl"><li>فشل كلوي</li><li>تغيرات في نتائج فحوصات الدم لوظائف الكبد (أي زيادة البيليروبين في الدم)</li></ul><p dir="RTL">أخبري طبيبك أو الصيدلي إذا شعرت بأي من الآثار الجانبية المذكورة أعلاه.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيداً عن مرأى ومتناول الأطفال.</p><p dir="RTL">لا يحفظ عند درجة حرارة أعلى من 30&deg; مئوية.</p><p dir="RTL">يحفظ داخل العبوة الأصلية للحماية من الرطوبة.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الخارجية بعد &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت أي علامات تلف واضحة على العبوة أو إذا كان هنالك أي علامات عبث (على سبيل المثال تلف في السدادة الداخلية).</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. هذه الإجراءات ستساعد في الحفاظ على سلامة البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعّالة هي ماليات النيراتينيب.</p><p dir="RTL">يحتوي كل قرص مغطى بطبقة رقيقة من سبيرانتا 40 ملغم أقراص مغطاة بطبقة رقيقة على 48,31 ملغم ماليات النيراتينيب يكافئ 40 ملغم نيراتينيب.</p><p dir="RTL">المواد الأخرى المستخدمة في التركيبة التصنيعية هي مانيتول، سيلليلوز بلوري مكروي، سيليكا غروية لا مائية، بوڤيدون، كروسبوڤيدون، ستيرات المغنيسيوم وأوبادري أحمر.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سبيرانتا<strong> </strong>40 ملغم أقراص مغطاة بطبقة رقيقة هي أقراص حمراء بيضاوية الشكل مغطاة بطبقة رقيقة، محفور عليها &quot;N1&quot; على جانب واحد في قنينات دائرية من متعدد الإيثيلين عالي الكثافة مع أكياس مجففة وأغطية مقاومة لعبث الأطفال. لا تقم ببلع الكيس المجفف.</p><p dir="RTL">حجم العبوة: 180 قرص مغطى بطبقة رقيقة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك رخصة التسويق ومحرر التشغيلة&nbsp;</strong><br />شركة الجزيرة للصناعات الدوائية<br />طريق الخرج<br />صندوق بريد 106229<br />الرياض 11666، المملكة العربية السعودية<br />هاتف: 8107023 (11-966) +، 2142472 (11-966) +<br />فاكس: 2078170 (11-966) +<br />البريد الإلكتروني: SAPV@hikma.com</p><p dir="RTL"><strong>الشركة المصنعة للمستحضر النهائي&nbsp;</strong><br />الشركة العربية لصناعة الأدوية المساهمة الخاصة<br />سحاب<br />المدينة الصناعية<br />صندوق بريد 41<br />عمان 11512، الأردن<br />هاتف: 4023916 (6-962) +<br />فاكس: 4023917 (6-962) +</p><p dir="RTL"><strong>للإبلاغ عن الآثار الجانبية</strong><br />تحدث إلى الطبيب، الصيدلي، أو الممرض إذا عانيت من أية آثار جانبية. وذلك يشمل أي آثار جانبية لم يتم ذكرها في هذه النشرة. كما أنه يمكنك الإبلاغ عن هذه الآثار مباشرةً (انظر التفاصيل المذكورة أدناه). من خلال الإبلاغ عن الآثار الجانبية، يمكنك المساعدة بتوفير معلومات مهمة عن سلامة الدواء.</p><ul dir="rtl"><li>مؤسسة الإمارات للدواء</li></ul><p dir="RTL">الإمارات العربية المتحدة<br />البريد الالكتروني: pv@ede.gov.ae<br />الهاتف: 80033784</p><ul dir="rtl"><li>المملكة العربية السعودية</li></ul><p dir="RTL">المركز الوطني للتيقظ الدوائي<br />مركز الاتصال الموحد: 19999<br />البريد الإلكتروني: npc.drug@sfda.gov.sa<br />الموقع الإلكتروني: &nbsp;https://ade.sfda.gov.sa</p><ul dir="rtl"><li>دول الخليج العربي الأخرى</li></ul><p dir="RTL">الرجاء الاتصال بالجهات الوطنية في كل دولة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ 05/2023؛ رقم النسخة Un1.0.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Speranta 40 Film-coated Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet of Speranta 40 mg Film-coated Tablets contains 48.31 mg neratinib maleate equivalent to 40 mg neratinib. 

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated Tablets.

Red oval-shaped film coated tablets, debossed with “N1” on one side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Speranta is indicated for the extended adjuvant treatment of adult patients with early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Speranta treatment should be initiated and supervised by a physician experienced in the administration of anti-cancer medicinal products.</p><p><strong><em>Posology</em></strong><br />The recommended dose of Speranta is 240 mg (six 40 mg tablets) taken orally once daily, continuously for one year. Speranta should be taken with food, preferably in the morning. Patients should initiate treatment within 1 year after completion of trastuzumab therapy.</p><p><strong>Dose modifications for adverse reactions</strong><br />Speranta dose modification is recommended based on individual safety and tolerability. Management of some adverse reactions may require dose interruption and/or dose reduction as shown in Table 1, Table 2, Table 3, and Table 4.</p><p>Discontinue Speranta for patients who:</p><ul><li>Fail to recover to Grade 0 to 1 from treatment-related toxicity,</li><li>For toxicities that result in a treatment delay &gt; 3 weeks, or</li><li>For patients that are unable to tolerate 120 mg daily</li></ul><p>Additional clinical situations may result in dose adjustments as clinically indicated (e.g. intolerable toxicities, persistent Grade 2 adverse reactions, etc.).</p><p><strong>Table 1: Speranta dose modifications for adverse reactions</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Dose level</strong></p></td><td style="vertical-align:top"><p><strong>Speranta dose</strong></p></td></tr><tr><td><p>Recommended starting dose</p></td><td><p>240 mg daily</p></td></tr><tr><td><p>First dose reduction</p></td><td><p>200 mg daily</p></td></tr><tr><td><p>Second dose reduction</p></td><td><p>160 mg daily</p></td></tr><tr><td><p>Third dose reduction</p></td><td><p>120 mg daily</p></td></tr></tbody></table><p><strong>&nbsp;Table 2: Speranta dose modifications and management &ndash; general toxicities*</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top; width:132px"><p><strong>Severity of toxicity&dagger;</strong></p></td><td style="vertical-align:top; width:640px"><p><strong>Action</strong></p></td></tr><tr><td style="vertical-align:top; width:132px"><p>Grade 3</p></td><td style="vertical-align:top; width:640px"><p>Stop Speranta<strong> </strong>until recovery to Grade &le;1 or baseline within 3 weeks of stopping treatment. Then resume Speranta<strong> </strong>at the next lower dose level. If grade 3 toxicity does not recover within 3 weeks, discontinue Speranta<strong> </strong>permanently.</p></td></tr><tr><td style="vertical-align:top; width:132px"><p>Grade 4</p></td><td style="vertical-align:top; width:640px"><p>Discontinue Speranta permanently.</p></td></tr></tbody></table><p>* Refer to Table 3 and Table 4 below for management of diarrhoea and hepatotoxicity<br />&dagger; Per CTCAE v4.0</p><p><strong>Dose modifications for diarrhoea</strong><br />Diarrhoea management requires the correct use of an anti-diarrhoeal medicinal product, dietary changes, and appropriate dose modifications of Speranta.</p><p>Guidelines for adjusting doses of Speranta in the setting of diarrhoea are shown in Table 3.</p><p><strong>&nbsp;Table 3: Dose modifications for diarrhoea</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Severity of diarrhoea*</strong></p></td><td style="vertical-align:top"><p><strong>Action</strong></p></td></tr><tr><td style="vertical-align:top"><ul><li>Grade 1 diarrhoea [increase of &lt; 4 stools per day over baseline]</li><li>Grade 2 diarrhoea [increase of 4-6 stools per day over baseline] lasting &lt; 5 days</li><li>Grade 3 diarrhoea [increase of &ge; 7 stools per day over baseline; incontinence; hospitalization indicated; limiting self-care activities of daily living] lasting &le; 2 days</li></ul></td><td style="vertical-align:top"><ul><li>Adjust anti-diarrhoeal treatment</li><li>Diet modifications</li><li>Fluid intake of ~2 L/day should be maintained to avoid dehydration</li><li>Once event resolves to Grade &le;1 or baseline, consider restarting anti-diarrhoeal prophylaxis, if appropriate with each subsequent Nerlynx administration (refer to section 4.4).</li></ul></td></tr><tr><td style="vertical-align:top"><ul><li>Any grade with complicated features<sup>&dagger;</sup></li><li>Grade 2 diarrhoea lasting 5 days or longer<sup>&Dagger;</sup></li><li>Grade 3 diarrhoea lasting between 2 days and 3 weeks<sup>&Dagger;</sup></li></ul></td><td style="vertical-align:top"><ul><li>Interrupt Speranta treatment</li><li>Diet modifications</li><li>Fluid intake of ~2 L/day should be maintained to avoid dehydration</li><li>If diarrhoea resolves to Grade &le;1 in one week or less, then resume Nerlynx treatment at the same dose.</li><li>If diarrhoea resolves to Grade &le;1 in longer than one week, then resume Nerlynx treatment at reduced dose (see Table 1).</li><li>Once event resolves to Grade &le;1 or baseline, consider restarting anti-diarrhoeal prophylaxis, if appropriate with each subsequent Nerlynx administration (refer to section 4.4).</li><li>If grade 3 diarrhoea persists longer than 3 weeks, discontinue Speranta permanently.</li></ul></td></tr><tr><td style="vertical-align:top"><ul><li>Grade 4 diarrhoea [life-threatening consequences; urgent intervention indicated]</li></ul></td><td style="vertical-align:top"><ul><li>Permanently discontinue Speranta treatment</li></ul></td></tr><tr><td style="vertical-align:top"><ul><li>Diarrhoea recurs to Grade 2 or higher at 120 mg per day</li></ul></td><td style="vertical-align:top"><ul><li>Permanently discontinue Speranta treatment</li></ul></td></tr></tbody></table><p>* Per CTCAE v4.0<br />&dagger; Complicated features include dehydration, fever, hypotension, renal failure, or Grade 3 or 4 neutropenia<br />&Dagger; Despite being treated with optimal medical therapy</p><p><strong>Dose modifications for hepatotoxicity</strong><br />Guidelines for dose adjustment of Speranta in the event of liver toxicity are shown in Table 4. (see Section 4.4).</p><p><strong>Table 4: Dose modifications for hepatotoxicity</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Severity of hepatotoxicity*</strong></p></td><td style="vertical-align:top"><p><strong>Action</strong></p></td></tr><tr><td style="vertical-align:top"><ul><li>Grade 3 ALT (&gt;5-20 x ULN) OR</li><li>Grade 3 bilirubin (&gt;3-10 x ULN)</li></ul></td><td style="vertical-align:top"><ul><li>Stop Speranta until recovery to Grade &le;1</li><li>Evaluate alternative causes</li><li>Resume Speranta at the next lower dose level if recovery to Grade &le;1 occurs within 3 weeks. If Grade 3 ALT or bilirubin occurs again despite one dose reduction, permanently discontinue Speranta.</li><li>If grade 3 hepatotoxicity persists longer than 3 weeks, discontinue Speranta permanently</li></ul></td></tr><tr><td style="vertical-align:top"><ul><li>Grade 4 ALT (&gt;20 x ULN) OR</li><li>Grade 4 bilirubin (&gt;10 x ULN)</li></ul></td><td style="vertical-align:top"><ul><li>Permanently discontinue Speranta</li><li>Evaluate alternative causes</li></ul></td></tr></tbody></table><p>ULN=Upper Limit Normal; ALT= Alanine Aminotransferase<br />* Per CTCAE v4.0</p><p><strong>Missed dose</strong><br />Missed doses should not be replaced and treatment should resume with the next scheduled daily dose (see Section 4.9).</p><p><strong>Grapefruit and pomegranate</strong><br />Concomitant administration of neratinib with grapefruit or pomegranate/grapefruit or pomegranate juice is not recommended (see Section 4.4 and Section 4.5).</p><p><strong>Use of CYP3A4/P-gp inhibitors</strong><br />If the inhibitor cannot be avoided, reduce Speranta dose:</p><ul><li>To 40 mg (one 40 mg tablet) taken once daily with a strong CYP3A4/P- gp inhibitor.</li><li>To 40 mg (one tablet) taken once daily with a moderate CYP3A4/P-gp inhibitor. If well tolerated, increase to 80 mg for at least 1 week, then to 120 mg for at least 1 week, and to 160 mg as a maximal daily dose. Patient should be monitored carefully, especially GI effects including diarrhoea and hepatotoxicity.</li></ul><p>After discontinuation of a strong or moderate CYP3A4/P-gp inhibitor, resume previous dose of Speranta 240 mg (see Section 4.4, Section 4.5 and Section 5.2).</p><p><strong>H<sub>2</sub>-receptor antagonists and antacids</strong><br />If H<sub>2</sub>-receptor antagonists are used, Speranta should be taken at least 2 hours before or 10 hours after the intake of the H<sub>2</sub>-receptor antagonist. Separate dosing of Speranta and antacids by at least 3 hours should be applied (see Section 4.4, Section 4.5 and Section 5.2).</p><p><u>Special populations</u><br /><em>Patients with renal impairment</em><br />No dose adjustment is necessary in patients with mild to moderate renal impairment. Speranta has not been studied in patients with severe renal impairment including patients on dialysis. Treatment of patients with severe renal impairment or on dialysis is not recommended (see Section 5.2).</p><p><em>Patients with hepatic impairment</em><br />No dose adjustment is required in patients with Child-Pugh A or B (mild to moderate) hepatic impairment (see Section 5.2).</p><p><em>Elderly</em><br />No dose adjustment is required. There is no data in patients &ge;85 years of age.</p><p><em>Paediatric population</em><br />There is no relevant use of neratinib in the paediatric population in the indication of breast cancer.</p><p><strong><em>Method of administration</em></strong><br />Speranta is for oral use. The tablets should be swallowed whole preferably with water and should not be crushed or dissolved, and should be taken with food, preferably in the morning (see Section 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in Section 6.1.
Co-administration with the following medical products that are strong inducers of the CYP3A4/P-gp isoform of cytochrome P450, such as (see Section 4.5 and Section 5.2):
• Carbamazepine, phenytoin (antiepileptics)
• St John's wort (Hypericum perforatum) (herbal product)
• Rifampicin (antimycobacterial)

Severe hepatic impairment (Child-Pugh C) (see Section 5.2).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Diarrhoea</strong><br />Diarrhoea has been reported during treatment with neratinib (see Section 4.2 and Section 4.8). The diarrhoea may be severe and associated with dehydration.</p><p>Diarrhoea generally occurs early during the first or second week of treatment with neratinib and may be recurrent.</p><p>Patients should be instructed to initiate prophylactic treatment with an anti-diarrhoeal medicinal product with the first dose of neratinib, and maintain regular dosing of the anti-diarrhoeal medicinal product during the first 1-2 months of neratinib treatment, titrating to 1-2 bowel movements per day.</p><p><strong>Elderly</strong><br />Elderly patients (&ge;65 years of age) are at a higher risk of renal insufficiency and dehydration which may be a complication of diarrhoea and these patients should be carefully monitored.</p><p><strong>Patients with a significant chronic gastrointestinal disorder</strong><br />Patients with a significant chronic gastrointestinal disorder with diarrhoea as a major symptom were not included in the pivotal study, and should be carefully monitored.</p><p><strong>Renal impairment</strong><br />Patients with renal impairment are at a higher risk of complications of dehydration if they develop diarrhoea, and these patients should be carefully monitored (see Section 4.2 and Section 5.2).</p><p><strong>Liver function</strong><br />Hepatotoxicity has been reported in patients treated with neratinib. Liver function tests including alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin should be monitored at 1 week, then monthly for the first 3 months and every 6 weeks thereafter while on treatment or as clinically indicated (see Section 4.2).</p><p>Patients who experience &ge; Grade 3 diarrhoea requiring IV fluid treatment or any signs or symptoms of hepatotoxicity, such as worsening of fatigue, nausea, vomiting, jaundice, right upper quadrant pain or tenderness, fever, rash, or eosinophilia, should be evaluated for changes in liver function tests. Fractionated bilirubin and prothrombin time should also be collected during hepatotoxicity evaluation.</p><p><strong>Left ventricular function</strong><br />Left ventricular dysfunction has been associated with HER2 inhibition. Neratinib has not been studied in patients with less than lower limit of normal left ventricular ejection fraction (LVEF) or with significant cardiac history. In patients with known cardiac risk factors, conduct cardiac monitoring, including assessment of LVEF, as clinically indicated.</p><p><strong>Proton pump inhibitors, H<sub>2</sub>-receptor antagonists and antacids</strong><br />Treatments that increase gastrointestinal pH may lower the absorption of neratinib, thus decreasing systemic exposure. Co-administration with proton pump inhibitors (PPIs) is not recommended (see Section 4.5 and Section 5.2).</p><p>In case of H<sub>2</sub>-receptor antagonists or antacids, modalities of administration should be adapted (see Section 4.2, Section 4.5 and Section 5.2).</p><p><strong>Pregnancy</strong><br />Neratinib may cause foetal harm when administered to pregnant women (see Section 4.6).</p><p><strong>Skin and subcutaneous tissue disorders</strong><br />Neratinib is associated with skin and subcutaneous tissue disorders. Patients with symptomatic skin and subcutaneous tissue disorders should be carefully monitored (see Section 4.8).</p><p><strong>Concomitant treatment with inhibitors of CYP3A4 and P-gp</strong><br />Concomitant treatment with strong or moderate CYP3A4 and P-gp inhibitors is not recommended due to risk of increased exposure to neratinib. If the inhibitor cannot be avoided, neratinib dose adjustment should be applied (see Section 4.2, Section 4.5 and Section 5.2).</p><p>Grapefruit or pomegranate juice should be avoided during treatment with Speranta (see Section 4.2 and Section 4.5).</p><p><strong>Concomitant treatment with moderate inducers of CYP3A4 and P-gp</strong><br />Concomitant treatment with moderate CYP3A4 and P-gp inducers is not recommended as it may lead to a loss of neratinib efficacy (see Section 4.5 and Section 5.2).</p><p><strong>Concomitant treatment with substrates of P-gp</strong><br />Patients who are treated concomitantly with therapeutic agents with a narrow therapeutic window whose absorption involves P-gp transporters in the gastrointestinal tract should be carefully monitored (see Section 4.5 and Section 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Effects of other substances on neratinib</strong><br />Neratinib is primarily metabolized by CYP3A4 and is a P-gp substrate.</p><p><u>CYP3A4/P-gp inducers</u><br />A clinical study demonstrated that concomitant use of strong CYP3A4/P-gp inducers significantly decreased neratinib exposure, therefore concurrent use of neratinib with strong CYP3A4/P-gp inducers is contraindicated (e.g. strong inducers: phenytoin, carbamazepine, rifampicin, or herbal preparations containing St John&#39;s Wort&nbsp;(Hypericum perforatum)). Concurrent use of neratinib with moderate CYP3A4/P-gp inducers is not recommended as it may also lead to loss of efficacy (e.g. moderate inducers: bosentan, efavirenz, etravirine, phenobarbital, primidone, dexamethasone) (see Section 4.3 and Section 5.2).</p><p><u>CYP3A4/P-gp inhibitors</u><br />A clinical study and model-based predictions have demonstrated that concomitant use of strong or moderate CYP3A4/P-gp inhibitors significantly increased neratinib systemic exposure, therefore, concomitant use of neratinib with strong and moderate CYP3A4/P-gp inhibitors is not recommended (e.g. strong inhibitors: atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, lopinavir, ketoconazole, itraconazole, clarithromycin, troleandomycin, voriconazole, and cobicistat; moderate inhibitors: ciprofloxacin, cyclosporin, diltiazem, fluconazole, erythromycin, fluvoxamine and verapamil). If the inhibitor can not be avoided, neratinib dose adjustment shoud be applied (see Section 4.2, Section 4.4 and Section 5.2).</p><p>Grapefruit/pomegranate or grapefruit/pomegranate juice may also increase neratinib plasma concentrations and should be avoided (see Section 4.2 and Section 4.4).</p><p><u>Proton pump inhibitors, H<sub>2</sub>-receptor antagonists and antacids</u><br />The&nbsp;<em>in-vitro</em>&nbsp;solubility of neratinib is pH-dependent. Concomitant treatment with substances that increase gastric pH may lower the absorption of neratinib, thus decreasing systemic exposure. Co-administration with proton pump inhibitors (PPIs) is not recommended (e.g. omeprazole or lansoprazole) (see Section 4.4 and Section 5.2).</p><p>Speranta should be taken at least 2 hours before or 10 hours after the intake of the H<sub>2</sub>-receptor antagonist (see Section 4.2, Section 4.4 and Section 5.2).</p><p>Separate dosing of Speranta and antacids by at least 3 hours (see Section 4.2, Section 4.4 and Section 5.2).</p><p><u>Antidiarrhoeal loperamide</u><br />A clinical study has demonstrated that there were no clinically significant differences in the exposure of subjects to neratinib with or without concurrent dosing with loperamide (see Section 5.2).</p><p><strong>Effects of neratinib on other substances</strong><br /><u>Hormonal contraceptives</u><br />It is currently unknown whether neratinib reduces the effectiveness of systemically acting hormonal contraceptives. Therefore, women using systemically acting hormonal contraceptives should add a barrier method (see Section 4.6).</p><p><u>P-glycoprotein efflux transporters</u><br /><em>In-vitro</em>&nbsp;studies demonstrated that neratinib is an inhibitor of P-glycoprotein (P-gp) efflux transporters. This has been confirmed by a clinical study using digoxin as probe substrate leading to an increase of 54 and 32% in C<sub>max</sub> and AUC, respectively. This might be clinically relevant for patients who are treated concomitantly with therapeutic agents with a narrow therapeutic window whose absorption involves P-gp transporters in the gastrointestinal tract (e.g. digoxin, colchicine, dabigatran, phenytoin, statins, cyclosporine, everolimus, sirolimus, tacrolimus). They should be carefully monitored (see Section 4.4 and Section 5.2).</p><p><u>Breast cancer resistance protein efflux transporter</u><br />Neratinib may inhibit breast cancer resistance protein (BCRP) at intestinal level as suggested by <em>in vitro</em> studies. A clinical study with BCRP substrates has not been conducted. As co-administration of neratinib with BCRP substrates may lead to an increase of their exposure, patients who are treated with BCRP substrates (e.g., rosuvastatin, sulfasalazine and irinotecan) should be monitored carefully (Section 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Women of childbearing potential/Contraception in females and males</strong><br />Based on findings in animals, neratinib may cause foetal harm when administered to pregnant women. Women should avoid becoming pregnant while taking Speranta and for up to 1 month after ending treatment. Therefore, women of child-bearing potential must use highly effective contraceptive measures while taking Speranta and for 1 month after stopping treatment.</p><p>It is currently unknown whether neratinib may reduce the effectiveness of systemically acting hormonal contraceptives, and therefore women using systemically acting hormonal contraceptives should add a barrier method.</p><p>Men should use a barrier method of contraception during treatment and for 3 months after stopping treatment.</p><p><strong>Pregnancy</strong><br />There are no data from the use of neratinib in pregnant women. Studies in animals have shown embryo-foetal lethality and foetal morphological anomalies (see Section 5.3). The potential risk for humans is unknown. Speranta should not be used during pregnancy unless the clinical condition of the woman requires treatment with neratinib.</p><p>If neratinib is used during pregnancy, or if the patient becomes pregnant while taking Speranta, the patient should be informed of the potential hazard to the foetus.</p><p><strong>Breast-feeding</strong><br />It is not known whether neratinib is excreted in human milk. A risk to the breast-fed infant cannot be excluded. A decision must be made whether to discontinue breast- feeding or to discontinue Speranta, taking into account the importance of Speranta to the mother and the benefit of breast-feeding to the child.</p><p><strong>Fertility</strong><br />No fertility studies in women or men have been conducted. No significant changes in fertility parameters in male and female rats were detected in dosing up to 12 mg/kg/day (see Section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Speranta has minor or moderate influence on the ability to drive and use machines. Fatigue, dizziness, dehydration, and syncope have been reported as adverse reactions with neratinib. The clinical status of the patient should be considered when assessing the patient&#39;s ability to perform tasks that require judgment, motor, or cognitive skills.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Summary of the safety profile</strong><br />The most common adverse reactions of any grade were diarrhoea (93.6%), nausea (42.5%), fatigue (27.3%), vomiting (26.8%), abdominal pain (22.7%), rash (15.4%), decreased appetite (13.7%), abdominal pain upper (13.2%), stomatitis (11.2%), and muscle spasms (10.0%).</p><p>The most common Grade 3-4 adverse reactions were diarrhoea (Grade 3, 36.9% and Grade 4, 0.2%) and vomiting (Grade 3, 3.4% and Grade 4, 0.1%).</p><p>Adverse reactions reported as serious included diarrhoea (1.9%), vomiting (1.3%), dehydration (1.1%), nausea (0.5%), alanine aminotransferase increased (0.4%), aspartate aminotransferase increased (0.4%), abdominal pain (0.3%), fatigue (0.3%) and decreased appetite (0.2%).</p><p><strong>Tabulated list of adverse reactions</strong><br />The table below lists adverse reactions observed with neratinib based on the assessment of pooled data from 1,710 patients.</p><p>The MedDRA frequency convention and system organ class database has been utilised for the classification of frequency:<br />Very common (&ge; 1/10)<br />Common (&ge; 1/100 to &lt; 1/10)<br />Uncommon (&ge; 1/1,000 to &lt; 1/100)<br />Rare (&ge; 1/10,000 to &lt; 1/1,000)<br />Very rare (&lt; 1/10,000)<br />Not known (cannot be estimated from the available data)</p><p>Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p><strong>Table 5: Adverse drug reactions due to neratinib in monotherapy breast cancer studies</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td><p><strong>System Organ Class</strong></p></td><td><p><strong>Frequency</strong></p></td><td><p><strong>Adverse Drug Reaction</strong></p></td></tr><tr><td><p><strong>Infections and infestations</strong></p></td><td><p>Common</p></td><td><p>Urinary tract infection</p></td></tr><tr><td rowspan="2"><p><strong>Metabolism and nutrition disorders</strong></p></td><td><p>Very Common</p></td><td><p>Decreased appetite</p></td></tr><tr><td><p>Common</p></td><td><p>Dehydration</p></td></tr><tr><td><p><strong>Nervous system disorders</strong></p></td><td><p>Common</p></td><td><p>Syncope</p></td></tr><tr><td><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td><p>Common</p></td><td><p>Epistaxis</p></td></tr><tr><td rowspan="2"><p><strong>Gastrointestinal disorders</strong></p></td><td><p>Very Common</p></td><td><p>Diarrhoea, vomiting, nausea, abdominal pain, abdominal pain upper, and stomatitis<sup>1</sup></p></td></tr><tr><td><p>Common</p></td><td><p>Abdominal distension, dry mouth and dyspepsia</p></td></tr><tr><td rowspan="2"><p><strong>Hepatobiliary disorders</strong></p></td><td><p>Common</p></td><td><p>Alanine aminotransferase increased, and aspartate aminotransferase increased</p></td></tr><tr><td><p>Uncommon</p></td><td><p>Blood bilirubin increased</p></td></tr><tr><td rowspan="2"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td><p>Very Common</p></td><td><p>Rash<sup>2</sup></p></td></tr><tr><td><p>Common</p></td><td><p>Nail disorder<sup>3</sup>, skin fissures and dry skin</p></td></tr><tr><td><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td><p>Very Common</p></td><td><p>Muscle spasms</p></td></tr><tr><td rowspan="2"><p><strong>Renal and urinary disorders</strong></p></td><td><p>Common</p></td><td><p>Blood creatinine increased</p></td></tr><tr><td><p>Uncommon</p></td><td><p>Renal failure</p></td></tr><tr><td><p><strong>General disorders and administration site conditions</strong></p></td><td><p>Very common</p></td><td><p>Fatigue</p></td></tr><tr><td><p><strong>Investigations</strong></p></td><td><p>Common</p></td><td><p>Weight decreased</p></td></tr><tr><td colspan="3"><p><sup>1</sup>&nbsp;Includes stomatitis, aphthous stomatitis, mouth ulceration, oral mucosal blistering, and mucosal inflammation.<br /><sup>2</sup>&nbsp;Includes rash, rash erythematous, rash follicular, rash generalised, rash pruritic, and rash pustular.<br /><sup>3</sup>&nbsp;Includes nail disorder, paronychia, onychoclasis, and nail discolouration.</p></td></tr></tbody></table><p><br /><strong>Description of selected adverse reactions</strong><br /><u>Diarrhoea</u><br />Of the 1,660 patients treated with neratinib monotherapy without loperamide prophylaxis, 94.6% experienced at least 1 episode of diarrhoea. Grade 3 diarrhoea was reported in 37.5% of neratinib patients. 0.2% of patients had diarrhoea classified as Grade 4. Diarrhoea led to hospitalisation in 1.9% of neratinib-treated patients.</p><p>Diarrhoea generally occurred in the first month, with 83.6% of patients reporting this toxicity in the first week, 46.9% in the second week, 40.2% in the third week and 43.2% in the fourth week (median time to first onset was 2 days).</p><p>The median duration of a single episode of any grade diarrhoea was 2 days. The median cumulative duration of any grade diarrhoea was 59 days and the median cumulative duration of Grade 3 diarrhoea was 5 days.</p><p>Diarrhoea was also the most common adverse reaction leading to discontinuation, 14.4 % of patients treated with neratinib without loperamide prophylaxis discontinued treatment due to diarrhoea. Dose reductions occurred in 24.7% of neratinib-treated patients.</p><p><u>Rash</u><br />In the neratinib monotherapy group, 16.7% of patients experienced rash. The incidence of Grade 1 and Grade 2 was 13.3% and 2.9% respectively; 0.4% of neratinib-treated patients experienced Grade 3 rash.</p><p><u>Nail disorders</u><br />In the neratinib monotherapy group, 7.8% patients experience nail disorders. The incidence of Grade 1 and Grade 2 was 6.2% and 1.4% respectively. There were 0.2% of neratinib treated patients who experienced Grade 3 nail disorder.</p><p>Both rash and nail disorders led to treatment discontinuation in 0.6% of neratinib- treated patients.</p><p><u>Hepatotoxicity</u><br />Hepatic-associated adverse reactions in the pivotal phase III study, ExteNET (3004), were reported more frequently in the neratinib arm compared to the placebo arm (12.4% vs. 6.6%), due primarily to alanine aminotransferase (ALT) increased (8.5% vs. 3.2%), aspartate aminotransferase (AST) increased (7.4 vs 3.3%) and blood alkaline phosphatase increased (2.1% vs. 1.1%). Grade 3 adverse reactions were reported in 1.6% vs 0.5% and Grade 4 adverse reactions were reported in 0.2% vs. 0.1%, neratinib- and placebo-treated patients, respectively. Grade 3 ALT increased was reported in 1.1% vs 0.2% and Grade 4 ALT increased was reported in 0.2% vs 0.0% of neratinib- vs placebo-treated patients. Grade 3 AST increased was reported in 0.5% vs 0.3% and Grade 4 AST increased was reported in 0.2% vs 0.0%, of neratinib - vs placebo-treated patients. There was no Grade 3 or 4 adverse reactions of blood bilirubin increased.</p><p><strong>Other special populations</strong><br /><u>Elderly</u><br />In the pivotal phase III study, ExteNET (3004), the mean age was 52 years in the neratinib arm, 1236 patients were &lt;65 years, 172 were &ge;65 years, of whom 25 were 75 years or older.</p><p>There was a higher frequency of treatment discontinuations due to adverse reactions in the &ge;65 years age group than &lt;65 years age group; in the neratinib arm, the respective percentages were 44.8% compared with 25.2%, respectively.</p><p>The incidence of serious adverse reactions in the neratinib arm vs placebo arm was 7.0% vs. 5.7% (&lt;65 years-old) and 9.9% vs. 8.1% (&ge;65 years-old). The serious adverse reactions most frequently reported in the &ge;65 years-old group were vomiting (2.3%), diarrhoea (1.7%), dehydration (1.2%), and renal failure (1.2%).</p><p>Treatment-emergent adverse reactions leading to hospitalisation in the neratinib arms versus the placebo arm was 6.3% vs 4.9% in the &lt;65 years-old group and 8.7% vs. 8.1% in the &ge;65 years-old group.</p><p><u>Effect of race</u><br />In the pivotal phase III study, ExteNET (3004), the frequency of Treatment Emergent Adverse Events (TEAEs) in the Skin and Subcutaneous Disorders System Organ Class (SOC) in Asian patients treated with neratinib was higher than in Caucasian patients (56.4% vs. 34.5%) but comparable in placebo patients (24.9% vs. 22.8%).</p><p>Pooled safety data of 1710 patients treated with neratinib monotherapy showed a higher incidence of dermatologic toxicities in Asian patients (57.1%) versus Caucasian patients (34.6%).</p><p>In the analysis of pooled safety data, the majority of TEAEs in the Skin and Subcutaneous Disorders SOC in Asians were Grade 1 (43.3%) and Grade 2 (12.3%); in Caucasians, the incidence of Grade 1 and Grade 2 events was 25.6% and 7.8%, respectively. The frequency of Grade 3 events was similar between Asians and Caucasians (1.6% vs. 1.0%). There was no difference in frequency of SAEs in the Skin SOC between Asian and Caucasian subgroups. The most common TEAEs in the Skin SOC that occurred more frequently in Asian patients than in Caucasian patients were rash (29.4% vs. 13.5%), Palmar-plantar erythrodysaesthesia syndrome (9.9% vs. 1.0%), and dermatitis acneiform (6.0 vs. 1.0%).</p><p><strong>Reporting of suspected adverse reactions</strong><br />Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><ul><li>Saudi Arabia</li></ul><p>The National Pharmacovigilance Centre (NPC)<br />SFDA Call Center: 19999<br />E-mail: npc.drug@sfda.gov.sa<br />Website: https://ade.sfda.gov.sa</p><ul><li>Other GCC States</li></ul><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no specific antidote, and the benefit of haemodialysis in the treatment of neratinib overdose is unknown. In the event of an overdose, administration should be withheld and general supportive measures undertaken.</p><p>In the clinical trial setting, adverse reactions associated with overdose were most commonly diarrhoea, with or without nausea, vomiting and dehydration.</p><p>In a dose escalation study in healthy volunteers, single oral doses of neratinib up to 800 mg were administered. The frequency and severity of gastrointestinal disorders (diarrhoea, abdominal pain, nausea and vomiting) appeared to be dose-related. Single doses of neratinib greater than 800 mg have not been administered in the clinical studies.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antineoplastic agents, protein kinase inhibitors, ATC code: L01EH02.</p><p><strong><em>Mechanism of action</em></strong><br />Neratinib is an irreversible pan&ndash;erythroblastic leukaemia viral oncogene homolog (ERBB) tyrosine kinase inhibitor (TKI) that blocks mitogenic growth factor signal transduction through covalent, high affinity binding to the ATP binding site of 3 epidermal growth factor receptors (EGFRs): EGFR (encoded by ERBB1), HER2 (encoded by ERBB2), and HER4 (encoded by ERBB4) or their active heterodimers with HER3 (encoded by ERBB3). This results in sustained inhibition of these growth promoting pathways with HER2-amplified or over-expressed, or HER2-mutant breast cancers. Neratinib binds to the HER2 receptor, reduces EGFR and HER2 autophosphorylation, downstream MAPK and AKT signaling pathways, and potently inhibits tumour cell proliferation&nbsp;<em>in vitro</em>.&nbsp;Neratinib inhibited EGFR and/or HER2- expressing carcinoma cell lines with a cellular IC50 &lt;100 nM.</p><p><strong><em>Clinical efficacy and safety</em></strong><br />In the multicentre, randomised, double-blind, placebo-controlled, pivotal phase III study, ExteNET (3004), 2,840 women with early-stage HER2-positive breast cancer (as confirmed locally by assay) who had completed adjuvant treatment with trastuzumab were randomised 1:1 to receive either neratinib or placebo daily for one year. The median age in the intention-to-treat (ITT) population was 52 years (59.9% was &ge;50 years old, 12.3% was &ge;65 years old); 81.0% were Caucasian, 2.6% black or African American, 13.6% Asian and 2.9% other. At baseline, 57.7% had hormone receptor positive disease (defined as ER-positive and/or PgR-positive), 27.2% were node negative, 41.5% had one to three positive nodes and 29.4% had four or more positive nodes. Approximately 10% of patients had Stage I tumours, approximately 40% had Stage II tumours and approximately 30% had Stage III tumours. Median time from the last adjuvant trastuzumab treatment to randomization was 4.5 months.</p><p>The primary endpoint of the study was invasive disease-free survival (iDFS). Secondary endpoints of the study included disease-free survival (DFS) including ductal carcinoma <em>in situ</em> (DFS-DCIS), time to distant recurrence (TTDR), distant disease-free survival (DDFS), cumulative incidence of central nervous system recurrence and overall survival (OS).</p><p>The primary analysis of the study after 2 years post-randomisation demonstrated that neratinib significantly reduced the risk of invasive disease recurrence or death by 33% (HR=0.67 with 95% CI (0.49, 0.91), two-sided p = 0.011) in the ITT population.</p><p><strong>Table 6: Primary 2-year efficacy results &ndash; ITT and hormone receptor positive populations who were less than one year from completion of trastuzumab therapy</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td><p><strong>Variable</strong></p></td><td colspan="2"><p><strong>Estimated 2 year event free rates<sup>1</sup>&nbsp;(%)</strong></p></td><td><p><strong>Hazard ratio (95% CI)<sup>2</sup></strong></p></td><td colspan="2"><p><strong>P-value<sup>3</sup></strong></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td colspan="5" style="vertical-align:top"><p><strong>ITT population</strong></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td><p><strong>Neratinib (N=1420)</strong></p></td><td><p><strong>Placebo (N=1420)</strong></p></td><td colspan="2" style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Invasive disease-free survival</p></td><td style="vertical-align:top"><p>94.2</p></td><td style="vertical-align:top"><p>91.9</p></td><td colspan="2" style="vertical-align:top"><p>0.67</p><p>(0.49, 0.91)</p></td><td style="vertical-align:top"><p>0.011</p></td></tr><tr><td style="vertical-align:top"><p>Disease-free survival including ductal carcinoma&nbsp;<em>in situ</em></p></td><td style="vertical-align:top"><p>94.2</p></td><td style="vertical-align:top"><p>91.3</p></td><td colspan="2" style="vertical-align:top"><p>0.62</p><p>(0.46, 0.84)</p></td><td style="vertical-align:top"><p>0.002</p></td></tr><tr><td style="vertical-align:top"><p>Distant disease-free survival</p></td><td style="vertical-align:top"><p>95.3</p></td><td style="vertical-align:top"><p>94.0</p></td><td colspan="2" style="vertical-align:top"><p>0.75</p><p>(0.53, 1.06)</p></td><td style="vertical-align:top"><p>0.110</p></td></tr><tr><td style="vertical-align:top"><p>Time to distant recurrence</p></td><td style="vertical-align:top"><p>95.5</p></td><td style="vertical-align:top"><p>94.2</p></td><td colspan="2" style="vertical-align:top"><p>0.74</p><p>(0.52, 1.06)</p></td><td style="vertical-align:top"><p>0.102</p></td></tr><tr><td style="vertical-align:top"><p>CNS recurrence</p></td><td style="vertical-align:top"><p>0.92</p></td><td style="vertical-align:top"><p>1.16</p></td><td colspan="2" style="vertical-align:top"><p>&ndash;</p></td><td style="vertical-align:top"><p>0.586</p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td colspan="5"><p><strong>Hormone receptor positive population&nbsp;who were less than one year from completion of trastuzumab</strong></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td><p><strong>Neratinib (N=671)</strong></p></td><td><p><strong>Placebo (N=668)</strong></p></td><td colspan="2"><p><strong>Hazard ratio (95% CI)<sup>4</sup></strong></p></td><td><p><strong>P-value<sup>5</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Invasive disease-free survival</p></td><td style="vertical-align:top"><p>95.3</p></td><td style="vertical-align:top"><p>90.9</p></td><td colspan="2" style="vertical-align:top"><p>0.50</p><p>(0.31, 0.78)</p></td><td style="vertical-align:top"><p>0.003</p></td></tr><tr><td style="vertical-align:top"><p>Disease-free survival including ductal carcinoma&nbsp;<em>in situ</em></p></td><td style="vertical-align:top"><p>95.3</p></td><td style="vertical-align:top"><p>90.1</p></td><td colspan="2" style="vertical-align:top"><p>0.45</p><p>(0.28, 0.71)</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td></tr><tr><td style="vertical-align:top"><p>Distant disease-free survival</p></td><td style="vertical-align:top"><p>96.1</p></td><td style="vertical-align:top"><p>93.0</p></td><td colspan="2" style="vertical-align:top"><p>0.53</p><p>(0.31, 0.88)</p></td><td style="vertical-align:top"><p>0.015</p></td></tr><tr><td style="vertical-align:top"><p>Time to distant recurrence</p></td><td style="vertical-align:top"><p>96.3</p></td><td style="vertical-align:top"><p>93.3</p></td><td colspan="2" style="vertical-align:top"><p>0.53</p><p>(0.30, 0.89)</p></td><td style="vertical-align:top"><p>0.018</p></td></tr><tr><td style="vertical-align:top"><p>CNS recurrence</p></td><td style="vertical-align:top"><p>0.34</p></td><td style="vertical-align:top"><p>1.01</p></td><td colspan="2" style="vertical-align:top"><p>&ndash;</p></td><td style="vertical-align:top"><p>0.189</p></td></tr></tbody></table><p>CNS = central nervous system.<br /><sup>1</sup>&nbsp;Event-free rates for all endpoints, except for CNS recurrence for which cumulative incidence is reported.<br /><sup>2</sup>&nbsp;Stratified Cox proportional hazards model<br /><sup>3&nbsp;</sup>Stratified 2-sided log-rank test for all endpoints, except for CNS recurrence for which Gray&#39;s method was used.<br /><sup>4</sup>&nbsp;Unstratified Cox proportional hazards model<br /><sup>5&nbsp;</sup>Unstratified 2-sided log-rank test for all endpoints, except for CNS recurrence for which Gray&#39;s method was used.</p><p><strong>Figure 1: Kaplan-Meier plot of invasive disease-free survival &ndash; hormone receptor positive population who were less than one year from completion of trastuzumab therapy</strong></p><p><img alt="" width="548" height="283" src="data:image/png;base64,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" /></p><p>&nbsp;</p><p>For hormone receptor positive patients who were less than one year from completion of trastuzumab therapy, the relative treatment benefit of neratinib within pre-specified patient subgroups is presented in Figure 2.</p><p><strong>Figure 2: Hormone receptor positive patients who were less than one year from completion of trastuzumab therapy, invasive disease-free survival by patient subgroup</strong></p><p><img alt="" width="535" height="305" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAhcAAAExCAYAAADPxID+AAAAAXNSR0IArs4c6QAAAARnQU1BAACxjwv8YQUAAAAJcEhZcwAADsMAAA7DAcdvqGQAAP+lSURBVHhe7P3Xd11Xnh2Myvab/wAPD/vFLx5+8x13XNufu12f21Xd5e7q6uquKlUplHKWSFEURYk555wJ5gSSAHPOOSeAAImcc87pZADzzrnW2cABCCaREEFxTWDtvfbK8feba+1wXkM3YEwfyKErerZHz8i1M3qORWyY/ubxUGoPM0MBA5XrCWrWzXDdEbTVlWHZwtn4YdJU3Em9j4zUu5gzbyESj51Dqz/C5LoR6e5GgEnyxGu2cHeQJsToYXRFAnQMmfS6mGRRSRGmz5yG3XsOIsKgjP6E7ezwoqD+MX30QEfFjqmo0SDoiWDhXcY49cNA6ch0myvNWY1FdIdli87hbv7JxjHGP/nY0Axnzg4OTwqNl35G460rjPKSQsyfOxtTpk5HXn4x0u6n47vRP+DAidOUeXYEasRR4plzhPKvm7IPYZ9NRjJOg7MrSFlYj/T061i8dAmOnbyBxsYwDu3ZgY/ffR0ffPIVvhw1ASs2bkN1fSOHP0d1OMhziNKzC5KiTBEhTiKTHrNgZsxAstaPcCSEIK8DDNDJMKFwFzrp3cl51NmpUmr2Rev2gHk4vHk7kLEHpm3mZqTXXYI+OndN6rR7s7UHPQlE56u5FrwWjbpJnpjZbef+s6GnRA+BV54IHksuPG/PyFVF7598/3Cx5vHwCjyQGQoYqFxPUjOG6+TA7fSjpCAHv3/rbXw6bDgKs3NQUFSG0sZW+MMRtDS1cDI0oC3EKaCBoIHFCSHTzYnW0d6CutpKdPg60NzSgWkzpuH7MaMNuegUMeEM6NRAVLEchiR65sIDw8YbTzFGY6AngoV3GePUDwOlI/MocqH0dHTkwuFZofHS33RynURCEA7gbvIdfPDe+xgzdgIKSyqQmpGDRsqyQCSC+mbKv8YWtIc6e0ZeRPKPV91cPfma21BXWYOArwUVFVmYt3AGvh8/CSdOX6Ps9CNQV47Xf/srLF+zGfnVbUjLL0VReQVqqqvQ2tKAxqZaVNTXoKS2Fq1kDX4ShfraBjTQNNXVwdfWgPa2Opw5ew53U7PQ1u5DZVU16puazeKtUwyDsHNPR3ttQfujJ2aP90DGHpWGrbl1I8zctb5eOPsXA3OhQ7TVejwfRi7k9qxgmsY8DF55DLnoXwnBJqCqyGb9dLQi6XHJPz28FAcyQwGx5eltpcehW0xUk4TsubG2CscvnMX7n32GudPnIvVeBiqaW1FSUY3EHbuxdMVqnLtyDT4f+bW2IkStqQia6utw/MghLFu6CMeOH0dScir+9Maf8fmXX6CBE1LjXiUSKRHRePLSOfykUMcM2Dk/bmw9HDHpxZALk3IMudC1ddcxwmMsudA8fx5lcXh1oHEzsOkM+1FRUoBzJ4/h9df/hAUr1yE5Ix+tzc3IysxE3KZtiNu8E6mZ+SQbXWYX189FlXYwfI0NOLptK9YuWYgLZ4/j/KXT+NO77+C7STNRXlmHbi7I0FKOP/76F/hh6nycuZONiqZWbE/YhckTx1N27sP27ZuxeMVSTJw1B0nMo6q+CQvmLcWC2fOxZtkyXLl4Gqmpt/DBhx9jzpylOHniHKZOm42EvUfN7kUXCZAkq50VnBeaV9HamWnS3zwEAwfVUSlZ3WrdCBGCaCDrppw9+W7ztxc6ROer9SR03Z9wWIX/7FDe0fw99OQh6KKHXLAgUQFko6iQKlwnbbZBrbuOikQ2Gr16flCBvFQ9I7c+pX6B+LFl4mAhc+/uDKO+ugL55aW4eO063n3jHSxZuhLljc3Ys+8Q5syYi3UbtmDYyO9QU8MJEyUXXZEgrl+7gmlTp2Dz5k2YMmUKrt+4ie/HjMHquDizY6GgIhgmStQ4vEzwxpY3vp4VSiNqnpJcaHZb8SU3B4enQXTMmbFjTTfHXrfGIBdY9ZVFqK8q5QLpJH7z+jtYs3UnKstLsGn9GkyfPQ+L4zZi1aYdaGxtN6RCt0u0q5GfdAfff/AOzh5IxMxp43Dw2GGMn7UAGxOPoLWDC7GIH6gvwp/+7hf4p7c+w9o9Z1HXFsFlytmpkyfizMnD2L07Hm+/9x7Gz5iN1Zt2ory2AZMnT8fI4V9jOgnI6uWLcPvWVXzy6Vc4c+YqDuw9grVrNuPUxdvo0L1qlqeL9dDMMTvL1I+ebuypdqx5CAYOqqPaq9fFoN9lL7zwUatBNH6fa5Uu1s0q/CdDT6QBoLSj+QsK2ie4Lix/ILkQKyO75KWNQk8jhCRwuqN0QpCv3arql3xfeJl55omhwF7KD039BUHlearKRME4bMdI0IfC3Gwy8yw0trQhcfsOzJw1F+X1zdh74BBmz5iFVavXYdg3o5Gdk0dCcR3hQACRcADXrl7CjBnTsWbNWk6Iybhy5TK+HvEtyckKBIL2Nop2LLxdix9TSocXCTveNQfVg14fPpd+NIIwZlyYhYQVML152PyVe1QcRd0cHH4M7HjSSNKt2s4u6pZACwrSbqGsKBcNLa3YlLjfPH9WUVaEDetWYcrUqZi/Yi2WbNiO9LxC3Lufiia/D2EOxsK7yRjz0bs4tH09pk36HvsPH8aoSbOxfOMuNDS3UR11wF+Sjt//n/+F6QvX4npWFe5llSIl5T4WLZiD3QlbcfTIPvzLH/6IFWs2ITk9H2XV9ZjE/H8YPQqTxn2PJQx35+YNfPbZ1zh9+iqy0nKwfesurGIeLe2kFJEQ69FptJ+9ba0FttWNBt5k6m+eCAr4NPPNa99Y2PbuzXOgNK3Cf7KCRdN7AF66MWnLqU/Q3jAkFyHKH3uvq4dEaHVDISR+JrbW664HX8I90fugJxPP8ijzMDxJmBeBH1keMxAjCLa34OTxozhw+AR8wQhqa6pxJzkF9W0+FBQVYVdCAtas3YDjp86jtKwCWzZtRhsnoZ63qK+rxrGjx7CW/seOHcV9TrwZM+Zg0aLlaG5tNoxaA14lFOPvonEYivDGdV/TSypsH/Y3PRjQ8UH0DcZjLLkws3aA8aFg9hSFtfVeOzg8KexI0p/IRYTkoq2hEqcPbMfFc6fQ5vOjod2HMxcvob2tGdmZ97F580as27YTl1PSkZGbh+PHD5OENJqHKv0NjTgUvxXx65fj1LH9uHX7NqbOXYxVmxJRU9fI4RxA2uVTGPXpx5i5MA5rth/CvkNnkZ9fjPPnTuLKxVMoLyvEylVxSNhzCJV1Haiua8KKlSsxb/4sLF00F9s2rUN+bi7i4jbj7NnrKMwpxulTF5Cw/xTa/dSAnSQXlLM95IL68gFyYQ4/1sTaLOy1jpqz1mZhr/tiILeBwsgMBIWNNV7Yh7nHpON59YENQ3IRNORCIseKHYY0qxu5dZsG7U8uhAfS68kktgAPM68IJNil8MMhFJNE5BUWIxghkQuFEAxF4O/s4nUENdU1JBklaOaki9C/qrIK4RBJHCdmFwd2Y0MDigpL0NTUgBZOury8AhRw8viDPja5tuzUqlol6CnrV6h9XypocvSfB+o1j1z0TqFY04MBHR/Eo4M9QQJRPHlIB4cHYXbDDbnoRMDXjNLCDJQUF8BH2Sft0hEMciEUppzzobKyDIXlFWgOhtEeCKChoZZyUDu3XPh2dqK5vh5FeZlccNWjuakRmTn5yC+pQIAysqszjOrSQuSkpyE1Iw8pGbkoKq5AR4fPyMr2tgbK0SBlbC3yC0rgD3WxDGEUFhciLz+LcjUH5SXFCHT4WY5a1NQ0wtcWQEV5FWoaW1l+zgLdovZui2hWxN4WEcxEeXBuP5npO/c92Gsde8MYiNz0gQ35eDwqjPz6l+thppcpGAyYvQ3bs3Oh4HJSyG7zMGEEIVJHbU2ZpFQpvfnAlbhRmnQyK+ZowvY5ARq56bUFeRhPr1BWkHYyXcW29+M4+KhchZ7gUbt39sJ1DdFXIVS2/ufesqoCtJt2YfPJTybCdqCzam6aje0ckdF1bD0VVwOZZ2M1g5qkg2noupMTS73T0/Tmz2FoQj2jvrVGc8Ea22eyaXVkVkZRxI4F9bleh+s/D2KCcy5ZP6WhJ9zNOIn6908rdpx2cfDYaxtepndM2eteY8PGQmPRBowanaLhYsP2L7vDSwLJH5pIREtN258PjAEab7xo/Om1To3vLsks6ROzTA1TzoUoseivwEbiRWx4mhCNHubsMjpGz5wprA3VLTejl6xiD3MoaWej04x5Zawxz7iy0smOZaVj85U//42/8gobwiBZat9IMYkpTVpVHpMGY8rZk8EqS6exq8y6lahkFVZpmyt7HTXeteZt7HXfsHbOh6kHw53SjTZN2Y10MGHkaue3zctcErLbsimM5pc3x3rjqPXstedm7YodayR/mD/T6xQnMHrFGvWjycPUOMI09VKv0mEbqVGUlimXUhIUTuTCNHInQmElxEqR1XWSMcrTdB5tITW+4nmdyxTNvTQmGGaF1ZHGnybC+F5mXWzUTg0yFZiDwxTWpNiL3grbxpNQ7C8Yhd6CDy3Y95/t2bPbssuQ7Ya1A0G7aUK1GesmO/3N8FGnsS/kbv7MAPHqqgETMekqjOxscUWWl7kOhYKGmNjnLuzAchiKUJ/aSSdjJqwxtu/NLS1zZQWC5pg35r1xpbFhxgLddfYEiU6aOxo32vmybho7NBonmk8aHzrTrze+dVOYUJCCPBrXCDGlwYMZr1G7Ny6jxbJxVQRed2sMSuLL7gWIwhN6/d0dXg5IsRtjBJftR2/sqUtl9HC5elfjxShGhuWIYDjqEy6CbFzpgjB1Bt0VSbqHRkQjonSUHo0ZK8wPkaD59kWH8jLheZafUuZlmJEkF7W7YOJJj6pYvNB4j+gbQV0hk4cWvCqC/JQCaY4hGNJLdnCz7ExPVu0qKz3PcPSacLrlrDnLkEw7hEDAz2LZuSR449yze+NdZ5lgULWx17aOVh8YMsPC6Sw5YEiGuZa/LZPVi7aeOtiFhPQq563JX2lYfWP1pwLavLzy2fJYD6Upm85W96uePMuwjzpFvHjlGR21M94V7UOrt5gni6HFsdquFyqb2blgRFVG18pQFWThVHhD6OhuKiI/Jt4Z1q0RFd52sCkcO8OEZyGVocJ6xhRCJlrIiDqafx6jUl/0F1reWeh1i3EcglB9PIEvu2HfqrEGkYpOE6Gb7GxG4y6mKGUQCWtgiMSp42w91e5qJ68TLXS2fREJ2bwUXlFMulHjMBShjmHfRaGr/sYILwlljR2z6uIYic4TCRkjwBnQ9DWvrTHeZiwIxt8MHq4EOR9F/q2j+berQFmiJswwCmfIB4WfEcJeWMkBmkBQc9bGs+NcQjQaSMlb2WYIRiQcJcMMbEiSyczGc3hZIR3BRYyRTxwfZnxFvXSm8YaDDEMYOd9lxrDklJSxdAyvJf8ZKEzFbwYPw5ojHTVuzIPpSiQ6hgP09VPh2UhMmUakgirHjn06KwW72xG9tlFNmlYt8sxxaYWjIkmFMj+5K6DGb3QMy1c79tFYlNEsvwnHcd2lNtDtHKv8ZXTrRrHMwpx61HxwiyZEJS+i0PsBLs011dnCym3lIbsKbNuDpWQ1mWOUFIl4haVoja8tZpj6QlUJSxerFiYtWy/ZbaL04dy3eVr3MNtAZZanmldG6cgoSriT/cuwIlLezlOYxNASIC9ZpadSKj/COlpiFi2n9TPkQgJBr0uGECYTCwQC5l6WKqVyepFlzIkZ6e2HgM/HjEUWooWj8TpbKxgJmVD0o1DqIP0F2VgR2tUJgpiYPasR1EjmkulE845C6ZpGG4KQUPeMB3W0JmJ7exs6Ojrg9/nR1kqWKz8Z004aWL2DQZMtxH4wOx30VpuatosOTAO6dYqNs908wqFs1ZxKJurkMCShzokZI/2NxoOZ+OpMCgHOR39rE8dOu1nx+ANBdHAc6Q0hb2VihYXGiFLQOGB8WTV/ZGg1PgqrHUmF1SWvOxk30ME5LCHI+JqvQX8HOtrb0drWgXbmFbtrIZKifE1yih8dg0o3HJTiYDitXhQhCo/8Ch7xdnjZoD60CkXPN4SCfvg4biTT1J8aN35fgGMoSlJtDP5JSXmkIjouaLTTakhGVPZJR0Q4BkMaR9H45qChQsPlF/ydPobhuKdeCfpDzIfKj2EURPHNt4QYTmNQ4lJDLiQCwnx7hiQ9w/52kgyWPdCOdr/fGOXbyYVa0E/iQMYSYp0UT/PE3sIXPVG5lJsWjSJYUeUqXcb6BNkmZrfBuBqp3mNXu6ieseTamxM6e22ltIP+NrSpXNStoY4mdHA+NrFtfZr/vg60st2b2O7+6JxVHJbSzC3t0nRSZigf7UKGonNSMsXv91EPSbf7TVmD9A/SX/pF3/FQe8puyitCo1tX7KMg9VEgSD7A/LXbpDoGgyxTc51JU+lEGN8sltVgfUByYerJUkRCbcjNuI/de/bj5PlryCupNgLN3AphYyscy8NK+nD1zCls37IZZRVVCLD3RESCHBiSbZIf3tasGs+wHhVadroFpBxNphYK30MmaIyQYsDYrR0PXqcMNXjlsgydJI2dkp+fh7Xr1mPylGmYNXs+Tpw8Yzqj576gMd2mjYMc4HV1dbh48aLpyJDayAw6DXDLJMWWtb1txiE9wkzL7w8Yu2kzGdplHIYg1C8xfeNd9nVmn2v1ECIZra/Bzk3rMOGH77B9ewLWb4rHpKkzse/gEbS1U/FLuXP8mB0EG9UQBg2Gbgk6ChlvTHiZSNAGObe0y1hZXo7VK5bj6NETFGJBNNXXImHbJkyaOB5Lli7HslWrkZaZZRSGt+UtQam5LbKj+elr9+Ho4WNoa2k36YtcaLXUn2wLKutQnb8OjwKVDxVKdzhAGVWDc2fPYM3qOGxYvwH5eUW4czsFK1esMa/Qm50uykDJ9zCVWojjxYwCI6CoEDmWJMJ0rYfcpRQDlGGtTY1ISbmH4ooaM0a1WKIItEqrqx2l5Tm4efsW8nNLsG1DAi5euGHeurNrch38NEFjt6SD45BlCNGBuo/50E3Pp3VTUbfWIJ7jfPTYcZgxZxH27jmC+3fuYcvqdTh35pxR7tJVYZZRlEU6S2SiU+VXfaQPDfnXPAPOnTyNDZTzDU0tJm+pe6vyRcg7TbtUVFYzflTuKz3P8KBbH4asRPzIy07DxBmzMW3WbBzZsx2LFs3H1PlLsXXnLixZuADTZy3AjEVxiE84iHK2Vae+ocS4WiDU19ehpLQAGRnp2LFjF44eOYOGehKUjjYkJiZgwvgpdDuOiopyHD9xEsePn0Md/aV70tKzuKAg8WKBVC7d0mpjvNtJd7Bx8xYcPXYCWdn5KCuvwla23dhxo7F69SpkZWYjGJDM4b/pV5oekFyIAKnh6yoLkbB1A/bsPYiLN1JxNSkDLS2t6GioQ3V5GdlKC8qq6tDGQpw+fADDP/8MZ85fQkNLGxlghAVtZOXKUFJcgWZ9zrq6Bg2NjWhpbYcvEEBZdRVqeS1yUUtFWlNTwwZpYLha82RvVVU1ysuqUF1VTwKjRpPgtB3gYagKJ7u7IOEpocqBx85p4oSZNXsO3v7Le1gdtwG/+N+/YsdnorGp2Qy21jbtarQjKSkZyXfvIS0tnWQkDvWNDYYh1nKwNDQ1GVbZ3NLEic32q6mlIG/j5Atx4NRiz64DqK9tRFNjKwdNtWGnQ7SJHNQvsWM5xphJrdkpQcO+1b1mCZtta1bil3/9P3GX42PvgWP4/etv4eCRE2hp83O+1HBM1Jvdi8aGRlRw7lVwngY5psJcbdTV1qCmWiuMMFqaWlFXU4fahjbzkaIAycS9lBSM/X40Jk6cwjHXYnYttqxfhbfeeB1Xr13HdI7dkd+NRn1DE+dxs/kccnsHV0+Mf/bseaSnZ6KooBjLl65AI4WUdi8aaus5LhupGOytEY9g2PnB6rnB+RJCSjREAlBLRZyISxcvYN+evXj/3Q+wYP4S3EvNoLK/asaJFKhkflUtF6YkI02tbajkuKurrYW/pRH+9g4UlVSY8RYKhlGcl4dLp08h6dZNbN2+C3czcs0ntzWua2sbjB6JhJtw684FxO/ejYzMAkwbNxPLFq5kOuVooWIMakyFfWgoL0Y5x2hDK2VhVTmKy8pRUdcEnwiNggRIkLraEGyvxYlj+/G3f/cPVNaL8OknI7By0UqM/eZbkqa1zL8Fjc3NjE+d5+Mqn2O3o60JVdWVZudAOxUNtVVoZn212Lty7hJ+95vf4m7qPerCFvi1UKTcrmYdtOOQnZuPhF172D7Npn3sfNdc4JnTw+hkkYsu1qG6FH965wN8O2YsynJTMWf2dPzpw2E4d/kaxnw3EpOnz8W5W+n47R/eQfz2RMbXLkoY5eWVOHToEG7fuY61a+OwetU6jPxmDA7sP2IWuZ9TV7/37kfYt/cAzp07g+kzZmLipJm4cOEm7qfl4CzrUF5RiQDrJmLmoyw4ePggJk+dghOnTiM3r4CE5DRKyypx6vQJ/NVf/w8SmO04fIjE7F4m24TzWxWT6QHJhdk2okJsri7G9o1rMH7CFGzfdxwZRTXw+TqQcv0iZowfh9OnzmP63OXIzS/G5TMn8eUnH2PhkhVIIBm5evMONmzcipkz52PatDm4fPkm5s1dzBXXTly6fAVXrl/Htp07sX3PbmQV5GPz1i1YsXw59uzZh1Wr1iCFwnPhgqXm2w3r12/BzZvJCAR0z0kdIMFrizsUhZPKZMslBiqBaslFmMw8Lm4t3njzXSxZvhb/9C+vs553OEH3YOmS1Th85BjSM1IxigJ83vxl2LGT7HLCGHZgKQqKCrFxy2bs4iQur6jC6bOnsWz5YvMhrf17D1FRVHGCJ+Kf/vEPOHn8PAfNQWzevIPssqBv/zoMHahjBuicXmceOeD1NVdLLoI4e3Av/vd//28UHMcRt34r3vzLBzh15gJS7mdg3YbNWLp0JQoKinCaq6clCxdiEudpeXERSgrysGXDeqxcuQZ3ktJx4cwlLJi9AMdOXsS5S7dx+dI1rFm5EsO//BKTJ081H3bTAmNvQjzefvPP2LN/H+YvWoyVq9eguKQMBw4exoqVq83XFW/dukNh9SWWLFnGMbgfUyZNRRkFfU5WLuK3xJPw7kVOTq4hFN509ciFd3Z4mdCFzpAPqck3MX/+XDQ0NJDIlmLn9gR89OFnWLduMxVMBnWFXimtQPwOyvmEBOQVFuDy9ZtYsiwOCfHbce/WdSris1i+fBUWr9pE0tGEzatX4NO/vIEtGzdizsLluHwnHYeOnqJuWGnk2UbqlPbmCuzcuQHz49YgM7cU86bMxcRR47CBeuJqShpaSGS7/e04mrADM2bNw+Wbtzhul2L2/Pk4eOwCqutbOe44u3TrpEvfDmpB8p0r+Ov/9X8wfuIcfPP1OGxduwVTRv+A9es2opAK9PDRo5i7YCF2HjyOGhL3C2dPUk+txBmSqJTku0jctAnbt+5AfV0z7ly7g9/8+jfYsm0n4hP3IOleOvYcOIxN23bgZlIKyXwHFpKAHzt1DnrwVMSir9EiOsxy+dEZbMfHw77BR198iYvHd2Pi+O/x0cjxSM3Mw6ypkzHqh4nYfuAkvv1hGnXCRUQ6dcuinSThEjZTXxQV52Pq1KnYumUHxo2dSvK3DCdOnMCHH36ATRu3ISc7D0dIGqZMmUozmwRhH44eO210d9ya9cjivNWULeciZdTo7zB1+nS0tdsdDd0q1S5mSmoy/u/f/4oLnmSTr/qhqamN5WdERTaQReRCe09UhhFfG7Lvp2DFqtX4jKxnzZbdZKG1uHPlJH77q7/FkYOn8C+vv8eV9n1cOnUKo4Z/Q5a0CaNGjcbMGdPJlL7H6NGTMYKNkZSSg08/+wYbKAAvXTyP2VwFxTHs2CkzsIMCaeH8hfj4vQ+xcdMWfEKScvvmVXz77ShMnjEfU2cswqq4LYbdqrzWWAU+FO/ZemUSoZAxpTXkIkxysQF//5s/Yt7iFTh+6gwqS3KwfvUyTJk4DaO/G4Nr16/iqxGjsWXHAezfdxi//MVfIzP9HpauWIoPPv2MzHoObly/Rea7G5999RUmsf2+G/k9CnMyEL95A/7l93/BvXu5WMeJt2lzPO5n5pvtOIchCM23nsnXix5nHSQFSU4hgkFyeu7gfvw///W/YtHCZRg7fgp+/4c3cPz4GZw/dxmrV6/Dn//8Js6ePYfMzAyS1JEYMWIYV3v1HEOpXIWtwlcUVHFrtuH44TN46/V3cObsNVy/fQ/fjvgOm9aux8RxY42g0Q9H6aHu/bsT8Nvf/gM+4Urn/Q8+QmFRMSoqqyjot2Ls2PEYN24CjpAUv/nm2zh27AQunL+E//2Lv0HSnWQK5g2YNXMOVq6Io1LYhlYKVW9h4M0Re/ZqbGrtMOSh3dgOxG/dQCW5Cr5AEHWVZSgpLMS2+F349IsR2LV7D1f3dSSXcfjL+59i8sx55hbv1avX8M3IH5BAwpFF3bJz6yas4YLrf/3qd8jILccqEtixX3+Fg3t24f2PP0fCoVPYsn03Pvn4MxKM1fjT62+guiSXJHkZfv/uh0jmKnvhjHlYPmcBFi1YjAXL1qCUJEXfwrhx/jzeoU45f+UyFT3H4tw5OHjkDKpr9OuonE4Moxsd3V3NSL59Ef/f//bXXEjPxolj51CUlYc5kyZiA8dwQXG50Vtz5y3En/7yIS5evoGpkyaZOXDm/BXMZd7fDv8aoyiHc3OKkMSF8G9/80/YR0Ix4rvv8Q1JypQZs7CUZHw2y1hEsrJ+83ZMn70QQd02ZFm0k2LuGBj2rTlh572eq3j386/wL396HZtWLsBnH32I90dOQEpmEWZNnoZ33/0Y//Sn90jE4lDX2M4Z1IXGxnpsj9+JTdSljU0N2Ls3EcuXLMannw7H1vi9XOhfxcQJ4zHq2+/Y9lxs3LqJDZz7ixcsw/Zt23GcRGrsmPGYxcXHqjWbze2kgoJcfPTJR4asaedTU1Xl1kZE6v1k/Opvf4FkkovzXKRMnT4fBYVlpo1Ndcy8Vlt34jW9yiLB0lLXiFQKiXwyzq2J+9lx61BWlo+8jJv4029/hxNHzuMPr7+PGzdTyEAv4vuRo8neEsxqadPaVVg0bymWLt6AA0cvIj2vikpzPM6RXVWWFWLerFlkONsxesJMbNl1EBvjNmLEJ1+RMW1hI3zIfC9izNgfMH3hasyYt4YdsxU19c3mqVk93hhhUT3FPdTQn1x4r135/X6y9HX47PPvkF9WhRBbvyI/DUtnTcbc6TPx9bCRuHErGSO+n4bEgxdw4vBZ/Pqvf4FMdt7EyePwxjvv4wgVSW52PhJIyIaPHoeZc5ZgxJcjUJBxD3t3xuP1Nz/mCqAVVy9dMETt9OWb5ueETR87DC2oUwboGM9Zr23rB5I4oNAVDKKb5PQYSeU//O9foqigFJco5N5772McOnAUR2hWUfj+/vd/wMmTJ5Gdk4Xf/O43OHh0P+obqnHnznUK56UY/vW3WLpsPU4fv4Rhn36DgqIKruSa8BkFeSIFy8ypUzCOgkfbueFQCLt27MBHH32EYydP4aOPP6WQ3WTuha9YsQrjx080CwmRig8//BhXrlxjPsn4xS/+tzkv52pz1qy5iFu9kcpgI1czJBesmGd6dx01XzwjD3syxmEIgtI31IyN6+Mwd/lGjpUOVBbkoKaiDOVU3HOXrMLquNXUH3nYsGoGfvMvb1GenUV+XgHu3LyFKZNn4MaNm2hursfGdaupB9bjv/+v/4t7GaVYv2IDpv7wAxerx6jMPsPOgycMuRj59Sjs5Mr/d//wG5TnF2DNmg3443ufIfleNhbPnod1S5di1bIVWMFxVlXbzLEFNNbXY8LESdi2YxvSs1Jx4NBBxG/fhdzMXCTdSkJ5XZP5vZKuzhbcvnYWf/f3/8w5lYTOYBfa6+oxc/xYrCMhyMzIxUKS+RUr1uB3v/uj2bEfMXwk59lZVFXVYerUGfjqy2FI2LkbJSXlhli//sc/49Tpcxg/aQqGfTPSPDOxgop8Csl2HsnKJpKwCVPnoCPUZZ/JYHmjy1COez0bpYdcO9Hc6sNbXFROmT4VrZWlrONyvDNiLG7ey8PUcVOxeP5iEqcE/OW9L3Huwm0Egp3mluhmzlPtuujZqaLCbKxbvRRjJ05FalYxFx7ZnJ+3cPPmdRzcvw+NNbXIzcjG6aMncPPKJdy9cw3jx43BggVLsXjFZoRYjvr6SixbsRijx05ie+ShpaEFJSRJ+sDZrTtX8Mtf/hV11y2cvXQTYyfNRU5uqd25MDUSsYjwGMFr3WRzEmytDa1ITUrFmXNnze7C9dspaNcTqy2VWExysGXddowYORknTl1CQXYuEuN3kAFtwr5dO3Hy2D785c138H9//Xv8MHEOLt/OwPfjZ1EQnURrUw2uXriI9Wu3YdmarUjX7/nfTcO8KbM4KNdRaH2PK+cPYfQPo/DR12MxZ+lmXLjKvMmY9FCNOkPFtQ/kWEU+lODtqJinolk+3RbRA50FBQUUtgvxxbDROHLmEnxUFuW5aZg/aRwSt27HyuVxyMjKxZotu5Bw4Ax279yPL0goUu/cwK3bNzBj7gJcI/loYr/sPXgMEym4Fy1eiYnfj0fWvWSkJLNjx81ATk4pkpJuIz4hEVfupJqHnByGIPopUO/SMxpDWoFJE3eHImivb8D6pcvx/p/fRiIFWRwF7Ccff4EtG7dhy/rNPG/B9GnTce7cOezZtxt//ssbWLl2Be6n3aXiP49lSxdTQMRhx84DnKPH8O2wH3A/PQctHQEcPXQUyxcuwoLZs7Fw0QLUNtZR+Ddh7arVJPufc0VyGecvXMJorsJWUuAuWrTE3OJbvZornyiROH78pNnFeOONtzj+7iI5OQXLlq2k8thGexpCIT1hz7rxoLO9TWJqGmOinp5xGIJgv0VazW8czVq0FrmFFdi9nav406fR1O5HQWklkpKTEOgoR0GW5NZiHDtzg0qvBZc4hqZPm2V+K6m+vhpxq5biABXcsG/GIz2zHFfOXsPyOXNwKDEeX301DLsOnaIc24cpVIwa45998BGyUu5j9ar1+OqHKbh7P4dE5Ay2rVuDDWvW4p5ux/gj0JsTehD+wsULOHz0IKpqynH23Bns3b0XRTkF2MX5k1NSCT/HWGtLBeI3x+HNt9/Hds4Nf3sI9eXlWDJrOlYtWYLUlDTMnDEPhw4e54p/qrnlEx+/E2vXrEd6ehYuXbqKpZyXItd6/jA/Px/r1q3HuvWbcPDwEVwnodq0bRsXyKtw5uIVNLX5sWTFWhw4fNr84qvZsWCrRqTbdAtdy2c9jMoFvp7P+Pir4Vxoj8Hp/bsxffJkfKJbQDv2mjbRb1ClpKZj6fL1JCDzkc++0Js7Z08cxdbNm1Fd24irV6/i6OEDSMvKRos/RFJxEwvnLzAL2VqSqK5QEIG2NuSlZ6CqopTtUY89iQlYvnQVbqXkIUD5o9+0yi/IxvYdrDd1/BGSvty8YlTXVSN+6xq8884fsSU+HoeOn8fS1VtRW6/bIqyYFthRYqHja2DlVLEuMrgABU9lVRWKysrR5tcbxlTt3QHUlBWhiKQgO7cIFZU1CLZ3oLGuDiVFpRxE1bh6+RSmTp6CsWOn4qtvxiKjoByZeYWoqq5iQTvgY2WKi8pRzLgtwTBCgTBKcgtQXFKKvPxspN+/jm9HjcS46Ytwl4y2uT1onvQVsRCTospm4dkRuoUzBOERDO8VVO1eNDc3U/Hn4156JgrLKxHs7ELY14YyDsba8lpUVVabV47K6hpQXF2H0uJSZKelo7mhHsFgAHlFJSguV/t1ooJsM7uwkCvYEuSRibe1NCAQaENRXgmaGzvQ1NKE4ooK8wDS0Gwhh/4K1Lv0jMaPeRuIF3rTI0ShUZCdg/R7aZwjBcjKzkNaWoYZAxVcMVVXVaO0tJRCux5l5WVISU9FRnYGx10jWjg+ystLUV5Zxflcj/LSKmSRWDTrYWAKgdbmFhTk5qGYY7GopBC+oF4rC6KQ+dy/n4ZKPTjc7uP4zUFeXh7z4SqVY1gPXbdz7uusB7YrKipN+GamFwgEuZIrRVlpuXleSm+zqDre2yxu5+JlhSQKdUBNBdZt3smV633k5+VyPLCfw1xIsX8DAR9lcyu6wk3mt5FKyqsRpIzXg5l5VJgNlGmhkJ8yr8T8rlIe9UZzS5AL1w6UMq3KohykZaShpKYepZSL+YwjeZhF2dlSW2+23e9RnzS0dsDf2oqqkiKUFZegg3qC4tFu2VM3dPg6mG4jgmE/y1uJGo7TAMNU6wF6XxB+6rlQkGM/P4PjNh2FheUsZyeVbSuK8/SAcj7T9HH1X2oeTC4uKjPXDQ2NDFvEedUCv19vAhYy/VqOcepMruYbGxupjAvNw/p+zqPK6mrk8rqZ5COL5V4ZtwHlVY1mx0Jvr2io29+Eot7t+ShVhGlW435GhrnNWVKQxXM6UjNzkFNQhGyShezsbNav3bw8kZaZjSb9giwboKQoCwe4wLiXlkWdWmlelAiyrqIuba1NyMrMQg3jBJm5Hs7tDPpNO4ZCAS7gw9ThVpe365VczlO9FdPZGUBTk+2/IvrprUY/dU5+7j0SrttIupuK3fuO4fL1VBI76WdvrOhNR9ELvS2iT3nqloMqzcbS6kn8w3ulp0v+Ztumi4VjJ4p6seDm3rBaiY1TXJCOxQsXYMKEaThw9DT8elpcDdjFjLo6GEaremVLsmDiKJpueChMCFkZt81tkfnL16G0usG+o6xBo/B6f1d5ecJoiKL39oiIhjpHA4eEgpNPddYru2YmmHM0HNs9xHppu8487GZniammJVZ6pYrOut2iNpSgZvxOMku1u5rEfCjFDCQmS29bCochB/ZN7PD1LmXMPOMYUP+KYJjPEauvOY901tyRv3mNmf3fpS8IaqzQ3dsR0JwN6cEwjhXzgJjGHseGXg/0MlKSykuvMRtpoJWGDF21e2m+W8Exaj7BrExVNrrp9VNdmvyj5REUVtfe2NfJkAoNcxXdXDPHaHjlbk2Pg4Uu+zk5DBWw/yj/9dpjaUkFlXIWSYV0RHQ80KKFXzjC1Wu3H0EumMxYUd9rbDCMxqJRoBR85nsMjCsxZ4aC3jmN+JhW2HyNU+JR8buoH0wiZoyJ3lAe0pgLLuCkp5S3xpnS07i2Y15fLKZUpd7qCjPF6PhTuvrGktmplz7TNSOyeDxosDKsKSevaWK/u2TKY8a9ddB49x5OtotK6yc3zRvJYxmlnZZBgs4FgT6EpeowGYZTfPrrkQTNVSu9WR7v0wIiHmxz+um1cbYi0xdV0J/KrF0PheGF7KF2kr0S5JLItLf7bflVRuOtb1EwH7rRiQdVWrrD6nmlqrmvvvDzJB0t/WXaj3H1caxoVZmYFJeP7gGzyZCeVcAFMsupcigDtq9SUM7qq9cUQb91wXoYvqCW1EMdJhMFVoKsdJcEjCmcEmFHMGMLrVLa0drSbF5H6iDDMU2lBpetW+REwg4IMgMJLtNCTMd0BCshNqkfq2kk0zPvRtNfWSmYaU5jUcFlGVrwPo5iyILpPdk1GNR1bFceAxpYcteHQmQxF/INk3jo9o8dnFYi859trZREFmxQdhcJhbknryYwHcWBpwmoSzqqz+Sq8A5DEGYMW6vgXcYa+x49e14XkkSacJwM9lLHKIwXrzVmCB39+m4Abd5zP3JVEC8ZxYlQoCmshJcR6j1jVPlqfts4QZGaKDwyEc2qBxJ6Ui6CHboa8+bS5GEP1s8KZebzsEWCLvs5OQwVSIlROZFcSP4EucLkQtWSAJ61y6bVsPmdDqkqo0hsLxujMWXkIscllZLGp76uyQU/ZRoTkbLTj2cyrjc6zFgw84AuPMnNR6M8qfVppITlb6MrGXkxBNM36tLGlbzkBNDnvLXIk2xUXVQWQekqTSNX9c0Ic+vdpuSN2/4fv7Jj2cK7lrFfwrRuZqFAu+aSPiWgbz2FWMhgSJLahrFlsOXVVz+7Tbls23WGNJetkjZ1ZJgw2878fAb97e0UzT/5My/pVRIu5aVXfPW9G01NW0vlYdPR/NaH9lRPES/t9qh2+h6HoBoY/cy2MItX046KRyvPSjHib6Gd+ZB8+YK8VnkVXf7Kx5RbFI7kwryiIw8lIEHCgtovatJZlYnoy5JWcZkwhn7p62xiiFKCZJHknBJRkklKynzz3drY+WwUVkY7HmZAMpz5pDHtuu+kRu3utL/uacaaosmdf6qAwnkNaC+GFvqTC2+wyZiPX+lMfzO/VHy1jZkNGoRqa20gse04YewPxjENtrGCi3SYaKq72KZNif8cbPraHK9CDKtBZliz9XUYijDj2FoF71JGwkdzyfM2z+9oIrD/jZ1uZhypnznJzM6GvCUs6GaEBP3b/BLBTI/++kqfhIbmnREOmts6cQzpOykSBL6ONhQV5XNRUGfyUgCTLcOZfKN5xo5tucvNQ6xQjXX3yIdJVgfmbITcQJC3w5CFxgx71Mh+kQXtIhhZLUUlQ7kVlHKW9JGc0jilv/mAlRnbJB9G6XAVrYUm49shwTERElEQ6bDkWDLfkFaNJSlVLVaZjnY1TEyNIbprLOnrkBrbKp3iSpeZlTrHdzjIFbzKosj8lyrRTrAZhyyD5ovqYLSKEjGy1+oYPYwfO/a9ca05YImShTeu9dVkFU3h9Lyd0ZuU0UrXzAObrDEmuuIZvacFoxbempuaL0yH/iJsEbaJ2dkIsZ4kG8FOP9uGabMO6o+wCICIgyFnNm2lYvrApEdfepnPk5P4afdRQY2HwjCuZIp0stpBXiqmqWt3B0MEzY67ectGO0DSU9JD2mxQ+0dTUVX0nQv7rQulYsmFSveaSVKhFIedZRpUf4xkt1fJUpSAl5o6rMvwSPabOoiDgYNG6lB9x3ZhQgyiwhj2o0wlnOSmbGkx4SikaLe0pVcJGwFktq3kRyhPy0rkq8OQgzf4zCBRw0XtqoGubE1ozEDgFc9260stwPYzA1F+PEc40eiqZ040x0x6ZvAzLTWuJoEEOp31tUU1DwMxDSkSc/WzgtrWU3QeYu0vDVTkmGJ7l7HG/CYBhY35bD7Hh/dDR0YIGAkVhSaa/qPtYOKx/83nvSUMNNnkrzHTp900TjVGrGkgqTh4cD9u3rxBPzt2jPCLQnGVlje+Y4WrkRNe/rR7YeQkBRQL68dxb/IfAH2DOwwxaHte/UeLIRSS6nqGTNv7ZsBw7FhZLrsUHqkEhZfEttn5kowzOkJG8o4JqM81WBje3vCw5MQMBR2UriHBzJbGqFK6mY/MaZdE8TQ+OaQ0qoJS8NQj9vkFusgorJQ3E9CmsXIx8pPhdDTGpM+DGZuaOzpbeGPdmweCzrHjni42P9WT11LA3g5dnzniTV9e21+JpZF+VH5Kny7iQcaitPTVUZZH0c38MpsANl21ktpbC3fjxjgKJx9D5Jimmc4ma5VPbaK5y3wUjnXQbS5z+4Mh1C562NXkb9quleECpn200WCIkEiFElTZFY9hzdrfy0dnUxfd9rIE9DV1djdTDbeF0NTQAj8HTzgUQXVZOaqqytDs60BWcSlqG1qZk1LsQHtbHXLzc8wTqVl5XPm0NJmO1z3e3kqpYUgg6K7fQ2hu0QMkGiKqpJpHXSz/aMU5ADSI1GDdJC9SltFkFJBhzNVLBZW4t9QaGDLRgaXhwZ7WQ08F+QXQb5CIuUYiPpSXFaOyth5BjvxIwI/a6ipU19YZFt/Ja33ERq9FifRpApsRYwYy7T8jaJzowbHMzEzz4JTGgIzIxrPAG0v9x5SX/qBAyQ6QtJwMsWZdRRIam5twNzXFfMFVs8RGk83MXhujX1qyaprI9KAnjA5e3F6j9PQ55wMH9uHOnTt0c3B4GKLjhkNJ00PSy8zAnjEWMz6lAOgWvTKw41crWip/z7UnruQgV+mdPjQ21qKktAI+P9WdFDeVtK/Dj9KKajTrd0CM8qKck4LTmQpDt/RFEIJRxWaJh/KgI8P42ppRnJ+H7IIiNAdIKnxtKCrMQXZRMRp99lPfZpdQxsR7nDGFHgAPD8upbWD0tHSoLLpFFPGjo7UFlWX6+qcf+pK2CcswodY6FBfmIa+wxLzhpYcvq8qL0awvODOQlYCWSAX8ndQfAbZbm/mSqL5sqnYxRWBIfb69qrISVTW1JFld5s2wkqI81NVTx7CdgyymNLPIgshDV6gJ9Q2VKK2uhY8LHdEPkRG9rl5WXIhcyuPCkjIEyBMaG5rYnnqxoA3+tnYEfe3sjy5zG+s17Tzod/ML0zKxdf1W5JZWoq25GVtWLMWS5Ytxt6AAX303GQf2n2FjMONIO3KyUjBmzA9458PPMPKHCYjbuBnlNXVmJ0MbG+bnlyNBtDQ3mi97FZdU4fzF6+aT32oMbdeqHvrJW7NDwXjqV9O/rGY41Gi2av3aajF9waHJBjdt9ULwsAH1cCiGZ2wve8RCnaWdGTJc1uvShSsY+fW3FPBJhnw11Vea77cvWrnevPfcWluNfbv2YtWaLRwQZchOSUbcsuVYsmwtCiv0VDCTMxNE992kHHn9M4EU/fXr17Fr1y60SdlyUnkrh2clAUpHhE7kpbq62uwSDBqxEJT2AOnLRfma3QkKyOLSEmzcvAllFeXGzfgb02vrsUYhq4aBTA96wihmjPCP2vVXW1+L/Qf2I+n2HVs8GzxqcXDwICHMU3SMaL0bXfrFjBeNvr7hjLOBxhzlXQ+5UDiOS5EDLul1i721pRbxW9dj+IhvzbeUtKiqryzH6ZNnsHv/YRRXVVFfMA+joRWHuoNzWD+cp9sd9rk1e1vEuyWhZwuSb1zE998Mx+jxM1Fc04rS/FyMGTUCoyZMxv3cArPtb34AUMUyiJavj/Fq07dWfSH3geJFQavyMM87abeBZfV3NOHK+fNYH7cZp8/eMq+O6nkU3WoqvJfEcn+D7yfPQUpmPlLu3sW2TetxcP9eNFEWmjsJ3SQn7S1IzSxGZl4xUhlnC8McOXgEjfX63Dh7hWSrraUeBxISsHLFapRU1yEjKwOzZ0zG9oRdqGttg0/6VTpYZe6mDqouxYHdiVi7ZTvuZ+cgRKUuva2fAZk85nu888abGDN+OnILyrE7YQ/mzJqP40fPIOd+Gu7evIa6lla0sXivGZXn78CNY0fx+UefYcf+4/C3tyNx7TKMmzoJadU1+OiLH7Bu9TZDQrq72tHeWovly5exw6Zh+bpt+Kc/vYWL127i3v1MXDp3Bc31TaiqKMH2+Hgk7j6Ek6evInHXIVSUk5W2teD27STkFhWhPdCBnNwc3L6VjPv3clBcXI6Ar5HC7jQWi9jcz0VWRj6uXbmJRjaChu/DunZw0W+gPAFM30eNHbmcDMZ45IJTlBUqZ53HfjcGly5d4UCPoKGuAgmJ2/HFyLEor25Aa301du/chWnTFyI1KQUr5s3Fprj1GP39FGzaxb4ymXBYcEDq/t7PCSIAt27dQmJiIlpb9Rnf2O13CZNnM1qxf/LJJxg3bhxyc3OfW7oDG5Ei7S4N5Mf+05n555PMr1m3FpXVVayr7c+eceShn4OsahXbMlF4YWiUco9Qp5FdCqKmvo7k4sDzJxdPGf95ZOkwmOC46ekkjR4Rhais6XHX6OsNZ8ec8TAO2sjXmNPoM2E5t/VskJ6PiEQCqK4sxN7ErXj99TexdftedHB1vW7pYoz85jsk38uAn8IyRPlYT0J869YNZGVnICM9HQW5+Th/5RryiospZrn+puI284npB/3t2Lt9I8aO+hoJ+06ioSOE00cO4YeRX2PLrj0ob2g05bHPRXhl7Z0nveYJYOqtQ2y8aJo8iRPZMLRoh4UkqKw4D+tWrUbijv2YMWslCsrsbnTI78f5fXswZuR32L7/BNJyS7Fi2QocJrGYPnUKcgqKDRnoDDUjM+0e1iUcRlJ2PrZt24A92zZi9SL95ks2/KxTmO3R0lCJ4zu3Y+L3Y5CaV4gWXxtWr1iENRu3oqK51dyCtz9OqOdAOpB2+waWL1yIDVu3YeOORNQ2t7CNOlFZWoyELRuxeN48LFi6GreT7mHmtOlYsng5ddZ+FGRl4xBJyYVryagnYXtNz0G0NtbgyI6t+PrLrzFu8lzUlJUiIW4xfpgyCfdqa/HpV2OxZvlGtp06rgMdJBcrSC7+8OYHhlnNXLQCl2/eMR/cmDxmGjav2YC7t6/hs88+w5z5q7B6zQ4K8GnmOw4njx7E1GkzMWvBIhSUFGL33n346svRWLxoHdas3oiKkiysXDoZ7374Lk5fuIW5M5djw7odyKUS1ju4T9jVzxmxgyU6YB4DhfJiaSKJSWhqaYoZkiFFw3FWVliCifpK3eXL8IWC8PlasC1+Kz4Z9h3SczgQmuo46fZg4oSZuHrpMlYuWYD5M+dh7JiZWMh28TEjM3CZhaeofk64ceMGJk+ejI0bN2LHjh3Ys2ePIRsJZOLa0fgxRnFlvv32W7z22mv4d//u35lv8stNaQ8U59mN0lWZdX4wD+Urs3zFCsycNdt8S8Lu1FgR3adX+znIqiEg0wMvDI09yWKN/rSGrH4UuTAXPxJPnIYti/fnMEThDQ5z8siFRluve4+0M3adpKyiF+bK7luYMaqVu+ShlLpIBq8j4Ta0N1Zh9+59uJWUjuqSUrz7xz+YT9/Po/Kqqq83tw1LuChdtHghF62JOHvyJHbFJ2DOomU4zcWZ3mjRboUeYtZt9dbmOixbMB1ffPQuVqzdhvK6dsQtXY7P3n8PK9dvQF5ZubnFIPFs1n+x9TCmp3JPCIXtH59HnsxDqrpURuZZiwDu3b2F6VOmIn7bbgz/egKS7hWbXYQ2rvy3LFuKLz74GMs37MClm3cxdfI07KXc+OLLL3H1zj1zeyPYXo3Tx49gdcIRpJeUYMH8Gdi5bhVm/DAep09fRqt2ddjiIV8Tjmxaj3HfjMKV1Ay0BtqxdtUirNsUj/KmNkMuDLoD5DytuH7qFCaO/gFrN22hbl/Gdqowjz106ofNgj6kpSTj0vU7KK2oQhzl1Weffo7NWxNQX1OLpGtXsHDFepS0d5BckEGVFmYjfuMajP1hLD58/wvcuXgeO+IW4Yfp05BaXYdPv/gB61dt4epKKy8ffCQXq1cuxzsffYX4fceRX1GDkqpa80Mzi2cvwVcffIKU21cw4puvsXv/KSTuPYGPPx6OG5cv4tvhn+NbFnzWosVUnhnYd+AQ3n9vGObOWY0J46ehMPculi+ZgAnTJiC3pAZrV+/Azu2HkFVUblbpXjv8tPAGi4wdMI+DQnkxzP4UlYR2iWSMzZALCvjiUjLKUTh/8Rx8YW0/dZkPJE2ftwyHjp8mYwyikp27atkanDpxHMnJN7BhzSa8//5wHDh/zbSJFvPmDRNtBz5h+V4WXLt2DbNmzcIBKkF96vrMmTOcOKefyZzi5JEZP368IRf//t//eyxYsMC4DRT++RilfTLGPBhG+YtAzZ0733y0SkLpmchFdLj2jMNoPJ00DkUu1K7JJBfMxgaPhjHmx+KJ07CqyjMOQxReX7KL1GOdHD3mxnYM6eix9JweRy54xfT0MKX89CWL1voK5HJBVV7Vgux76fjwjTdw9ept6pnPkZmfZ8hFR1s74rdvx+q1a5CdmUE9k4y4jfE4eeES05PSZtmYrR5EDASakHr3KpXyDoyfMhf3sypwLzkVe3YmYOb8+Th79SqCVJqmGiqYKa7K4pkfAyXixffqz6vopfkKr3k2JID0e0mYOWMm4nfuw4hvJyIjpwIBhmtrDyAj6Q4S43di1uLV2Hv4JKZNmYHEXbvx9bff4fKtFPOYgK+tnGG2YPP+s8guL8fSJXOwbe0qzJk03fwsfXs4wvqxTTrbUV+Yh7XLVmL38TNo5QJ2/arFWLdhKyqaWs3Net0a0o56V6gFt86cwtTxE7Bm0zYsWL0eRdW1Rj506/ZROIjz584gh4v9wtJS7EnYYT6JPmP2QhQVFiIt6TYmzFiEPJKW16qKc7F3dzzu3L2NUydP4eO33seMMd9h4piv8eE33+B6bhneensYFs5bSYbDxLv9qK0swJRJE/DxVyNxKy0P7ezN+1nZ+GbkSCyauRCf/uVdJN+8gO9Gj8SWHfvJgHYxjQ9w9cIZzJk6HsNGjMT567dQXl2BLdu2452/fIVpU5fi62GjkJ56BZs2zMG3Y79DZnENTp+4jQ3rE3H80vUhQi5kNGh6B85AkK8VmQxvyIUV6LopYieTdctIScKXH72FHYnbUNPcZH6E5sL5K9h/7CyuJ6XgAknH0cOHcPLIceRlZyAnOw3r1m/F/KXrUdnSZp7K1d0Q+yyCclDajy7bywLtwsQ+cyGons8Kb4enuLjY7BYcOXIk+jyQdR8MSNBaBdrPMDv7zJH6rxtlpWUc/5tRxVWB/MzHfEz8GPRzkFWy0QjuHk8aZRE9Gb/eLC25qKvHgf0He8iFla+0qA0U6MdCcfubPrCtYRWQjOpoS+8wRKE+NGNHJEH0Qhd01JjiqaebjcXr2V7oWjeFNe56yAXDigjoocqG2nIs58r7zTfexcat+1BVXo3vhw/Dtm27MGbyTJTVVDMcKU2kE+cvXMDUGdORlpqCe5SRew6dxJLV69DcUIsjhw8gn/Nar8a2t9Xg5In9uHTpPE5wJV9V225+QfrUiVO4dvMGCqmQpViNSInWI1oB7+JHoXds68849BplZuR0CDVVpazfdqxZH0+ytBWFJdXYmrgPyanpOHfyBE4cO44rt1OoW3OxY/tObGbYhSviUMCFh253BAO1OHnsMDbvOIzqxkYcOrQHGzasw/p1W5Gdno8jnNs3b13C4UO7cProUer3c0jKykNFdRlmTPoe06fNQV5pLS7evItNW7ejo6OR5KcNBel3sXblaqzevAsHz17Bjbsp2LvvIJrqGxFqb8VhtnFLIIis/Hysj1uJhQsXY9Gy1SgpKMSdq5exePUWlLT58Fp5XgY2b1qLjPxcssY8bFiyHCvmzsSSxbOxaO1a3MgswIqV8di96xDa9ZnX7iAqSEg2rFtrfiXv2t0087v6pZVV2Lp1K5KvJWHXlq1cbefi9JkTOM5OPXrqMtau34ys9BTkZqRgI/3vpmWa342/eOkKVq7cgt2Jx7GRSrMg7x7LcR079iaQXFQh7X4xDh48i6KaevNEa+yA/engjb5Y8+jBZ8YRj0ZoakDxX0NKg9mMMx6025B04zKWL5yJhN07UF5bg7OnL2D7tkRkF5aYB3du3LzOtt+FzPtpaG9u4IRKwqVrt1Ba22Ce8lV6Sld59aoY2X8e0M6FboXo07sengcJUHzvmw0yz4O0PApW0HhjJ8aoGjJm66AbpcVlWL92g/k8vNy1cyHYYxS6iHHwLq2Tlzavoo66Mqo7Jktd18SQCzWnjaUA0UA/FtF8+5g+sG3R3zgMYUT7Uf1kb4pojBiHqLs11qLlU98elV1yyoxDKVdjou4kDeWlBdi2fpX5PY+z528j0O5DKgnAVsrCG8n3zfMWSlNDs6K6Bjdu30JDfQPKispw+vxVXLmTjPbWZly7cgklFRUkLREE/I04e+YwTp48jtKyGvM244ULV7Fn915UVJbDr695qjgqswpiKvDssHNdfzZJ00w9FzJshS49a+JHelYWDh8/i8ycAvgDIRw/cwHp2Xm4cukSidJhc+vBFwxAP4N+VKSIZKqd+lYET0SgMD8HGzcmoIhyo7yymLr2JG4lZ8DX4set8xeoL25Rhl5E4k7qkKx8NPmDyM3LwuZ1KxG3ah2y86uYZjpmzJuP1pZGlssHf2sdblHHHD57E8U1jSRrheY3VVqa2tDR2oSMjHuGKDa3tuL6FaadkIhbSffQwAXa0X172RfpqA124jXdR2lra0EwHEaIpoMR2phJKxNpaW+DjxVpJwvx6XcrTAvpIRyyQvq1tLWz4mwkuuuejH7TX1+N9Hd0oKszZH4jQz/RK9PR4TMfGOmkezv9AyHdAug2T+m3t3XA1xEwT+/r4R69ltRB4hEgS9XHOfQ6kp4GftnUpi0rj2ZA2VPshJNDkIStrbWRbdJmnlwOsj3b2a7m4yWss755oHbRU9H6Poa+0R+km54/8uaDZ2JtPwdofNy/fx/nz5/vIRfPkwQ8K0F53lB5KisrSaYPoa6uLur6DIhWr2dU9FjsSXkc2H8Ad0guPDeDHouDQwxixs5Dx0qMZ6yX52zdNId757Hc9GCnr6MFLdQ/QSPrKO/ppt+yCek7NzaogZ7TCMvNhKF+8AfMV2V1S1lv3NkP0vGvO4xAoB1+vz4vbvOTfLWv/YseWQJgEJvBoEOZSZupHmFTfpVZ0G+TqL7Si0afmrpYuefzU/ZTR2u9YYtLXcswGem5yMnJY7v50C69GVLb0DdAvRm2r7GqHdVmihuim4hES7N+KyWC7JxCpNwjYdAHt0RausgFmH8HyY55cJRlsN/eYXt16a1E6m6VybS3n+VkH7H9i0lCMiivG5rbzVdcXzNldHAYotAXIDWwpXg9MqCz99bIzwUSHjKqm74Q6NVvMHdUDLk4QHLhvnPh4PDSwfvej876DtDTwJOlguTr85CnvTLMXjty4TBkoUnjKVez0hhERTsUoDqqzj8VeXLkwsHh5UWvMu9ddOlasiOWPPSH/DwTK1Nj03oWeGVw5MJhyCJ2AnjKtv+E+DnAq5NXT+/8PCb6o+DIhYPDyw3JCU9WeHLxcXJD/l4Yz+7JnGeBJ8M8OHLhMKQRO1FiB26s+88BqlvshBeedbI/Do5cODi8vIiVF/1lx+MwkLwRnjT+w6D4XtqOXDgMWXgD1SMV3lnuzzoJhhq8esZOTmEw6+nIhYPDy4tYuejtXnjmcegvb7y0nlXeKL7KovQcuXAYsvAmijcJPLfY658L+tfVs8sMFhy5cHB4udFfbjwpvHhe3MGQNY5cOAxZxE6Wh9l/TvAmu2cfTGIhOHLh4PBy48fKRU/WxMZx5MLBweG5wJELBweHwYIjFw4OrygcuXBwcBgsOHLh4PCKwpELBweHwYIjFw4OrygcuXBwcBgsOHLh4PCKwpELBweHwYIjFw4OrygcuXBwcBgsOHLh4PCKwpELBweHwYIjFw4OrygcuXBwcBgsOHLh4PCKwpELBweHwYIjFw4OrygcuXBwcBgsOHLh4PCKwpELBweHwYIjFw4OrygcuXBwcBgsOHLh4PCKwpELBweHwYIjFw4OrygcuXBwcBgsvBb706uxP78aaxf0c6ydnZ0P/ESr5zZQ3IeFdXBwePFw5MLBwWGwYHYuYsmBziICnpvn3h+x7rHh+rt7aTk4OAwtOHLh4OAwWHhNyt+DRxL6k4FYd8/EEpBYAuHtTjyMoMTaHRwcXhwcuXBwcBgs9JCL/kQg1t4fsWEfRjK8s4dYPwcHhxcPRy4cHBwGC+aZC0Fnz8Re90dsuFhioR0Lmdgw/YmHIxgODkMHjlw4ODgMFnoe6BRiiUCsm65j4YWLtXvXsQ94esYjFkL/tBwcHF4MHLlwcHAYLLzW2tKM0pJi1NXWIhQKoaGhAaWlpejo8JEYPEgkOtrbUVVVhVoKpoh2KuTVxTBdEQqrWpSVV6GTbp0mXid8He2oqa5CPf0CgRCDKoJnYo8Mb+xReOHsf49xcHB4PnDkwsHBYbDwWnZGGsb/MBoTx45BVlYmzp07hx07dqKsrBKdIg0MFIlYtd5N1lBWWIp5s+dg2fLlaGhushxAHKPLjz17duKTL35Asx8IMaY/0IE7168gfuM6HNq/H9dvpaLNF1BCiNCvtc1HEtLF9IPo4p9uqiir5qYWREJMhOGUfrCL6dGwOOhSmUym9OY5lvw4ODg8ORy5cHBwGCy81t5Uh70J8fjso/cxa8Y0pKakkGTkor3Djw5fEAUkEy3NHQgGIgh2BJCdlokZk6di1OjvUFBRgtKSctSVVyPka8TBg4n41T+8h6YgECC5qGuoRuLWDdi9eQNy0tKRlVeJpo4IQv42bF23EucuXEUr8yivLEVZVQVJSQg5+cXYtGEjCjLvoro4F0UltSir8aO0qhm+QCcam5pJfMrQ0tLSc4slEomYs4ODw5PDkQsHB4fBwmuRsB9Z9+/i2KH9eO+dtxG3Og5FxaVU4m1Yt34zpkydhenTZqOqsg5H9h/GhB/G4fOPP8EPY8cgYd9u+s3C5+9/iktnj+L06cP4m1+/g+pWwG92LtpxZE8C3vjtb/D9iJFISSuEjzwg4/4t/Pr//HdMYbpHTpzHyG9H4avho7Dv8FmsWbcVr//hX7Br2yrMmTYa7334BabOXo33Ph6J28mZWLkqDjNmzEBSUpK5jSNioZ2LcDgcrZKDg8OTwJELBweHwYIhF/k56WhprMP27fH405/+hKPHTuDmrWR8/sVwXLl6E2/8+S/YvWsfhn/1NRLjd2LpwkX47vvvcPnmNZw8eQZv/fENbN2wEseOHcAv//5ttJFAaOcixLRb6iqRlXwbk8eMw4hRE5FfXoOa6kL85v/+T6Tcy0B+URXit+/C19+MwYq4eGzashNjfvgWZYUkPAe34N0PPsWOPWfw4WffIyklGzsTdiEhIcE8F+IRC7dz4eDw9HDkwsHBYbDwWktDLa5ePI+WpgbU1tYgPj4eJ06eQlp6NsaNn4w9ew/i00++xOlT5zF+7ATErYzDrGnT8c3IkVi8YgWWr1iNt/70JrZtWoV9+xLxi1/+ERUNYfPMRW1tJZKuXUJBZjouX7iA5as2Ib+sjuSiGG/+6R9x+sxFHDxyBhMmTsX3P0zG0hUbsWPnHowZMwqFBXdx4dw+vPX2+9i87SDeePtzZOWUIis7Fxs3bsTRo0fh8/mi1bDPXzg4ODw5HLlwcHAYLLyWknQLC+fPwZXLFxGJhEkIalFVXY1wpBO3bidj4aKl2EuC4esIIiU5FauWr8KKJUuxZMkS7EhMxM6du7BhzXqcPnEQ2+I3Ydi3E5FVWIdgdxfa2ltQnJuF4wf2In7zZqRlFsAX1hskzdixbR327T+Ey1duYuOmLdiRsAfHTp5DWkY2Nm3aYG6d1FYXYvGS5Vi7cQcmTJmD5JQMJCXfxcGDB5GVlWVuhXikwu1eODg8HRy5cHBwGCy8hu4IuruopLuonEkIpKz1uqh5M4NGJEP62+jwLr3AwTB008OUetMDxr2bUYO0RBCgk5+GKfKPlk6m28krnsMMF1b4br1eEjZxTV6M10k3+TN5m19XCF2d2v+wb5AonvxVJpXRIxUqh+zeB7wcHByeDI5cODg4DBZILkQUtAMgJU3NThjlrnPUCHoF1DrwELUzhlHsIiVdJAP6roUhAQwWobtJT2yhiwSF5MW8dmqSUGRLBiwFCTOYjCUyJm2SEVsmpqVk6KzSyVvwCIaM+zCXg8PTw5ELBweHwcJrVmU/pXL2NLyBLhSfxIB/IgEyJojnZUgLSUzUv8cjmo6+cKHvXMRClEPpmTA0Jhnj4+Dg8DzgyIWDg8NggeQiqr1/NCxxUBpKRVc9RMBzMOQiYkLYkDrqNgz/aURLFELXxvBKexxmnyPq1uPl4ODwXODIhYODw2CB5OIZECUC3VHi0EsAorYeBx16dzZEGrp188Tc1rDUpIdcmIOIRYjuIdrpKyca4+3g4PBc4MiFg4PDYGEQyEV0V0JXcuhhDR650E0Qj1zQ0/6bxziMRWyD/p0I8mgfEjXRaXRycHB4PnDkwsHBYbDw48lFVOFb0iAyYGmFJRYkBeaNEFr7kAsZe8PD3AgRuaCXIRdeMB4ULsxQ+rPkwvhabwcHh+cCRy4cHBwGC69JYT+t0o5ygKilP7nQuyL9yEV0N0LGkgtzs4PuIhd6vsL+2Wu7A2LeODFhaMzbINEHPB0cHJ4LHLlwcHAYLDwHctH3toilBDHPSogXGIvohA0nmyUXdNd3NnilNExcEoze0Aojo0RsOOvg4ODwrHDkwsHBYbDwbM9cGBjtb60G3nV/EtDr1mPrOfQ3sTbCWPq4ODg4PCMcuXBwcBgsPAdy4eDg8DLCkQsHB4fBgiMXDg6vKBy5cHBwGCw4cuHg8IrCkQsHB4fBgiMXDg6vKBy5cHBwGCw4cuHg8IrCkQsHB4fBgiMXDg6vKBy5cHBwGCw4cuHg8IrCkQsHB4fBgiMXDg6vKBy5cHBwGCw4cuHg8IrCkQsHB4fBgiMXDg6vKBy5cHBwGCw4cuHg8IrCkQsHB4fBgiMXDg6vKBy5cHBwGCw8Gbl4yO+FeT8lZr0HshG09LnuZ7NX1tbfHnvt4ODwfOHIhYPDUICn455Vz8Wk80ByvQ59vLwLmj7uPY5Rj6hLj/sD8Nx7/Ugueh16bJ6FJhKJoLuLFmbS2amfPe+i1f4sun4I3fv59O5uHrv0I+kKQTcG6FI8XshurvXT6QpnYkfjGjemS3eFMbF5rRzkHw1lbDbWSwQVOKbQ3mV/09WlNpUtFiRYbBvPzxjjaqHrrqgx9q5OE/7BdJ4fYtNWuQRTrkHM81GIzfdhdoeH40WRi/5jpv+1g4PwLOPEC+fF0V8XdYxce41nex7oTcuzxRrpQqNGafdgy2h8aZfutDLci2SsXiSZKDzZ60FhjJ4wWlM6mmkpntSmgpq4qnun1RnmSkHYAkrL5CHfboRNWRTBpsWEjZGbXIybYtsoxuhC+ru7O0Rb2Diq7CQXfZV3NKwx3REmGGGoTlvKLpKHLqP49ScXKCljukUsIrJ1mdTCLHA4RDcyBpEGUySFUSN2sQpUhsbNtGCY54hJR+mDhWQzGH8b09pM2V4mRNvRg3cZa9TBndHOkwmH1QqC3Ei42PbqUv2ZsCIQxq4+sG5KSX2jODbV5w+vfBrEhnDGXL8oeGWIhcrzIsv0MuFFkIvYMePZ+/ehg4M3JjxZIznoze3HjRcvvLHzL0LZGJHOeYBcPE/0yt7+eUh395reMW8Xg5YMSCl3dgYZgWWU7gxSDyhJGqnILuli6dJoOwidvFZTUJUyXepdo0eZhvRlj9JVfMalnzRqhOmHmEZQ6agMaqdOZSB93IUgI0hPRyJBUyZ0Ki2rg6STVValpTIpb9WjS5sOjNPdHaAJWQ8mS3IRLQFBJ2PsgVABlQpJQySsSPpnYvKKGhubrqpwRC4qgCUYZueC/zqFmWFnhGmoMobl2MpFOllQNqoaWoSkUy2lwvNPaSg9u9vxEoL1NqYf5CRCETGdxmu2g5kw/DcDLzp45GB3L9QaNp5aV62hdvfQM+lMB3txny96JwTzVx8SsfYXBZXBK5sQa3d4NF7kbRGvj3R2/eUwEPx+f8/40LyOVawPgxdWi1ezgKXik04xilT+xkiKWruFbEq31+Xp8WB8L48IlbfnY+STqYM1RunTyC6lHg4HEQoFTdkN+aAONvWRAo+2hUmTpEt6QecI3cL0t4SAZ+rqLhEGBuwK8Rz24tmaK7yMCSLlzHNXKEwq0Q1/l3Sx8qLRn+S70T8mZVNOaSDTzvIzZMjrF+kCtjl5QCTS5ZELefQ2Rg9Y4C6RClNRJWTyMaGVjMIqK0MlmJkhI3LRLgQz1pV0ndkSUiymYxyYVicbRbANqIbRADAuNLY8FrIrjr16qWAawFpj4TkbcsV20KQxg4QdbBvYDijdhlJIQ0KNs8KFzMAI0NHrYEVReqYPBsrwOcFMDJMHu5r5yphBG3X7KWHbR6OwF7ru3flxeBxeBLnwxowVjnY8eW4ODh68MaGzjPDkY0X+iqNVthQ4EKSSjepbGmmtqKQ0B+kYydq+8uTpoDRMYj3w8vDks8rdu8OswkiB2x0F7UIoUDgUYjiSg64A9WJ090I6U+G0o8BKhKkrTRtIT9CPVIQ6gfXUJgB1iIiFrSHro/zUfkwiwvkWZJrhqH7uZHzTlKY43fCR1IhAdHcHGSVk/G0yKqvakfFYPrmZOwxqM7PwF/VgMJarMyyiwVrRn+TCpExj05GxoE2VUiJkRF2moqqMDa22sHnrSplEPUxDqFNtwVkfhqHFEBA2CoVKt9fLTKDHThNmw0TCSsteD2h+RpBwNUpSg8U2Jrq9+hNmF4JtpoFC8smwtg1lZxfbcCJ+JizbUv5e5OcMTWqVtbW1lcxaE8BO9BcFU99oGUQozGRzeCq86GcuAoEA2tvbTR96Y8rBQZCsEbyx4tmfBHa3lwq6O4BQmAqTOkZRjZG/kajWbg/KS4uSwZVnVtdZGa5HA8Ayaj9ApaEKMOVTgULhdp47eC2iYCKyLpwn5pkGRuPByF7tUDB+gEftOlgPBmc2IaYfIe1AZxt1SgjhALWyotAz4u2UKDjDSrUrOv+ZJ/VPJ/NmbC1oTZGZbpjEw9tgUHOZhW6XnxbtkoiSKC7zCDEmz6IpPeTCJGxMNDZL2Rn2I+hvR111BRoa6ozi7/D5UFvXgHYfq6SgCqsCKWVFM+RCJpoeD+aeDytotu0Vid6hYAgtTa2GZZmwCqcIHkxka/25wiMXpk20E8Heb6pvRFtrG921ugujqbEOzS3NZJxdCPh9qKkoR2V9G/yK00M+NHBEUjjEopPyeUMTW0pcyujo0aM9OwSm/H067qdDrOARPLtWxQ6Px4t65kJjR+MmKSkJu3btQmVl5QsbQw5DExoPIp8ao8GgVtK9O6WPh7SYyKof/kAH6hua4OvQboB8ZKL6TgcjLqXBtVzTeXDQs2MhXUmFrOcKu3n2+VvR0NRI2W6JhOQ4SBdCoXrq3Cp0tPooz4Jobq9EZXUZSkor0e7XcxVEZ4jhA2imvGujfo0EQmitb0Vbsx8BtlVABAXNzNKH1qY2NDe3Gz0SYnqNDfWoo64JUqeHQ2wPwxvYMixTJNyM+voqNDS3IhDWDjEbirpG+rujrQM1NbUIRAKm/P6OZparChV1TdRbAZKYMDoiIbSzriQXFrbRTfK0qZGlPMIoKsjGuO9HYdiXXyDpdgrOX7iO2bOX4M7teyyQzbTX6NompmcKtK2iDjXbNBoYbISm2joEfEGkpWXgwMEjaGsXQ2N4puUxTA8x1p8nDNFimxtKGYG/pQ3L5y3EyiXL0N7mQ25ONiaN+wHzFy5BUUUt0u7fw3cjhmHH3iNo0S0UMsZubV8xKRnTYk80+Z4enkLYv38/Tp48adw8cvSioFVvRUUFB3sNGhsbe7baHZ4ML4JcqH88Ynr37l2Tv/rP7Vw4xEJj5P79+xg1ahSuXLlixobGzpMsHLRz0dkVQCDUhGPHj2Dy5Lk4sP8ClZ9d+Q9MLqSwo0v45w1qbvO8oXSkdiyo3EUwfO1NuHDhNBYsWoqz55KpC3VLQrqzA3mFSVixcinitxxCRWU1duxaiz/++ff421//M27cTjX6FV0+tPkacC07A3ezs5CRnIoNS9fj4O5TqGrkgpT0Ap11qCrKxpoVm7Fp816U19Tj3v1ULFowH5OnzMP9jAJEpIOYr9klQQQVZZmYPGEcZs9fg7omv9Hj2hVvb27Arh078Oaf38Tde/fMxsP5k0fw9jvvYNaiFbh9+y5S7iShrqUVLUxpAHKhHNSBbIRuFo5FvHn1Ej75+CN89+0Y5OSUoKiommynm43DRsjNQ2lpGdvLh5C/jQowDTdv3kLq/XQ0NTWjMD+fRCKNLKyJq+4KbNuwHufOnMHho8eRuO8gGqlQMzIykJ6ZhfySMuQXFCIrMxP5RcXwhe2Wv1FiOtP8bGAqxoN3Jrlqqq3HkT378c2Xw1FTXY+Uu8mYOnE8Puf1taRUtq8PC2bPQNzG7WgKcIBysHZzsJJcWnLhkbxBgCf4tdI8fPiwmeRaUUgIvChz8+ZNI3y+/PJLrF+/HrW1tUZJqWwDhXemr6mqqsK+fftMO6rNZNR+A4V9Xkbpe3ko3z179qC6urpnfDk4CBofJSUlGDduHLZu3WrGpsZIc3OzIR3yKyoqou4pRUpKCsrKykw8hdFOsJ5bKC7JwpRpk7Fly2589slYZGZUGHH7k5MLZmLIhbkVEibXYF6dAZQW5mDd2jXYvmMvZs5cz/o0cZFNL5KG8qpMbNu2DfNmr0V2dgFOnz+IxcsXY8S3E1BUWk2dyFpEWpGelYy43buRlJWDXVvjsWdTAlYsWoc79zPgJ8HqDNdh99a1iFu+AVu3HcCh42eQkJCARfPmYvGSdTh9IQU+vxZlajcWtZvzNFCLfbsTMXXWSlTUtlpywYI1VFfiwJ5deO+ddzFvwRJUUp8nbNmA8RMm4ei5q6iu4WJlTyLOX7+NOi5+H0MugswwgMz7Kbhx7So++/QrzJ69CElJLLgviOtklFMmT8OcOQtQkpuJ25dO4/vvRuPLYd9i1PcTkZycgo1r4vDNN6Ow98AxXDp3Aa//0z9i+bIlGDn6e3zPuFl5BVi4cB4mTZuBXUdOYsHipfjh+1EYP3UGUnIKEe4kW+UK3ZSKhRyMrn8RMExcOzUiFjIkF+3NrVhFFjvs0y9QXlaFYMCPPLLSXXsPILekAqGADwtJLtZu3okmbY2RTWq7LaRdH7UNr+1zF88fZtLS7OZAnjVrFo4fP47Tp0/jxIkTL8Ro92Ts2LH4t//23+Jf/at/hV/96lfYvn07jh07hlOnTg0Yx5m+RrsGcXFxRnirPeWms2cfDBOb/sqVK7FmzRpHLhwegBaUOTk5+OKLL8wY0ZsjcsvnYnXmzJlG8R46dMjM+cmTJ5s57902UbhOKm+Ri/ETxnKMb8Ff3h6G5KR8ilrpuBdLLsxtEZp7d29j2pQp2Ba/F8OGTSdJqomSiwDKKrIxf/5CzJi6iqSjEoFwM0orynDqzDU0t/lYR5bY34CjJ/ZhZcIuZBaWYNnc+di2egMmjZ2K4+cuoj0UQCRQh7lTfsCKJZxra7dj5ZrNuHTpCsZ9/z2+GvYDbiUVQJvgppS6E8Fyhf012EtyMW3WKlTWdrA8bBUVTG+jRPyUG/tx/NRF5OcWYs7USRjxzbfYe+wsGpvqcOfmJSxYsRYlrR0iF6aZe45qeNvYlmB0hf0oyMlER1srTp86i7ff/gCbqdxam1qwZP5cDBv+DWbNWYjc+8k4vjceXw/7Gj+Mn441G3eQYWYgYdsmkovvMH9xHC6cPY8P3v4z0u6nYsWatXjnsy9RVluHs2dPYtKMmTh59Q6m8Pz18C8wefY8XE3NRIiMVU/EhlhAlWowuv5FwDyHwhFiWLZui7BjO0MRNFbVYtTX3+Du3VSEgmS3RflIy8xGc0eAg6kDC+bMRNyGeLRo54KkSw/aql1kmJg1gwRNXpELTW6tePXshSb4wYMHf3KjfJcvX473338f7777LsaPH28EjW7bvKgyvWxGu1ArVqzAxo0bDdHw2m6w2087X8pr2bJlhtxoB8XBIRaSNdqtuH79Or6nItRtT8nLjo4O7NixA+vWrUNubq7xF9G4dOmSieOZrq4ggqFmHDl6CHPncsH21XgUF9dG9dzDyIV03vPXMObBfGXUTfKjXQuRi+4w0u/dxcwZMxC/fR+GD5uCzAySCxbBvBUSaacOuIeF8zbh9q17XGD7kJ7JBfydTLT59LAq4OuoRfyOjdi8/zDyy8qxbP4CbF+3ETOmzMK5K9fRTEIWDjRh4YwJWL5kOdat34a1G+Nx5ep1bGD7ffnlKOw/SBLSrhc2dMtJZQwh1FGDPbsSMGP2SlTVtkGfr7LfuwqTB9SzXMkor2xGbXUTrl+4gKXLlmPhqvUoLMnF/Xs3MG7qXJQ2tfU+0GkaIWrs0TZGR0sjjh7ch7ycbLRwZZ2QuIedmQhfezvWx63A8K9H4ujJc2hrqMTti8cxgopxzsJVOHH+Ok6fPYd5s6Zh+PCRmDl3Ba5cuoyP3nkDly6cxaTpM/DbP7+N8rp6FBXnYd7ixdi67yhWxK1hGl9g9+HjKGsiaxITjZILvSVhy/fyw2PYhmSQXOgW04kjR3H1wkUkxG/nRCjBvdQUfD/qG3w/Zixu3ElBaUkJvhv5DSZMnYWS6nomwvjscA00u601ePRLZdVkl1LQ7oCgOmgiv4hVp/LUMxfaDpWpr683t2kcnhy6jbR3717cunXLjsXomJQZLCgPLx89cyGS6nYuHPpDtzs0NkUeRCZEKjRGJG/Onz9vdk/T09PNLRLdWtMumAiIdjAKC4uYAhVhRyMuXrqIhYtW4MyZq/D7zTsVNFFyoYzMQeNdy3ezRHvusPOJGWnsm50LMgiSi6rKMmzZsgVr1m7F2jW7UFLUjL27DyOVcv/w4X04dvQ0jh2+hsKCcoQjfpKCq2YXI0RFqG8kBQPNOHnqGNYl7EFlQxOOcoGwkWR9/dr1yMwpwKHjJ5GadB3njx/EEurXLdsScOnqLRKu41i3dh3GjptO+2VcvnQLiTt2obVNbRxBU10pFi1agGEjxiE9owB5uQU4ybSKC/OwbMk8fPLRh+QA+0y5Th49Rj1/HteT76OppR5Xr53FirVbUNXsE7lQg/YnFxbmPktNFQ7t24vkpNuG3TQ0NqOgsNhs8+TnZGDf3oNITknnqroJNy4cxf/7//4N/uoXv8awUeNx9cZNHDmyD/sOHMbpczdRXlqOg3t24M7tm9i0ZRtWbdyKuuYWdnobku/dQ3JmLnLy8phmIq7cvovmgL44RmKh14lYnsFTnYOE/g0ahXHmQAtTWXuvofra2nH+zFkc3H8ABbl58Pn8bPMkzJk9E4uWLEVaZg6KS4q5ylyPVWSnRRU1Ni0Sip73lQ1DHpwW8pSClIG2tWX3HsJ7UUaIVYaeu0d4nHm0EbkQWbx9+3ZPm9lVnyUag2G8vtJZ5EL5i1y8KJLqMDShsalnA65du2bssXNc4+UqFa0eBC4sLDRhRJD1mrx2MMrLyxgujKbmOtym3rqTnIoOX4BjzErHgcmFp2F+LHpS7IHnYm/F2PGvvMynskkwwuEAMjIzcfT4GeRkl3KBGcHpUxdImNJw4vhRHD96CqVFNQgF9ExEGLnUjU3NbdHFJBd7wQ5kc9G/Ln4H8kvLUFFaQh1yknojmW3hw/kLl5B1LxXNDbU4d+4srl6/Zd4AKeTC9fDho5TlR7kwq0PSrRQsmrfIPP8YZj71teVs+x1mpyM9PQ+5Wfm4cO48CovysXnTeowfO44LzLMoL6vBmZOnceXaddQ0tKK5leRoH/vsdgpaWGaSi95G9RqjB6xAOOBHc1MjWSArxd6RstfXwPQRDb2q2srKdnT40RVuw8Vzh8z9r+mzFpG9bEVNfQNa2prQ2tGOdl+Q4SNob66Hj2mJpDS2tpnbHp1cfQfDIbQFdQ5zRdqCFqapr3rqT9tEtpNssV4aPNCgFp5zRMRAI54QcfN3+NjWzQgH9dpUF9o4WRoa6tHc0oJAKAw/V+aN7Iuahgb4ea0wRhmYQUtj3ieyk/B5wxP82iGQETxF9CLgKSqdvbIJnpvD46F+1O0QkQuv3Qa7T71+0y5YW1ubURx65XAw83R4+aDxoYc3NUZkjx0fuvZeT9UCRzuYPp9e2YyYZzN0piTgOURS0Y6A5KnkBF2tiSEXBrIp/V6Xp8eD8b08PCOYehj5ZMOr/C3Ugz4fF9Istp5lDARYbtaplco+oo9SUTeYZ+sYtlO3LxhQD7xq8e/z+5CakY7svFy2iR/tba0IBtg2kS7qWT+JSdB8O6mjvcPsTISVjtqWeTY1tzOdLuRnFSA9JQ0hpq29nQgX883NTeZV1fY2puEPmcWu9E9zcwuqK6vNtT58qbZvo9EbJ2XlFbhHYtTCvIK8HphceC1hHLSqbqWFHcKC6TdAqNJUBF4H6c+4ZuXsI6MsxJFjR3HwyClk5pbCz8xD9NftmlCQgksWbQsx3bDeBOFZ93nsR096O1zfdzACiJUVPKH30sGrUBTepWdUY88e5MAxddbEYH01MewnbNnabB8jlKPhLcFTH0TT4rXCi6RZl8GBmRhEbH+Y8qksdPupTWz+Ml75hIHCO9PX6FVUb+dC0NiT+2DvSAk6q7+8aweH/ug/VjQuLXGw817uMp788SC7whl3/um2uqSnfmNEoayxbvbqeaA3rd48HjSeLI8tt77EbD+QyDLq6cpoUvrUg/nwllbV0XBm10O6l2eRkVCIRCMSJMngQj0coJ9yUXzmo2f5vLRMMozZHaLi1we2bLLyD3WwXZUOA4aMe7RMykuBWAaVM0RjkjP6XjJXoVU0hZfcEAGy8dhbD3nmwhyUCA9KKFoKUzETUTsYLApNREpRtWRx9ZSrtvpD+jAH40j92C+CMSEmYT5tGiUXTMaeGU4MSHY9e9DzESiTJSsTvTTXrMRLBVNmaxW8y1ijIW4GHP885WjP1piBaELS33Su7Bayh/S0jUKoXzh5bKrPHypHLPpf/9Qw7RJjYuEJIIdHw/vOhciF2lDjTivC/u35PKG0PTLo9VN/5eDg4MEbl974kN2Tk7FjxiPG3tgSvLCSn3ZBbKWnNbIrnec17nrT6s2j14gjeHbBK5vZlafs7tRvepjnPmxA8+YG62N0riEeiqWDSJOeLbN10bN2chPhYGrWTe0inWwYBR14aZKgu/YmrAZXOB5UMPOWiFLRY61Mw+SrcjCU2k96WW1rk1JCTF4/UtY7b3WSCUu90z3SZd4WeQLY+P0gx2jJDWSXsZCrZ/qiN4yDg8OLw4v4iJaDg8NA6Ks/H46Bwum6n6YdUPnKQQREf1F44Wg8ax/EOPb1e0ieBvIzz1w4ODi8inDkwsHBYbDgyIWDwysKRy4cHBwGC45cODi8onDkwsHBYbDgyIWDwysKRy4cHBwGC45cODi8onDkwsHBYbDgyIWDwysKRy4cHBwGC45cODi8onDkwsHBYbDgyIWDwysKRy4cHBwGC45cODi8onDkwsHBYbDgyIWDwysKRy4cHBwGC45cODi8onDkwsHBYbDgyIWDwysKRy4cHBwGC8+RXMT8wskDeJTf88LTpP+kYX+Kcv8YDNVyObxMcOTCweFVR6we6a9Tnk3HPCW58JSa/VU1k7UO5kfa9IOs+jHXmJ9mFcxPsuqnZPVr8fZHbh+OnlgxkNtA7rGQv5fr04SNhUrWv3S2Ti8eKmts2WS35XpcbR0cHgZHLhwGH08ijz3zUyI23xeR/49Fb3l7NEJM8XUy7jFugtxiLqOI6pGesFZ/23A6yo9n69Cb32Og4ErnKcmFkrdGkU1mOuiH4Lt0CNHaySMvbQ40OgQYOmBiSSVGyxqDnsBReyw89ygejEzIX/kr9ZiwgsLTqI1s6vpd/+jv5gvGXwfFjWlomSgpil48PWLTekgS/YN4xh68a5a1W7/Xb9tcv5eP7rCxm1qYARCN4ODwhHDkwmFwIZkk2SX5FL3sa6WJyl0je2M8Bx2e9Iw1Py5jr8gPpOB59DdRxFgfRL+wFnKwZZUmUKuZINGMZfda06iDmAJ52tGEo5EXpEektzutQzdDSX/bdOUgP55lZRATPwolK+NZYu1KO0LLs5MLJWhK45GLiCUXcjKZyRag8ZtYtuD9IRcv7f6+nvujIH+lLDNAWCbpNY4a8MnJher0HMjFI+AF6W9ij7ajY3aFDLkQ2YjWQuU3dXBweHI4cuEwuJBMkoSKyiYrzLxT1EiieaovxnPQ4WXkSdGYcj4lYlPqk4Ln4Zl+sE4P8RwQCmfL+jBy0dOSXlAT4BHkQnpbOwF0GJBcaHNAVgbpyS96NvaopcfOg04K+3zIhSwqKBWxiuapblNBQy6CNL07Fz0w/p5FPtHiGzch1v1RsGXqNQ/CS+mR5EJlNddRY7pExlw8PXrSeTi8IP2NVz57rXI9SC76hDV1cHB4cjhy4TC4kEySHIuRTbTqqtdIoknGWnnX4/GTQBkpX8/8+Iy9YvdJIdaxj4eFddIxWvfHwgtrtW9PiXWwiZnWNKl5blH3nhbmdQ+5MDqPJprQA+RCsUQujJ+nP2Ohq6iLOelgU9bxRz/QqcgmGS99Qy6k8CyBkLH+OopcBOlnh1JP7OjJKsaoIo8qeJusGlHPasQqUh17IsrhIegbzov/aHLBc29AIlome/H06EnnydEbxZbPXsv+GHIRtTk4PCkcuXAYXEgmPSibPLlljSSaZGysPLbWnw7KcBBkqFcXz0TR10lH5e2ZJ4ElFz1p9CbWm4rnFnVXK8e69+wv9CMXohb2Uv60aVfD/ps0rC7yEA1jzoLXlzbCjyYXSs5L0lqUic1Yl72V4bFbN0pCdLdF7hlMXpSflFwozf6DORo2llwYKEy0sX4M+qT1ZOgNHltu2fWsiNd+tly9yevahndweFI4cuEwuJA8elAueXLLymJPISkc4Xn+pFCGgyA/vbp4Joq+Tjp68jvaBo+FDduTRm9iD7pF3S0xiB6o52y700jfKjm69yUX0UOPX9TNOBDRALYPbQClaXRrVI++pjAyfSEXJeKZvvDixJqesPbCXPW4696NDF2sW3QwRaM8ObmwjWKNiUjzMHgVt+F74WX6uPiCwthy//Sw5fPqrWtbf8GW3/r1XltjXRwcHgdHLhwGF1ZuPVwmyW8AcvFSwpO/NLGL1EfUx3rpGBO3xzwePcn3WAZwe8BdxygJUNvHlNXqWflZJ3OIFscL1usgu6djrafVT1E/miciF92mQL2I7pQY6Nxj7y0BT8zGxJObMlRa0WtVwtuOMc7WrT+5UPz+5EI3XR5KLvpc2tAeufDqYM+Kq0Et0zeNaLAovAI+iP5t8qPhJfNAerZ++nsUrL9XThvn547n1vYvCEOl/A8jFy97+z4NvLrG1vlVqv/gQu34KJkkv35yWKcnbP6B+i4WA7n3d9P1w+I/HWJksNJTkp6Jojcf62Flt0xvXKvXZPrClDNqfxrE1s3aZdTeMYvmniDSsx7RU7vwaK3RuF7ZPCN3E5J/lmSYt0Sj/v3IxYMJiAR0dVmCIdNJeydTkOKXexdz99KQn3LrlntnGJ00imPDMgSNIRWsXCRMP1kVxaQZpjcrp7Q7FQ4IR/RGhGVTii6aEGaYThr7SKktk9JQASyHseWSg32A1IaPKC3lo1drTDxem9s1UeLBfxmV01xGC9et+tHBMx46O3sJy4+G8mJ5umQirKPKZvJWnkrfGtPOND3lsFENImxj2xJeHNXv5wGvfb16e/bYtuhv98IMRXjl1Njxrl8kRC7279+P27dv9xljXju+ClBfeMbrG68dHJ4VakMrbx+E3CTbpSMkm23782TleEwUrz88I+js9ZXXd7HhPPf+cXXtoX+YZ4PS9RQa0xogOZu3ymHlupHtkvXyU9lo6zJuNEbbRd1orN6VRqP6VyMppagSMIvwWKNwJi+bp3Wzdbe6he1O3WfyVhIqrklKbRGinTqFeSgJqk3TH9KfNp4tt5S3DWPLLB3LXAw3UB6dXcFHkYtoQ8kwZ3WCFHNEHUlXmc5OKm5eC5ZwyF1hRRyCpjCdjCsuFCJhUGVMujyrol0RW+lOKtZOU3imTfdIxDaIGq1TbiyD9K7SDzNuRBWTq8KoBZSv3tWNnk3aJq66qAvhKMmJhDWIbbiuLuVnCY1tdDrbpAiGjdgXahUvFqajouaZYPKz9TflihIMuatdVedIpzqa9IjXEYYzddJk4FktaerEcqoknaajYx5U/RmgfzvLbvuq9/wyGUH9F2t/kfWora19gFxYITJw+J+jEbyFh0yYix5Bfrp2eBaofY2kMld9wXFviIUlF0bmScZRBMY2u9dP3lyRie07bz71uutsx3H/+fWw+fZ8oEJHdabSjEnWy8LkRXneG5blkS6je8+CnSZC3SS9J5ludJjqrTC0s/R20U036U2ladx1Vv2oR8yCVemobZSLznLnhU1BbR2KphstjWlztochF/Rjf8gvQn1q1BIjd1O/dLNs0lOGQDBdZSC9zhKbPJWfjv6Qr5dcyNijV3FRFhlW0CjlaOFoVBCdLRlgGPqFSQjIFWxF5aZBYxqHGdHdx0KanQ0pQEY2Faaf0u1Ju8duz+Gw0le5lKeULd10VnwTrndQmVW/KZTKZf3DzMPrSkENbPxVFqO4xd7CDMt86K/oMophyUdv+jJCf/uPgqIxI00mY9cpmrmph/FWfS3BMXWRX9RfQdTWqpja2A4kTSZNVK+2Pw/EtrHX9lIAVVVVaGhoMNfeuBFi7UMJXtllYse+maAvAMpf5EK3RW7dutVTJp2HYvsNFlTn7OxsBAL6Fk/vePP6x+FZwPFupG/vHDYwbSy5Kh1hV8lGbtG50+gJzRMvqLV481rXnvH6x7u2c0l2e44dy97Zc/Pi27hKw3g/A5S+Zx5MTPkoE6MvpVdJrOyZ9aKXZ6TMFTtMBa4dCqv3rIz3jPxFnmQRwYgwjHRdH33CU1AES/VWPMMQlIfqbPWz9AmzM7pEUU0kkgt0B0w5FUX+pmxRnU4P4xChp2k/2Wm0xJWu5z+CLIu+avVabHPYYqswKggTk3JjBasrq5CRkYHW1naTWUiZmo4JI+xrR0VhEZoamxFkyiEaX0cbSvKykJ12H5nZeSiub0ELIwZDLIJWBqawaihPIQIdHQGm0UbFIaVOd67ItVPSyLgdbaqsFGgvuZBRPAtZ6Mb0y8pKkZ+fj6bmZrS2+5BbWIzyqhqbrgaxqse4IheRzgDqGqqQX5CP1rYOo7TNwDYtwk5jAyoPbyB6A9RD/+vHwhazxxg2KcM8TQ/SXpiXj5zsHJa9je0VQGVlOaqpBIKqO+tQVVGNjOx81DW1m50fkQ3yuuggUJ88ZZmGOMykjMKzt7e34+LFi2bF3d/fu/bsQ80I3uo4FgOFHWwjcrFv376edvQEr879w/5cjbBgwQI0NTUZuxGY/fwdfizYhj3aJRZys/pDclar5GAwiPKyCpSUVCAQlOIDmptbUFBQAJ/PhxBlu9c33hiNHacmVbpboiJyYe2VlRXIycmB3+83YXQrULosLy+P6TdH07Pm2eDVU3V+sMaGDKjOLJNV0tKtQbS3taK0rBIdPi10RSo4D1mPmtp6ZGRlIb+wwOgCxkSIcqOhqdHsXFjSoHQ74WPbtXZ0UO/6qB8q0dTQaHRthHXTYl9tV033qspKoyPCYeqVilJkZuajvtFP3RItr9qxM4iAv5HtnoeSshoSFBaTzmZXvDuIlvo65Ofkoqy8Cn6fH9VlZQxXjmb2mT+kuB3oiITRzOK9pm6QUeK2WVRo5aZUSR4CHbh25QpGjBiBGzduGWbl7VCEQz5cPHkcwz74AOvWrEMzO1CMpampFonrV+Mruk+ePhuzVm/EzbxiZk4FLzrELMTAOlnYTjIlpXnvXjbOnrmK5qZmo/SbmupY0BD2JB5FSlKGIpjy6fZKkMYoU7mpyNEyq2KnTp3AqO++w86EXeyYEiTuPYTL1+9wcAUZRHVih5AdidQEwx04f+k0xk+YgOs3btON9TJl06DXbo1J3OThDWp7rXyteSooeKxR+Zmht5XVUFuHj9//AG+/+RaycrKRei8Vq1atQMKuvSjixKul/+SJU/DPf3gb5y5RIajaLJP6w5Au1c8k/PNAbBvr7LV/S0sLDh48iPPnzxv3gYTMUINXPpWtoqICa9aswbp163Do0CEjWF8EPHKhBzpVtthbIq8SRo8ebciFxpHgtcGr1g7PH2xDCdwHZJLcLLmIRKgDKLfa2tqxK3Evli1dwwViNRVgFxeJBVi6dClOnjxpCLl3q8PrG2+8ak719p3StfJd5tKlCxg/fjwKCwtN+JUrV+Jv//Zv8dFHH+H69Rt0U1jFMdGfAb311LF/cmZBYQS29B/tXQEEOpqoW69ix449uHLlFgIB3aqgfOMifnXcWvz67/8Bn37+GW7evmX0ZWFxEfbs28sFcT3TZw7UHz4q+Ltp97jgzEJ6Whr2Je7CqWPHUVdfH30cIYIG2k8fPY5Vy5eTyJSiproCc2fNwOt//AtOn01CB9lFWM1nqhBCfV0xZVMc1q5PQEOL35CULj3mEPbh8J5d+MPvfo+ly9eitroWZ48ewpLlK5GSV4KS8hJcv3oeNc2taGTxHk0uaLrY+cXsmN/97nc4fvwUFZgNzzUO2lrrkZNyB7PHjcWXn33BRJtJLrqpyFtxbMdWvP4Pf4+FS1fhj5+PwIbDp1HT0Iy8tHTUVNaREXWhqr4MaZkpKC2vRNKdTFw8f9so0KS717F69VKk3r2P/YknUJRbgfqaWqSlp6GwpBJFpTUoKC5HVnYuauhun4/QwAuSpWZh5qxZ+Ojjz3Dg0HHcuHPfxNGqv7SoEJnp2SQXGowhVNWUIn7nJrz51ls4cPA4qqoakF9QhNa2Jg62MNlbIdLTM6nM2pg+m4ON7A1mnZ8atpGN0W6F2bGIEosulu/G1WtYvXwF9uzag+KSUmzcvBHTpk7B7LkLcODIKaSmpmNt3Dps27EPRRW1ZqyKAAXJLjQARC7E1n8u8NpbUJt77d7a2oojR47gwoUL7MdeYSN/L+xQg1dGGd2G+A//4T/gP/7H/4g///nPZifmRcB7W8R75kJlkxDU+VXCd1yMiFx4/ePwvMD2jFG6vZAbDWWsVsQiBJLPu3fvx4QJ05GbW8x53W12F7799lvzXJDmuYwWFtp5qOQqvKSkBKWlpea6vLw82nfqQ7t7IXP3bjKJxAfIpvIVuThz5gzz2U3Ssox+KcxfJEU7ds/W76qpzf1BIxjyYwS2iAX1VacPZUU5WEcSsWFDPGbPXsq6VBty0eEL4MLFy9iydRtWrl6FjKxMsxOxe+8efPPtSFRU2R0ILUq1K7Nl53akMUz8tm3Ysn4Dli9agrupqQhEwuYZxTbKy4O792L65CkkKNSBGfewfm0cNm9KREFRNUJqAxVUK3bq0Pa2amzZshHTZyxBVV2rISl6+aGtuQaJdI9bEYek1GwEfD5cPXsME6bMwOX7OWhqb8LxY7tx9mYyqilHHvLMhYwag41OJeyj8Hv99ddx7NgJ68tgWimHwgGSi9v4/vNPMGvGbDS0dyDIEF0RP64cPYC/+q//H/z+T+/io2/H4uDla0jYvQ+rl67E4gWrkJ1fhNXrlmDNumU4evwkFiyIw4Txc5Cbk4tFi2bg3Xf+jO3bduK3f/8W9u8+jrt3buO70d9h6/a92H+I4ecvxmKmlcg029up/LXNxMHa3NKMC8xr7vxFGDFiFI4cO4vahhYUkjQspJJevGApDuw7wAGchWXLF2DC5B/w1ttvkyluwrZtu7F4yXKcu3AeWVnpWLhwEbZujecgz++jsDwh9KMEkdfYMUbEIuwPYN6s2fh//n//DZMnTjLEadnyZZg6ZTLruQKb4/dwtbsBf/vLv8Mnn3+DjJwSE7f/zsXPTTh69fHO6geRiw0bNpjVx/Tp042ZOnWqMTNnzsS0adN63Iei+fDDD/Fv/s2/wWuvvYb/9J/+EyZOnDhguJ/CeG2ldlP79fd/FcxbXFzUc3UnaJx5ROvnNpdeBB5sQU+/6Da1FoUiAZRdVPAnT57BlMmzkJNbaOLpWZgPPvjA7DbotoYUtG55z+LiMSEhgYvd41i/fj3l9EKcOEHdxH6zbzDYNGWysjIwfPgw3Lt3z/h3dHQYInn48BE0NDQyjGSK+poZPgMU/aHGjCW7JLd6iqbLj7S7NzF9yjSSgj0YNux73L+fZ3YoQuFOBIIhlJVX4NKVy2YXop3ljt++A599/gUqKquYFqjc/VTmx7E9MYGL7WIsWrAAG9euw6Rx43Hm7Fn4QkFzh0G3lTasXoOvPvsc129eZzpb8eu//RU+/+wb3E8rMotTs3OhwrJP/P56JCbuxOw5y1Bd12w4hx5VyM++h3/69S/x1p/exu6DZ+APhJF08wKmUPdfupeNYFcAyXcuYP7qTchu9j3qC50mRXPWg3NvvPGG2Z5qbWtHekYWbiWloI6dE26vw6HEjfj9H95ETlkDImRmXZFWXDx5AP/8T/+MfUcvoKy6Fskp1/HlV1/g6JGz+PTTUUhI3IvdiRuwYf1ypHBFvmz5VgwfMcmQiyWLZ2DShNG05+P//PJ1Kvj9aKyvxdp16zB1xgIcOXQMf/6X3+Fv//53+OSbsSxHA9ukg4M1gKaWVqQXlCErNxdjRo7AqG+ZTkEpNq7biunjp+PU4VP40x/+iPj4zRg1egTJyQ589Mln+PDjYfjVr3+Pf/zdG1i+ah3KK6owc/YsssW9qKwSoxTD7TJnQ64eWOF5kybWcFCZY6+JhSfAtIMhgtFY34A7t26z7hNx4uRp3Lp9B9988w3L9hkJ2Gk0NrYi5W4qlq5YjTUbthiWK+hBGj3wOVAeLzu8NvbIna5FLrSa2bNnD4o5qbSCkYm1DzXjla2oqMgIwr/5m7/BX/3VX+Hjjz82QrR/+J/CpKWlcW5txenTp1FWVmbKJnetBvuH/bka1Vm3RbSL45EKb6w5DAY82aj1sBZDdudCba6d8UkTp1Huk1wwiN6iS76ThO++HYWamhrTN20d7diybSvi1q5BWno6bty4gbmz5xi5KeFn+o/GPBPIHHJz86h3hjNsJhdfetOiC4VFJTh37oJR4nqOT+Ek062keXYonf6ms1O32lkpEgvpKXSTXKTeJrmYioSd+zDi6x9wLzXT6gJGCLHu2dk5uHLlCsdmPc/XMGXKdLz+R+pZ0z5si5Y2Loi3YQ91VAnnrJ4d2rhhI9twkrll7AvY50y0AC0vKcOGdevNbdjGxgbmlYo5cxbg4KHj6CBJYZNFITLSgh07dmA+F+j1DU2mPdVHwUAbSgtysHNHAqbMXoLa2gYkXzuL6bPm4HJqLgKdQWTcu4ExUxcirbbt8Z//lhIVq3/zzTfNdpKIxtFjx5Cwax9Z1Q3cunYGRTnJVMgbUVzVzopwFR5sxumje/GnP7+Nq7fTqfiCqCxNJyudgAMkF199PQ6nz1xAScF9HNy3naRhE1as3o4RI6cgPS0da1cvwLTJY1FaXI7/+5u/YPM2bYuFcPnKVYydNAdHDx7GxFEjsWP3IRQ1+BBkR6izurp8ZFr1uJNdhI6AD8lXzmHNqtXmoc7D+09g8vdTceboKQz74jMcO3YQw4Z/jg2bNuBjMrqvvh6NL4f9QGaXjvrGAGobWnE3NcXcmjh95hx8fv1svB0oXj9om60X3qSJNQ+SCy+uJpPdKuMFjZ7mPXXiJNLvp+EOJ1RJSSk7tpEKdB82b9lmHvC5eu0Gbt9JRjIJhgieBqEmizcxZH5O8IiF4Nl11oNYelZAStFTCLHofz0UEFsmPWClvtf4kf1FlVfPXOjZlaSkJFMGT6kOxfYbTAwfPpwCtzF6Zeuv/nEk4znggaGkNu0lFrqVrVW95sHRo8cxfdosZGXlmoXl2dNnqANKEL91m9m5UH/oDYrTZ89g9A9a6d83t04UbtWKlajhIlAyobSs3CwCJRvTMzLxyaef427KPUM49FDkzVt3zK6AiuaZ2DdUnhWx6fYaySltD0hXaccmiKqqEuyI347duw6QFGxDRXkNEhP3kPCWIBAIsh2yDPmt56JTZGj0d2Pw67/7R+rIXBKvbvOG0zHq4u3btxu9rLksUrBlyxZkZmaazQDdgj116pS59amH4DXX7969a0iZdnOU/uXLlw3p0A6H2lg7O4mJiWZXT7efcrlQP3v2LPO9j727dpqHZM9evmVegrhJcjFx8lRcvHMfwUgAN6+cwfwVG1Da3vFocqEJpk6Pi4szW7nKTCsc+zAmyACLEbdyMebOnIjklHT4GV4sqbQoh25T8N6HH2PNxp1U1g3oDreQLd3FnPlLSUyOoKXVh8Lce9ixbR3OX7iMFas2s5BzDVvLzUnFymULcPjQMXz06bdYtynBkJaqmlpcvHqHRKUCqTeuYfHyOJy7mQp/QFtNQXS01GNLfDzmLF+LHJatO9SOMq5OGsnwgh1dSNySiBmTpqEgJ5udUY29+xKxYNEC5jsFO9nBW+P3YlXcFhSXVJvyqUPWkiGXlVf2DBK9FqR2GVgAy80jFjJ9yUV/KA0vHbH0q5evYOb0GWaV29bWhsNHjrFtLqK9w28Y9k2y88VLluFO0l3j5qVrdlXYISIZPyfEtrFn11nPKIiZa4J45CLWfyjCU1ax5dS1EZh9SOpPB+8jWhJAse02VNtwMKC66taQ7uWrj2QcniMeGEr9yEWXyHUnKirKsWzZCnz26Zc4cOCQeXNkCuWybn9ocat+MnOGCVZVV5uHHGvras0zB1KoWuHrLQndKikoLDIyUSvybfE78NWwr7Fo8VLGqzEPS964edssFmO/2fQ8R3xsmr1Gc1/PxOnhbUsuIhEf7qemYu2aDUil/vR1BKnUd5uHTyXj7BuarQwr+UH5f/MOSchW89KDdnaCQT0XWIB46jw9JK4dx507dxqyoNs/ei7t6tWrhlzMnTvXEAu5p6SkYPXq1Sac8rl27RomTJhg5oDkkfTP5MmTzfMuIhXa4Tx69CiyMjOwavkSyox9aKb+qayswqbVS/HFl19i3fY9JEdlOHv8IG6nZqI+3Pn4nQuvUyUATecagSi3qJ8eUOEgEeHwRKQaUWTADCOG05ZQVydX/hxEwbB9RkCdr/tO3XpjhA2nLX452feAyWY16JiXXntlFPPQo+4fKQ/z1kdnCCH66+10fYhEccA89PERbQbpQ1vdZFLmdVfGJ0G2Y1pB6ac3UvSQClPVXT9TJhJdQ5qYLPS0srl/x7B2m02rGQ1txdex99wL40vDBIxh+8S49odpPxq1qfkgimkAz922h4zJO2pUlmDItrd1601fYRXv5wSvfby2ll27aXqASytvOx7V1tbPC2fbcOgYr0zePPIIqqfMvHA/pYl9oFPXHvqH+zkbQSs47zan5+adHZ43NFeNxKXsssRCxs5dzWG1PYPIrrcHFIOOmjfmTJksY+VfL2E3RgKQUHzJRrvg8s5Mx9i7jPy0srSvbH22Pu+NK1uskdaQ7rI23R6RItJZD7RSfkknRettHzC1dVVsne3bLCofy0tFpbBSgXLTjo52IrS74C1gBE++CDaN3rbS2Quna++h2L46vte/x6iNVDamZV4g0B0D6mE976dvWVVVluPW1StobmtFC68fSy5iC+xlGpuh8WNtecVO98Kpcai06e91mgiBCiV7mI1l3PVAj4iIwrEwUu66t2ManwPOkA66+0M88N80vNyYjvwDGih0tx/BEhtkZ/FPNpaaQUJsMHWgIqtgiqayqhzaktOtjoghIuFoGegd7TiWIkySw0h96kET2x4Dg5FNhgxvrgeGl16fdFVUnmVVsZWvKT6N+bCK6s8L2ZW25yej658b1C6mv6PwJo13jm07nQXvPNTgzaWHlfunhkcuvN8WGartNpjo3xceXsW2+GmgNrbGkgrJf81vrx/U9ubSyupoP2ju6I0JKWmRBPoYP/WZpxQVXlAUWT1y4clQXes5C7npHCtbbS7PAuVtU9GxvwlLqZgwLKsW5DqbnQzpM4ahl+pgv61k6+W1j17VFUwdmZjIiBI1+pGRZUSO+8sXIdZNdyFi/T1j2jao21N93WUEnW05WTY2ls72g1kqjNqQCz7lRQWuT02IB0hzPpJcKMHYs5eJd6ZF/8aotvo4h2AKYfwU1hISo+CjUMfaKCywUf4cIOx4dbZNkPGicZSz7p2pEqqYtrLs509tJUQI7O6CGofutKvtdX/NEByFUVxlqLCm83rZo9nZYH5m10LZKEMZUww78HvqK2favcH8cEQzo3lYKC9Nr/O9Mz2MnzrPTgy2BcPr6H2pTQQjoHv1dPcmm5koJr+H5fhyIrbtBbWTB/l5/eCNuVj7UDQ9/Ux4q2Vd9w/3U5jYj2gJXjmE/mF/zkb1lokdW4L8HJ431KYa/2pzK8etW+/4k9zvu4vb20/mtrT6K6pXYmWxic8/RY1GN7JRdisnrZuNr5A2nDXKQ6n8WKhOSkDpen+ei9JX3awxX7vU8tfoFysLVGeRBcF8Ct0QLhvWhmd6Ji7TYDDTRixw7DNbve1nzxrPkjED+T0sjuBdDxRHelkwC3rZGUXurA3D0Z/FVh+FqFefiFzETrrejJgYG8Gs6ulur6MVoZvtLIZlwyi+IQHRBhHUwSqY+V0Rk6YtpNcbsupdZ8GkF7V7QUzl1cq8MuTCMEEpX63uo4ywp6yMYYPSyE0kRLscllwwBM/Gy6TfZbZQZJSmTL8GjjHPgv7peO2t657Bb8pmjTrNbAvyLHf561pnL6x1/Xmgf5sL3tlDf//+CmKoILb8EohCz4or6vdTQzsXseTCK8uLKs+LwkDyTXjV2uGng+Sc2lmLgL5zXE0uPRErCz0jNxn1l2cXvLPcGdLKTJrYXQ7Z1Zu69shFH5Jhjs8CW6e+xqbplc+b93LvIQrR+otYqN7ys2RC7qqn9KcW4JaIKY4X1sbru5DyroWBxnV/E+suDOQeey3YdHlNN/7bMLw2t6lM2URq/I+/LSJ4ifaHGqaXXDCMaRxla60mU5OZVL/cjCNttrAebPqeiTmZsyrnNbxFb0jlHK2o92c6RDdG5KY0oqFtBEL5MowhFRqMdkDGwm6vyajUvR1k6mMLNSgYKG252JpZeJPCu+5f9p8TYtvjUe0e6xc7roYqYif9i4T3QGf/n1x/1fCyjZ+XH558lXm0/PL6RmfPxCo6ITaMOUeNRxw8I3jy0vr3ytFnR2ydYo0ts9Bf53km9vrB+KqrCIPRsjR0idGF/cdrbJpPg8fFic3H2KPh7UkHSyps/iIZ4ScjF4+CuseoZ68tCKvuCZun6WS7P0AHUxgVzlrNpYEcTIgYN8Em3Otu07F25RRleTxaN4W3HWGvhV5bb3qxJtZf0LXC2bT7xndw+Hmg/zMXDg4/DawM/nnJ1tg69TdPg4Hie2YItZUpig5RY1hGjJ0E6MeTi2g65CtU5aQXqnt0QUbewj9lYt0suYjuEJh4DBy1KpqBChQlF32aMcpadG3dFMajA73koi9sCj1pPBYKafN5uHny1PrgKaMp+I/MycHhqeDIhcNQxUPloOcxgOdD4/zU6CmIDrE6xMLzNkEeith4jw750yJaD1MkHaLlM9dRfWx0+RO8LfI49CEX0Xz7kAu6ma18hZFDtCwyKko0So+bTl4Qg37uvbZY86wYKM3+RmGeHCa0Dk8X7cdEcXD4UXDkwmGo4qFy0PMYwPOhcX5q9BREh1gdYuF5myAPRWy8R4f8adFbD1suaXGvfN5in9f8fy63RUQlTPrRfHtuNUTdZLd0o9dNZxVFxkDufb0toheee6+tTyhrjbl8OsSmGWs8xLo9OhOvGCZU7IVxeDieIqiDw3OBIxcOQxUPlYOPEJIPjfNTo6cgOsTqDotY15cPsaX2amIqGz1bf9memVyIMIg6mNSiefR5joGnnjD2oqc8EVq0y2EQdbe3UGLcdaLppScKaGmJd2UOMcaz2sND4AXqCSNLNLMe4yHW7VGJ9ks29sI4PBxPEdTB4bnAkQuHoYqHysFHCMmHxvkpEJt5j12HWN1h4bnGrvlfHth62Cp6Nemrh3VS3Z6ZXDw1estDEqEnMXq3UeTuPZ/RQy5USlr7kAvz5Gx/cmECGRM98dBjs/AuZaJl6PWWRenq0VPlJONBgfubXl/BSyrWDOgoE4OBvGUcHAYbjlw4DFU8VA4+Qkg+NM5Pgdhy9RREhwd1h+f6UpKLaIF1MlYepGZNXaKOqpu0+nMmFya7GERzi4UulbsphFR4tImjQUUXem6hCNE+se5ROtHzkGc0lHfQuffEQ4/Nwrvsbwx6Hbx0e7x6rvqbXjzUp79HH8+BvWUcHAYbjlw4DFU8VA4+Qkg+NM5PiT7li73oNbFXLx2ihfZ0pA5Ss0alyyFql1b/6XcuBFMqe4oWsQ/6uNlAPVaLGMdYDODk4OAwMBy5cHBweB6IVb2edn4x5MLBweGFw5ELBweHwYIjFw4OrygcuXBwcBgsOHLh4PCKwpELBweHwYIjFw4OrygcuXBwcBgsOHLh4PCKwpELBweHwYIjFw4OrygcuXBwcBgsOHLh4PCKwpELBweHwYIjFw4OrygcuXBwcBgsOHLh4PCKwpELBweHwYIjFw4OrygcuXBwcBgsOHLh4PCKwpELBweHwYIjFw4OrygcuXBwcBgsDBK58H66JPbnTKKg04M+/cP1uzaX1q3XRzbPWPS9GihEf7fYK2s8m0XfqxcNrzRDq1QOLyscuXD46TGA5Or59WqaGGuPeWo8PpGBXZ8BT5WgF/hRkWL9HhM2xqvH2nOwHg/a7FVfxPoN5P90eCy56OzUj6dadHV1GeO56ZfPu83AoHv0l9N16OoK8hyhXyftnlsXw1N5M4yChukuN8XtZuRu2elnfnC9O2zOujZGcTtDtHabuF3MuLs7Qj+aTubFa7nJjynZvJiRUg8yz5DyVbpdkWgYls7kz/JFGL8rbIzCGD9TDjqZtPXL9DZNW176RyI99kfCK38/mLRVvmgaprwsY9SD+ar8ame2oXWyZ5oQD2o72w50p+mKWkwbDpThEIAdJyqrHT+69s6DBS8PL0/BtPUg5jlY8Mqsc2z5vTp69qepnyMXDoOO6FDUSVK4m3rBSjLjYIRYt+ScZLBkNIcy1YYVuwqmoc1wks1GZpr0NAfoqXHOk8a8dTU+PGrOS0YzkahsV9hoVLpbPWKSNrqEhglFQzw9TMYqj8ohY9Mxzj1XPKu8ystUUmVTGVlWOqsKveHUDkGerV7sYvmlU3vCMqQtbzQ/E9m2j6mXslFipv7Sm11W35kcFEL5Kk26KKySkZd0tsJL/yovk5D1N01Mu5U1uqAxEZWGNQoQDtt05f5IcqHGiBVeHjzhpfQ6jSK0hfD7NCKEMDq7AvQLmSspY5MGw6i+Cq7spTyjNuOn9GxHMz7Dh6VJTWtycIT9CHeG4WN+pjRm0Ej5qyGsEpa7LanKzQZlGiIWQXpGGFedFWKAEK8VzgwmuUcCNOxMNqhKpGFuasK0NQhs49mGk/Hq379dHoCC2aB94DkrvpdGJKyOpWvUU4PK6zD1sQiPQqpcMn4WzdYhahi3y6Slq6EHjYHm5ma0tbWZ9pPxFOFgGLWrZxc8t1j3l8V45e8P1aWysrJnfsl46H89EBy5cBh0RIetTlJ9ku1W5hMUZN1aKZlFqB/+QDtClING92roStDx3EXhJ1kRoSAMU0tKiWo+dNLdhCPC1CVyD2vhR70ToUw3kbupg6gwlQaTViGMovSFtejUJdOh/uiMLiJ/HJSQrYetm03H1pkuPBgXc1A45iXdZRbhXayz5qrKQd1kCilSIT+dGdwQAZ8pp5dmMBxke0QXv4rISilnv+qptJSO9Gu39BrjM1JY7WXKGC2nl5iMKSTbifl0d3ttZ/1MMjxbeS2yI3lj9WIn9acCdUr/8Nqmb6M+klxIOCnBYFCsiZ0bs2JXZjJKRYNBjaMOr66ujgorKmoq7Dt3bmPBgoWYNnUWFi1cgXup2YhQw4eC0cEgAsI0OznIIkxHcXJz0pGRnY2AFK4aJBRGR2sj0tLSUFzbCFEWMyhCfvanvdLAU7UiIh+REIoK87B+/TrsTNyF6rp63Lh5E4sWLcK99CyjqAMcWcEgG0aNyvybGhqwO3Ev4nfsQl1Tm00rQjIREkmyCknQWW3gtcPTINpcxoj4iKh0stLaqZBjE8u5bdNmXL14me5dVBzl2L17Oy5cuopWXxhtvlYcO3EYB49dRAvZRRc7MhjymUlj0mVHmB0dczV0oLZqaWnBkSNHcOnSpR/Vdk8Lr8+8MdtDcF9SeOPPg64DgQDmzp2LqqqqnrrJ/Unr6ciFw6AjOmyNfKJUpcSnLTr/dTJKrRP19ZXYf2A3zXE0NLQaPZ2Zmo6EbTtQVVFlxXTUaCoYwzBRXWbdzVkKzypmKcGcjFRs37weBXmFdKc8oO5pbGrFibOXcYfp/1Tkgmo36qBCMy+Sh24umPNzc7F372GUlNRQRtHLNA3L3u1nO9Qj7X4O26YetXVlbJt9uHb9Njp8qp9AHUDlXlvTiNLySlRUVeDo0WNIuZuGYECESnmF0NRYi/179+P8uQvw+XyUxa04c+YCr6+iuanDFptli7A8SjMQaMGN61dw9PAxNNQ1WrJH/2AwgKtXL2Pl6lW4n5nDdmzE/n27MG3GdGzeuQt3U1NRUVoEH/W1UnrsbZHCwkJcvnwZRUVF6OjoMApRZKOJCTc3N/HcgtaWDnYcCYCvGTNnzsL8+QuN4JOiKyzKwVdffYUfRk/C5Imz8PEHn6O8sBxBfxCNra3wscBSrh0dfrS2dyAU6MCFs8dw5NQp1LX5kZWRj/TbyagqLaQgPIjr9/NQ0xZAE1fAysPX0c7yhNCia/aO+k+t1dHahMOs+B9//89YvmIlsnPyqNiuoLmlnWXtMmX2M89OssYwSUZDXROWLlmFD97/BHn5JWht87E+fjMwJKzb29vNqjsUEruzK+6nhWLEGqVrdixYnm4OhA52+tGDh/DVZ1+gorwaB/bvxZxZk7Fg0TKcvngL9U11OHfuON77ZCTySptJUEiuEDBkKcj4nbrFY2iRUh86UHtpghw6dMiMJcFT/D+mHZ8EyrO2thYnT57E9evXOVEbeojGy4j+7aRrzcPx48ebuunaC6M6Pkk9HblwGHREh61OA5ELyb3OcICyvBU7E7ZhwsTpyMstRUeTH/NmzMGxw0ewfNlyNJJwSBaHueBroQz3+wI0fgT8AaMs/dQnRokbTRnhXA+htbUZ61evwK9+8T8x4uuRhrQU5BVh9OhxOHD0LCrrmqnPJBOkN1SmaGF/FBRfefemY+sck6ohFqy/yAWVfn1NOXZu34ZNm+IRt3o7qqtaTWDp0nC4A+fPX8Cs6UtQkF9KRV6LjZs2YOz4iaiprbfpdQUYpwK79h3FnZR0HDl2GPGbNyJu2UrkZBcgzLR0K+X2jcv44z/+A/75H3+LG7eScPbCFWzZkoBFC1Yj9W4eIkHKYhrzGAN1Sk7OfWzetB7r167DERIMEZIQF/L5Bdn4+uthOHjoGOYuXoXrN29jzOhv8Iv/80t88e143Lx1G7t3bkNOcTlaKIseSS4koKRMS0pKcPz4cRw8eBC3bt3CvXupiFuzkqum2ZgzezHit+5DeXkpFfg9vP/+R1i4YKlZeVP8ob6xDFMmT8XYH2Zg6pS5+OyjT1GalYcT+w9h6co43E5KQVlRGQfWHmyK34G7t69j+4aV2LF3Lwpqm/HtyHH47ovhOJ64HcuXLsPZm+nYeeQcZi1cigsXLlEBHyBbO4kFS5bjxp27dluJndcVaEdFfha2rFuD9995F7t37SMLzCKhCCI/Jx+b1m/C3l0HUFZSidycIuzcsQ/Dh32Ld9/5EMlJ97Fp83Zs3rYLDU3trFs5Nm7ciN27dxuF5e3kPG6FGDu4BjIGtBhyQRPs8GHWlGkYO/p75OcXYfGiBZgxdSzmzFuEDdsOUEHXYdPGVfh42BgUVNVxAol1tkdvmWhwiH0PTXLRSiKp9tu+fTvy8vJQUFBgzoNlsrKysGbNGvzrf/2v8V/+y3/B2rVr2ab5xgwUfqgblbt/m2VmZmLMmDGGXGie9t7v5AjoR0YGgiMXDoOO6DDUqQ+5oEOXNp2N7NN9/iBOnjqKyVNmUzEWI+d+Ad5/6z1cv3IZX5jFVg2jdKOgMJ/zWkrvJE4eP0VzjPpmCVfad5iUdI5VktqyN3PC145zJ49hCfVDHcnF/HkL8dnnw7EhfjcquKDU8xfmWQXG1fnHI0oq+tS359JAuwwiPvYZkBAy7ieTPEzDtu27MOKbKVxIV7E8apJOLpZrSQC2YfiX40kuqlBeWYYZs2ZgztwFqKptMgmH/U24euUi4rYkIre0AouoL7atW4V506bgwsUbaA9FEAyH4GttQEl6CpYvmo9L129jedxmErYNmDltCfbvOQtfGxelzDfC9opE/NSrJzFp4lhs2rABK1esQGVlBdszhLLyAnz+2SeYT927cecBs8Pf1liH9JwCnE/ORVNrOy6dPYFNiftR1BF4smcutGORm5trtrW3bt2KmzdvIHHXDmzeshFbNyfiyKHzSElJJnPajQ8//JhkYhaZqJhkADV1hWZ19U+/eRuzZizEnZs3cffSZQz/8FMcOHIcI0aPweFDx7Fi5RrspaDLz0rF5B9GYOS4scitbsabb3yE9UtWIOXCGbz/l3exdf9JHDhzFaPGTOJgPMuV8FW89fa7mDpjLmbPX0QW28aGiqDT34aG8iJUFuVjNRvoww8+Mfm0N7Vi4aw5WLV4GVYtW4Xly9cy741YSTN71gJ8+N7HmDh+Mr4e8R0mTF2AazdTkZJ6H/PmzcOxY8fMFrTXLloJPwqxA2wgI+g5Ce9Zi85QGLeuXMPH73+A27fv4OjhA5g47ntMnDwN+4+d42QJIv1eEoZ/NwGHz14nudFDPyHzHEnElEnEYuiRC7WVnreIi4vDF198gVmzZpn21HnOnDlma/95G6U9bNgw/Of//J/xP/7H/zC7Z4OV12AblVvtJTN79uwe9+nTp+Pzzz83JEFt7EF2t3PhMCRgRVvUSPlLZkbHplkLUW5R2XZyxXz8xCFMmjwTebnFyE7Lx1t/fIP64gY++uhj6p9CQwDqGmqxalUcNqzfykVgktndXclF6sULVznurWLWbQ6J1EikkytyP9Kpm3LzCuGnsv3yi68o79fi+4kzcfjUeS5Gw+YWtcr3bPBqGVvfqDGy2ZPPrHT0tkhq8k0uuCdh89YdGD58MutTzHboRltHG1LvkwQs50Lyw9HIzCghSQjg7Pmz+PjTL5CdV2JIiK+9AYk7tyN+/wlkFpdi/vw5iF+3EpO/H4XTZy6jJUg9qPwjPjSV5iHp+mXkFpdjGcnFqlVbMHXSQi6y96KtqaNHbejWyPlzJzFu7Gizc7FwwUKUlZWyLX1obKrCunVxLMOXmL1kDZraAwgF2pCUko5rLGM79Vdq0nWMm7UQua1tjycXUgp3797FlStXkJycbFbxFRUVOHHyKPbsScDBA8dx8fxNHD9+GOs3LsM//uM/YfiwUWiob2YKIdTWF2Hs2HFkSUtRU9VAltqJ22fO4jMSgjPnL+OjL77G6bMXcfjICWzcvAlpd69h8pjhGDV+AslFCz74YDh2rN2MrGsX8fFf3sEO5pdTVoMZsxcgISGRHXIX/+eXf4fps+bjzLnLLC/JBTsx7GtDaV4WaitKUVVRialTZ2LFijVorKnFVK724pYswWp23iQSoakzFmH1mq1YtHAZCcx7+PSjT/DP//InxO85iqyCClQzzr59+7Bt2zazglS7aNdC50ehzwAbyCgdbdWTvYdIxnKzc1BXUYUVS5aa50vKSoqxbPEilm8mktMyyWDzUVlWZu5vnb12G6Ggbj11IcyR1qnBqxFnb9oNOeiZi8OHD+PixYvmOnaFPRhGxE/Kc//+/Th9+rR58FF5ygwU/mUxseXXbcHJkyebevZvzyeBIxcOPwV6ZZ7+xCii45MKrVuvMWinucuPQ4f3UldMQmZmISpLazBy2AhcuXABEydO4lhtNDsLepDx4KHDJNcLkZ6WTiKSg82bt2LXrn1obWtHTh5X0NRZhsaQXGSl30f8po04euwUapvamdZkrF2/GTMXrsSeQyfMw5S2XM8PvfW1RrC73CyV2bVgG3BhWFKQg7jVK7E1PhHTZ65AfkE95X4mikqLsO/gLi5wR+KPf/gQ58/fIDnKQXZ+rtntLyypNHPc31aHPbsSsGnXIZTU1GHT5g2IX78KaxYtRNLdTNzLKUAZ5V5TXSUObF2PA7t24F5WLrbtOoi16+Ixb84KnDtzB8X5Fci4n41wKER9FKBOvYn58+Zg04ZN2LljJ3Jyspl/Jm7fuYrVq5Zj775DGPbdRFRTx7c21eFW8j2ks798wSBSkm5g8rylyGdfPPaZC90r1xastrW1zWQhAWZop2FaJIpoa2tCVU0xV1cLDKsM6oHNrgDup9/E6NHfY+rk+chIz0OE7Kalkgxo8VKsjluPLTv3oqCkHJev3MCuxATcuX4W82aNwzSmk1vViiXLNmPrmk1IOXcCY0YMx97Dp9HYHuZAPIozp06ikQJyyZIVWBm3gQ1ZZwYLM0ZtZTlOHD6I2zeuw9fh56ArxPkLVxD0tePGhTNYvXghtm/eQtJ0C8dOXsDqdVuxYN4i/DDqO+xJSMCEiVNwNSkDDcyrrr4RZ8+eNQRDz6DECvJHof8g62+UjiEppNkdZHq7dybg8L79uHzhIidTLe6lpuLIwUNksffQ2NKKUyfPYFfCbpy9dBllJDxKRHHDTCNaoqgZWlA9RVL1zIXIhdrNU5KDBaXt3baS3TM/F6guIhcTJ07seebCa1NvfD4Ojlw4/BTwpJJV4tIbUciqLQYq3KamamzdtgHffTcGly8nIdAewiHKwn279uIC5aGRkwrOY3ZODuLjtyM/Lx85WTk4eeKkWWhWU8EeoIzJKyg0b9i1UMFt44L1o/fewXjK84payfHzWMpF5ZaEA8guLDfZm3QlH4zt2aAU+hvBLkbtQ6Z25yIMX1sz63oRW7cn4NyFW9Qzfmwj0cjIykB1bQUOHjyMObOWIYnKe/e+ROzeuxdXuKhs92vHOoLOQDOV+R2s2ZSAstom3E1Jxv7E7TjDRVxFRT3J02nq1au4e+sqPn/nzxj51Re4djsJGXlF2Lv3EHbE70VJcTUun7+N+XOWoIUyWq+i1tZU4Ah15+7EPcjMyML9e2nYt38P7qfdxdZNG7Cd5d194BjafQE01FUjPSsbde0BBIJ+nDlxBPuPnUY1F8uPJRcDQ00mwW0Vo32aVJ0fRm5uPsrLK9mYWiUGUVFVhBtU8LduJKO6qpbMiIFJUmpKy3HzZhIq65rgp1t5RTWK8gvQWF+K9IybSE5PQ70vTMLQgMz7WagpykXq7esoLq1AKNKN+tpatDZyxUYmW1VZg1tJKWhs7TCv4UjAtjQ14X5KClf7BQjo3hvLKWarV06DHU3IuJeMArJBHzuqud2H7LwCpN2/jzR2UIMU+/00ZBaUwU85HWT84uJi81Cr97yF8pB5UsQONhkNZpOOMbSzDYoLi3Av6S7ZYDNC7Kjy8gq2WY25HaKHfCrYRikp9znwahBgvb3EtHshM1ShdhK50G0lPVypentt6PB4eO0UO+Z0FtnX7R+RBF2rTfsTqkfBkQuHnwIahdboz45Pgyi5kEJr4yo8Lf0url69zgVcmXmro6mhkfLwnnmgUA9qUmKYdESqtfjSA51tLR1mx7e6uorzIYzSsnIj55WLjwouMyMd169eRlpmJjpCEebTjrSMTORRj/jNc4EWj54pj0dvHR80vZCMptHtEREMnpuaG5GRo92Wdugue2FRKZpbm2gPooGL2gK9XMCFZ0FRDnXSfTS32BcXurr1lmUHw9Ti9LlryMwtZrgWFOTmoLZCbdGJsooa1NRUobK8CLcuX0BqchIamlvMW5iF1DVFJFd6azMtNQsH9h5BwK/XUMPMO4AK6p68nHwEfEG0Ms+yMupCfwdKiwpxNznZvMghvRXwtVG2tyBIvVtVVYlzZ05RZ1chQNnzo8mFPnQlw9Lo37hJwWkrylzRsc/HP8wgMsE4qBiGA0Hx9ERriBa9QgqZ7gAiXa1064SfwfQ9h27RUL23zEFog/FaL9/KjUYKWrkqrQAPyltCVgpbYRVd/kYB642KTsZj2fV9DJEg3VJQOHtbwb5+KuWv72Fo/PMUrY9ViJ7Q9gT5Q2GDPQA5K31t3ZvvZihvkTG1i6kby2HysuFs+0Xb0MT1plkUKlO0bEMNXrtJEerWhHbCvDaUu8PjEdtOsX2s8acHVyVsvTdvvDH6JG3ryIXDoIPDVSO210THpS4kPiXvqCe6u/VmXsB8p0K74VZg86SPUdCihauIiZeG/dATz0YES57Y8a/pYURo1BiZLz1EDyPL6SnpqW8fSV8ojj458FhZ/lzADE39ZUzlTV3MleasKY9CafGl+lmZb2Q/AlQLuma5dRa5kK7kwrOuvgVNJADyV/2UNK0mLV106hVT1s/oSaM7FF+34217tbW0czHeSn+1kPpCn0iw/kpHRkU3bUmjB1O7tOANh2wZmbbyFrkR6ZMs0nMsP5pc2M5UQVhoZUqEdUuCUEfJzYaRkZ0eNPqYie19FcCSAhk1omWyIXr7EGRDaADYsaXwJBGdIirMWy3MvA1J0MdGeK1wpmmUPMOYMujMa+1a2IHGnMygtPeWVH4JYQ08OzBtp2qXgMFjytb7jY9Y4a3zI/H/b++9ouvIsuzA1Fpa+tW35kcfM7M0o25pqXskjaSl7la1r6nqLNdVmVVpKiuz0jtmkkx677333pOg9wRJgAYkQBAk4UmAhAcJ783zwJ6zz437XgAJJjNJgga4GzgR17u4cc6OG+Yx2ooPNshfnhIMERNh2qN9YFptmxFtqy+vhY1/EWHbpe2XNrNf1hg6PBoPGycbbucmYcf4+4ytIxcOgw5OQxFvJ+LpLHpU3zOSDrmgowEVHa1TWUQ/BCXRNFTmYpa6mkHUi9Tj4mE6IQcsTOe+xmuwqYmWMWY+H8BaGMty7IWj+iXN9zlfng5YjydSp7GN0iNprG2B3jphf6TNbL55EJSr19T5TCd59GtP5nMP+v0OsatR9oPxnkTkAp5jq1/dlIFRoiJlxcRm8iOXrJuv4tpxZDq+xaJ5JI62Wj9UJnG846BtZR0y3r20kd6HtMxLCVxN8WyZpos+2W0R00guo7CShHGzbmOoxZBzlcFCkvA1VcJMBNNgjqdKhCsRAQSEqCi50MFlud5AiYuTqcdbySBZiPGJX4noksQ8DOwcR4udNqxP8nBQdGBFvEFgGk3HgWE6CuNYhkggRDbNEm0bDGz/HglbkBUfmJ/tIAwZMwl0tUXfvfYOlLRJmaC237SX8FJ7YqBl9KvnRQHb1t8AWr/Dk8HOHc4jCqFzxwt/GBy5cBh0cAp6asmId87Tw6mqRkAMVS+/2RPS+LBYflF3ovtMRtUXkpiamUH6dgf1MpW+pqN9sReAYmSp9zVEwHRiN/SCk15JS51Kd1jSRfT2Mg00LzQZ+mwgLTd71enSL9lJ800EiZR+fVM8Em4+jy72TjxsornopG0NiJA4SJiIjg/Ti7AcHb+ojKmWJWEK0QskLkpOqIPFRyPLPKRbQi4MydACtT4tk8dA2sVAfqRSbbHaTdYp4y316DewwhKmYx55QnKhKwkcEQM2gCxK2ZAqNh4sunm16nWcnZZQfo8iTEbFDrEMiTSDIgMXI4OVSSbeQNCOuDGwvLejZXOShPkKjQwch0ryctWCNXLykK3qcpiyK+Zn4WalRNNRyMZkUnGgmJPtjnKw1SfBSixM+5X56tFP4DuNI6scSHzgq1VcBjTt8+A5TZiI7LW7JlC6ZZ75YMvMBCAh4oSh35MXDOyLNXqcgHoriJ1yeGLYb1vY8aX7+46vIxcOgw5PJ3k7EU9n0kPVyyUE1b9c9u8W/Uvj5MWL8C065jHaW0TmtYrMc7OCLXpU9Db3nPMaLulobLmSzk+BK3mRP37FWY2i6HVrK1SHqp5n6cw5uGANfmG9Ebmg1p9ukABd2VcLxHZLqxksOj4ito4fBkuA7U1ccJNQ0ZYQXG0Ii9005IyEQMIlOcPN9zz4+q3USTvJzJ5wNV/LFNELbtpHyUcCYWwh9Yo3VmJbGWmyil/bwWMjAeKPhrufjFyQPbEgW7mp2IAGWRkSl1m0chPOb8Pz9z6YMyxl8I0SiMFkq/jIATtPYhCWvQ6l5OMkCsoBkC57NTJQyua9JGV0hpXa76qzbebgyMTsMU/WMj1XPDj8FKbgYMjMlAku5ciBo9/GU9ifaKhbU1pwAlN5W2X+UDDLw8SDP4jExW8g7MnDL9jxgIXkYGu8/EdkbNk+MiSyWr1fR7+v7BcRbD/7RdjVLofHR//x8/vpftT4OnLhMOjgFBTxdiLm/FcPlRiVG/UzzNeGGc8gL7HoQJINXoT1IMRnI8QwGnvDeClLr6KZ0OgUPvNnfudC4gmWTaPpGcIodb3UQRvO2+W6KkAboLbLZnocsF/9pW959FEYw9pMCvZdfDZQEnClIRbppMLUuxQarhumE1vHLEwnkVESE/Gq8ELTIwwcGu75YChJgURoIlrtKG21Vxkf/NRnGuVfUksy2lPaTN6RsHclWBgfVwjI+LNySe6NF8dZn5PhsRFGFyEh0fRPcFuEjTPkgQUR3Bu3HmtVbmwAG2NXLpgvPkxiMO3KBRmmuCQ7H2ykP959liUDIym0JIqyL5l0ZlJyQMyVvKZnDbZeL968W2zaxhiucrCaeFqmkz3byHHWsjhqzCNxSpSkIdboW/jd34Jkf6gIeMIYFin9Yv/ZUYElGOrjRtrBeiLSPq1PGq55dKZIAtlJiPx5Bb+AsGPXfwwfZfwcEjDnU9/x8o+njfeP86PgyIXDoMObstxZiYNTlHNaDSIvG0XX8o+JJE5XJqjZqH+ZVP+sPmYA46m7WUTfOU/1TbH6nXnU75VHcpHQtCbMFPq4MG3tK33Lo8/U5o+lS3Q7TRUbpInooc0y4Ron6dSeShu120zHVRnmFbeaAonQMZP/aMQbI3pYnl6Y0k4wB8fY0xvMzLwsQGM5VkK2tFItwKSNHx+W4cvvpbL6R0vxjttjkgsiXqz6BsbAafqGei7zH994oXFYfyKsb8jD4x4eo9AjIGKORN84RV/fD4It7AmKsHl155Xl7XyO+M7B4XvDkQuHFwJWB/sV2oAYKM13pSf6pzcYOPTZIVG3ryXxQBsmYp0Jhw+JsP4xfSGxiaSPTutPHMdAYd+NJyAXDg4OLzMcuXBwcBgsOHLh4DBM4ciFg4PDYMGRCweHYQpHLhwcHAYLjlw4OAxTOHLh4OAwWHDkwsFhmMKRCwcHh8GCIxcODsMUjlw4ODgMFhy5cHAYpnDkwsHBYbDgyIWDwzCFIxcODg6DBUcuHByGKRy5cHBwGCw4cuHgMEzhyIWDg8NgwZELB4dhCkcuHBwcBguOXDg4DFM4cuHg4DBYeCX+cyTxH4/xwfP2ifEn8cX3Qb8Aek1QwvV4sPkHKuO7yn5YuIPD8IUjFw4ODoOFV/jDqvyBVCUX/MlW70/tsUbwJ1qNaJiK59A8JpkX0ifc82lek4bbxE+5xjEQsfH8fWNsftn3iaDDtlLcNs5KvxYSfaIJdXgh8cA+TgeHIQVHLhwcHAYLr/AX4Wl69Ufhe6PijomtFzcDNUJ/WV5FLa3aaTrEkHtkxCZVQyxh+hv6nllmuPkleIZwSx9DfRiQXJg0fWOY32txnwjWZ1spccxqRdOwrUzDAIGE2exWjIMbSeMFejsHhyEJRy4cHBwGC4mVCyUXPeIWwmDJhWdZLTlIWFtujMG25CJOJ5RcGCpBMM6a/d44CdAaE/je5MKXv0+EDe8XF0/DeJaXqPdbSeIbL7/n85wODkMOjlw4ODgMFl5JkALZitD82gt4RtBJqvBtckEjnFi5SJTDcEntrV4wjnmNz5bGUB/i5frQ369gKd+DXBDxeG4Y7+XxYKPjQeqQTTygX7yDwxCDIxcODg6DBd8DnUb8buu35CAerhsa6wHIhYYbcsE4hvclF57xJ+Ll+TBQWBy2NF8ZCoaTWPji4uVww/j+efrjOyt2cBhycOTCwcFhsPBK3CB7ttWYV25pjA0dMMTA25gEApPm4eQigl4hGP1Mfj8wtF9MnzoIL42GsZZETQkwbICaNBk3/eroAxtPseVav4PD0IUjFw4ODoMFIRdB2dE4G9NqzCu3iZUHa3LVIWJ2dCTWImjWTSn0iaHvDaFHyAUfv/TdrPBBQvTZDBIUU2bCEd+JQ0r10vVJ0Aes2bYgUZNJbf4YamI8l0ZyY2NMX4ywTaY3Dg5DFY5cODg4DBZeQbQdkWAngqEoukWiUWtw+eaIMbF81rOH4cYG645C2NQRcTCtGuZYANFAK0KhANpCMXRFYoj19JhyvDzq6hHq0cN6TLhGeKLPl2qYkIaeiJQZVb+G2zgPMYlj7b183sMrje4evW1j0rJt8fYpYWGyHsSiIekziZC/fXSTEjk4DF04cuHg4DBYeKWxsgDbN67B6nVbsTvpBNIuX0dne7tY2IgYY76YCnR1BHEtLRNdbR1q3WNihCk9XLkQiUpYWKwyTXwkGkH29Ss4vm8L1q9bg1XbknDwxDmUlpZJXEzTsUw147GQkIYIyFu0vJgYfs/Ch4StBMNCKCJBSRMWDhJR48+0UanT1k9EIhIXE3IhZIHPgcSkzBjzkLgwLdsnlZr1D6EOEk5yEQmGcON6Bo4fP4z6hnrphymf/Y6S+Ai8KhwchhwcuXBwcBgsvFJz9zo+e/9t/O2Pf4GxE+fj049HIefmLURCnUIEIggIIWisb8XRfUfQ3tAkV/pc4YggJJY4KhY+JAQgGIlJuh4lDiQXGWnnsWP9Yvzil6/idx9/jd2HTuJO4R10dgc0XXc4IhxAJNyBqJCHkBj+iBCAqJQVFoPfI3Vm5xWj8E4JeoJdiAXaJS6IsNQTjDA/2xAW8hES4hBDKMTVB4nrDkp5ESEbUmaoS/eBQEDc0j7hCkElD70IdHch1B1CWNLv2bkVH330Hm5m30JQmIUhST3yJ4RFyYo3Ug4OQwyOXDg4OAwWXgm2lWLZvGn48auvYfzkJfji83FIPnUay5bNx9ZdW3Hg6HEcSjqKbz4bhZK8QlxMScX6zVtxMvkccsS/YuVabN2xG0mHjqFdyEMoGhYD344HlXn45puRmLh4DZq6I7hbdAez58zHngNHcez0GZSXFWPL6sVYtWwxLly5jrzCe9i5fReOHTqMvJx8fPzZaIweMwlZly9g9oTREn4Ay1esQXJqOo4lp2LitBmYPX8e0q5cxcyZc3DixBnMmTUPp06cxNnkU5g/bxbWr1+DGdNnYOaM+ZgyYzHuVtSjqOQe1qxejZVLViPvRg5OHj2Ij4VczFswX/pwEnUtQmR05UJIDm/lcCnDwWEIwpELBweHwcIrwfZ7WD5nMv7xn17Hpm0nkJ6Wi9Liuxgx4kPMX7YAF69dw6kjyfgf//G/4WTSIYwd/Q3mL1mOidNnY2/SYXzx5SgsFaOfeikd3eEwQjE+zxBATUUuxowZiQmL1qEl2IPKshK88+57WL9tD9KuZaKi/C62rVmMkV9+himzFuLYqVTMmj4HZ06cxt3bJXj1l29iyfL1uJ2Vgdd/+rdYt3I53v/wM2zdfQSpGTfx1gcfYMbcOcjNL8Avfv5rrF+3Be+/9xEWzl2A3Tu34+23fovJkybg9d/8DhMnzMI//ORNpF7JE3JRhnVr1+Ljdz/BmiUrhbQk4asRn2HZipVCaMYg48ZtBKUP0d6w3vLR2zQODkMQjlw4ODgMFl4JdtzDstmT8PZ7X+BeRQtC3TG0NjZixoxx2Ht0H5q6OpEvBve//4f/ioM7duPzzz7Dpu27MG7KDOzacwijv5mI/QePobWzGxExxnzssifSgfsVtzBq1AhMXrYRraEYaqrL8cWIr3Aq9TI6AkFk37yGuZNHY8aUCRg9fgbyiypw9vR5bN2wBVcuZuC1Nz7A4WNnUV1UiPdf+xl2bNqAL78aix1Jp3DsfBo++mokzly4gIaWVrzx5h+wedMujPhkFJbMX4zD+/fhk4/ew6IF8/HO2+9i3Zod+Nkv38eplBs4f/ESpk6ZjAkjJ2PB9Hk4tG8PRks7d+zeiy9GTUVWbhHCfE6DPekBYhHZODgMQThy4eDgMFh4JTt5G/7xL/4c//Uvf4wjpzIQCQC383Lxm9/8FOOnj0dNczM2r92Of/e//e84uicJq1euxJt/eB9zF6/C0ZOpeO31dzBx8kzUNgoxETsc4kObgWac3rcW/+k//Sn+5rV3cb2gCFnX0vAP//hjLF6zCZ3BEE6fPIIP3/oV5kyfgi+/mYr06/nYsHYTVixahjv5xfhSjP/EKXPQWV+D+eNH4v2338KrP38doyYvwHtfjMX/9Wf/Ge9+/DGu38rG8hXr8Id3PsJbr72D37/xe8ybNQP/7b/8GV7/9a/wl//zR3j9N3/E//0f/hpLVu/Brn378dvXX8eM8bMwdcwUXEk9j7lzZuDLr0dh2eqdqK5v01dnu8NdCIf5pooZKAeHoQZHLhwcHAYLr/REahEKNqMjFEbAe5WjtyeKSKQLwWhIVyNi4RhCnSH0hCKI8oHOcERvf0RjPQhJWDgS1QclvRdCEYt2oyfciO6uZjRHIuiWtD2xkD6AGRB3uIdvbIQRCYohDwXQLfkZFuMrqyK8FRGSeiIiCHUjFuyQnQjLkrBOSd8ZDks+tkPaIO2LSJvCgYiUJ20OBoQYdEtYCOFgGEEJ7whI/6TuLsZL2mhQ2ixxPZEQoiKhCPsv5fSat0p05YJut3LhMEThyIWDg8Ng4RX08pVLvnzpXaTrIwbc8KVN82Epz2v2It6uD2yYCZfEvbxBImTB+ASmtL5pTGw8LBFpd+JIpCO4tT5f8r4gK4inMDub1gvxBRhH3BsXU5+Dw1CFIxcODg6DhVe8vYODwzCDIxcODg6DBUcuHByGKRy5cHBwGCw4cuHgMEzhyIWDg8NgwZELB4dhCkcuHBwcBguOXDg4DFM4cuHg4DBYcOTCwWGYwpELBweHwYIjFw4OwxSOXDg4OAwWHLlwcBimcOTCwcFhsODIhYPDMIUjFw4ODoMFRy4cHIYpHLlwcHAYLDhy4eAwTOHIhYODw2DBkQsHh2EKRy4cHBwGC45cODgMUzhy4eDgMFhw5MLBYZjCkQsHB4fBgiMXDg7DFI5cODg4DBYcuXBwGKZw5MLBwWGw4MiFg8MwhSMXDg4OgwVHLhwchikcuXBwcBgsOHLh4DBM4ciFg4PDYMGRCweHYQpHLhwcHAYLjly8AOjt7fVcfd0OfeHGZmA87rg4cuHwomGguTzczvun1V9/Od9Vpo172uP8SHIRi8U8l6mc0tPT89QbMhxhx5NjbMfU7v3ja/0PE3+aoQR/Hzkudi4Oxb4+Cb7vuPSPd+TC4XnCzke/+G3LQDrRxn0X/Hks6Cf85fjj+/ufJdg22z4iGo1qW2wf7L6/ENw/LJ3fzzIflt7qD78dsuJPS/jjrPQPt/he5IIZbMUE99bt8HjgmPoPmH9MrZ97ykBh1m+PD2WowfaP+/4nnEMCdpys286HR42TIxcOzxN2fnJv57B/7tow7v1um+9hYLqBDDRh97YOK88Ltm1W/G1iH/qHW3//vH6/dRP+MfXHUWycDefejps/H8WGE/58dm/dVojvJBf+xLZwim2Mw+PDP472YBGRSET3/gNn99ZNMI//IPvjhhJsv2x/KcRQ7OvjwB7//srUysPAOEcuHJ43/POU5zbnL2HD6PfrOX/6h8GmsXltmdz7y/Cn4/55wF+v7adfx9m2+fcUgnubx4pNR/j7zjCb1p/flkH46/WX6y/D+q0Q/jL8eCS5YEZbKAsYqBCHHw7/2PpZId2EPXj+8feLPRZ0Mw1h44YKbD/t3o6Fm4MJ2GPuF45T/zGycRZ0O3Lh8Lzhn7P+PcWvCwkbTvku2Hi7t+cD9wOVRbH1PmuwTr9us22xoJvxtm02nT2/bZw/r03rj7NlWreNs26CbpufYf40BN12b/PZvQ2zaYjvtXLhr9wW5PDk8B80jms4HFa3f5XIjrU9cP4wv5/S/+C+7OjfJ7sfav18EnAc/Ock95w//vliw62boNuRC4fnCc5bO3f9Yucu9/3T2bCHoX9+6/ZfwHHvd9t0zwO2/v5tsyvY/eMJe37bMfHbC9sXCsEwlmXj+6flngiFQvFwlusvn/Cntekoti7rtmnofiS5IOzBtZmtODw5/OPZ/yBZseks/GFMS3DPYzSUcOrUKRQUFGg/7QlF+MdiuINjYcfDKg7uMzMzcfXq1T4Kov+4OXLh8Dxh5y6F5zbnrX++EoFAoE86f9zD0D+9LdeW7Rera58XWLdtF9tidZxtlxXCnt+8CCX88RSb1/oJ5rFl+evxjwVBvwXjKbY+f17C1s80fhJk6yK4H4BcSAFaiNnbq+mioiIsWbIESUkHUFV9H+3tbZJGGq1/BAv1OucTbvxum0ah/r7xfrdxxHcJ2IBeDohMGgmgKx6sdYjvYflfJLBxbGqPXEnW1WPlsmXYu3sPgsEg2lpbkbQvCXPmzMWNm7fQ2dGJg/sPYNas2UjPyIzn65Hjo8XocRs6WL9+PdLT07Vf/klLDLW+Pgn8ioLjw/3Zs2exf/9+vSJ52Jg5cuEw6KCOkh1noJmFHhgu8zEmBol6vKmxHrt37cTOXXvQ2Nis8dfSMzBPdF92dnbCoHGO95vHfSBxvWoXjEEsKS7C5o0bkJd/G1Hxp6acw7RpUzFn7kJk5+bLuWFIR8w7RwYfdiSM0K4e2H8IpSWVMhamDZFIFPfv12DNmnVYtWq1pmnk+IhdSLucLoSL57T0MRZRg36/rgGV1TWoeVCDowcP4VbWDRmviNrEnt4edHS04MiB/Th5/Bja2jvQ0dmF5ORzOH/+AtrFpkj3Fb0xqV/KDQa6ceVKGo4cOYKmpiYvUshGJCT6+Co2bNyMBjlGJBa5ObekXbtRUFgkbb6PutoHEh4Db2j5yIXtsNTkGW3ue2JRpKam4u2338bV9GuorKnH2dSLKCzIl/gQYpImIIPCzvb2SGelgSE5wGFvEvTKQeNBjdAvaXpiJCtcBZHqZWB4UENSR0yMZC8bJWlDEhaLSv3SHMYHo5xYojRZloRHIhIfkfSxoEzKCly8nosOqZetllrkj4xLfDFONNOr75iOgwdWOkDF8SAbLw2MyIRZNHse9mzcihWLl+pV572Se/j6yy/xyedf4tqtXJSVluGbr0fiN7/7PTKzC9EjE4hjwn5H5eD39PKQDlDhS4oNGzYgIyND5gqPoAFPpsFERUUFUlJS5OS6IgS63Qt9cWEJQ//9uXPn5EIgqc9ypx8cU0cuHAYVnHPUS6KTqMF5jatnMqciHSqyET3eE+nE0UNJmDBlFgrvVqKtuQsf/P4PuHj2PBbMn49qMVxiIhCR9GGxAbQttBkRcdNG0B0Wu6CF90ptYlOi4Siaa6uxZfVyLF22Ho2t3Zg5dRJ+/uo/4Ze/fRfnLmYgKnYoKnaLOlTb9hTA7vmF0POPdi8SlL2MhLSxoa4a+3bvxfbt+7F2zT4xzO2aPhIJ40paJv7wzoeYPGmGkovW9iYcOHgMU6bMQ129GHyW0dOJ2poq7DpyElkF93D69Bns3bYN29dtwu3icnRzfGTkO1pqcD31LCaPGYtb+XeQfCENu3YdwNx5K5FbeE/GVIrSAZCNEIjyotvYtnE9Nm/egqPHTqBTyAjbfqcgF5MnT8Lmrbsxbc4yNDZ3oLL0rlwEbsamHQdRUlqKPbu24F5FLVrkEPQjF1I4DZRPyJhef/11zJUDHAzHEJZkAWEs3YFOVFUWY/3mTVi/dQeqK8pwNGk3Ro+bivXbD2PzzqPCsCIozMmVybFEKj+AvXuSMHvaZOzauR3jxo1ByZ0CHD18GBNnzMKBAwexb+tW6fBCbN17AIfFf7/kLmbPX4BN23egra0Fp04ex8yZ87B27S4cP3oBNWXFmDtzNP72l2/gYk65Ry7ImiLG0EZJbrRXT23i/CD4Z5cPDKJy16UonjEUGdtNK9Zg5IefYvXiZbhTJJMg+RQmjR+H8xcuo7EziOQzZzF76kycOHsRTZ3dWlAvyZjsSeh69Zixt0MDJBe8Aid7piGsr69Hc3Oz+hsbG3X/tGXatGn4l//yX+JP/uRPcPHiRa2HddbV1cXrfpGEbaLYdjKM7sNyXnHlwl7x9QeVnSMXDoMHKidaLV789CIkIRTRUEYZW+HVejQg7i65sj6E8VPmolCu4lsaOvDZux9g4YzZ2CZGrq2tTZPfvnsXcxcuws49e7Fj114cOXoCY8dNxMlTZ5V4RHkh2hOU+c3VPOBuwS18/t5bWLdpN1q6AuhqbkCznMsnU66jqtasvvMvJBeiYi6eCliMXxIQ3SwX10p+egIoyruJubNmY8fOI/ji8+koyKuT8zWKzq5ObJb2TpsyH3m5xXqBUFZxD2PGTMbsWctRU98i5UaEBzQg7fJZrN6RhLzSKsydMx+7N2zCrHGTcOb8FbRKWSQXrXIBvmbWdEwaPRq3CouxdNUGrFyxEdOmL8GO3SfR1hEgF5O2yZgFu5F5/iymid1Zv34DlixbiQe1dYhGAkg5exJvvfUmko6cwgdfjEd5VR3SL6fio4+/wI79yegKBJF2IVn4wB7UdgceQS7EX1dXg7/5m7+RSpbpPOBBiIgxDHR3YsvGlVi6fBlmzF2AdatX4NjBffh//8ePsGXPMfz2nc+QdT0Hq5YswaKFy3DwaDJOHD+B13/1cxw/fhQ//emPcSPjohAGafB7n4oROYesK6n4QIzrguUbcTE1BXOmjsPosePxzfhJyEi/guPHDuONN36PseNnY9TIaci5loaxIz/E7OXrUR+KKolIkAseSLNywXD27pmj3+yyXitcEuwhC49I20MR5GRcx6iPP8eb//wb5OXlyZicwacffYg33/kD9go7PXUqGV99+gV+/us3sfvwKTlEwtrFeHCVKCIlklD18oQeIiC5+PLLL/HVV19h/PjxGC0nx8iRIzVs1KhR6n/a8uqrr+Lf/tt/i3//7/+9nEhvyQk9RutivQOlfxGEbRsxYoTu2d5vvvkGr732GpYuXapLl374VzAcuXAYPMg860cuSHP7kAsqZi7Fx+Rqvqcbp08excSp85F/txLBQBhJ23fhd//8OmZMmynkogMRSVvf3ILV69aLQeZS/B3s27dfrrC34nLaVVH3ou+10LDuuZoRaGtGyomj+OLLccgvrpFrrwhqq+/j4IkLaAtwBV1E/p7cRjC3Obesfo9L/JyTNLSrPYYA3cq6iskTJmLr9gP4+KMJKMh/IDa2B63S5g3rt+LtNz/Apx9/hczrmRIewoULV/H7tz9FUUmF9C2Irs4abN+2HrvE2N+uqMbs2fOwec1aTBs7AWeFXHQIuYjJWPRE2pFz9SImjx2DnXLhvmj5Gixfvg5Tpi7AViE29U0kF9JGrv6HunFBjsO4UV9LGzZg7vxFqKislrZHca+oAJ9//hmWrd6AURNmobU9gHYhaxs2bsXMBWtQWV2NguzrmDh9LspbOga4LUKj7JELXgm3t7eqcv1GGnb/QS0amltR19SK5qYGLFs0GytWrcSUmXMwb/YMHNizA//jL/9WDOE5/PPv3kdKShpmTZmC9es2oaGlEzezsvCHN38n5OI4/vqv/wrX01Nw+tRJfPblBOnAfTnoxRg3bjIOHr+I1tZGjP7qA/z+nfew/9BJlJeXSL4j+OP7H2L6zMViYCbiZkYapk38CvNWrEezDKQ5vLwpIu4XnFxwWS/+AIwEdLW2Y8OK1ci8lIZPpI+nk8+gtrYGd+/cxvGTp5GSloEKmUAV98pw+vxlHD59noVo/gDJiRQS6xFSpetbQwMkF7w9xJOTwr5y73/G4GlLSUkJjh07hvPnz6OlpUWffWE4MZj1PolYsH0cIwpvixw4cOBbKxc63zw4cuEwqODc/I7bInodJBdIvdEAouEOHD28H6PHT8eN/BJUlN7H/OmzcTnlEj768BPcKykTA9uLoOjMQ0eOYc7c+cjJyUNx8T1s3bod+w8cRFd3N8orS9HR3qx6sL2zC1UVZaguvYe585ajrKoZ0VAYt67fQHZhiV6UceWXzyXQtnIB+fHBzrAAU4h19S1S0vBxAG/1orzkDlYtX4FNm/dg2tTlKL3XiNt37qBJDHal6Pq83CKcPJGMrKzrqKgqQUlpFRaoEa+ToQ0j0FWHA/t3Y3vSYVTWN2Hrth3YtnEjlgkhyLyei+LySlTfr0BlWSHKivJx4vAhHDt9Dtt278d6IS/TZyzCydNpqKiuFWJTpBeqvZEQcjMzMH/WDBnXbdi+Y7fUW47yslIlEimiF78eNR6btiehqaUNFSV3cenyVezcfxyVlVUytumYOnsBKoUM+sgFh4EDxKNuCEavDASfjeA9n3nzF2DLtp04m3oZ+bfvoru7E5npF7Fx8yYsEaOYdjEVp44ewutv/kEqOoFPRoxDRkYWju7fjyVLliPzVoEc6EosnDMLe/fsw9tvv4mL50/K4B3HuElzUXz3Hsru5WDS5OnYd/CcTJR2pJ49jAkTp+Fmzm1R9I04IQx01KgxMsCr8M3o6cjOuoY9O9dh4aoNqO2U9movLLnggZQQ+beH/ZnDNCgO67USkRNFn8iVdoaDIZw5fgI7hYUvWbgIhUIqLl26iO1btuDGrRw8aGzGueTz2LVlBzJu5KBGmCEL6ZG8IWGcfKYlpsSCJQ8NkFzYBzotaBwfttT/NOA32npsZG9JDeVFg20XheNiCRBvJ1ly4W+3IxcOzwycdyKccSQWXLXQ2cfpSPUsF3+qo+VKvrWxBju3bsGIkROQcjkbjXVt2Lp+C7Zs2Izt23cKUehGSIgIyyi4XYRNm7agVIxeXl4BkpOTxQhuR2NTI5KS9uJucaFU24MysTc7t2/DycOHkX7tFlo7wwh3B3H9agbauiO8E63t49+T2wiWYMWUxK0V8xCq1ERyoRJGd0cLLqamYueuJKSmZqGpKYgtou8zxUDv23dI7ORB3LtbjrKye9izd7uEHURa2i10dPKCJ4JopBVZ169izYYduF/fgpvZOdizaydOHz+J2pom7Ek6glOnj+Pgvm3Ys2UdrqVfQU1DM+7cLcN+idu584CQsXqcPXcZs2bNRaCtTQ5SGA21D3D04AHs2b0XefmFyMnNx66dO5GXcxNHjxzBwcPHUd/SLrygBDs2b8ZhIXv5RULqOjrFhh3FgSMn0Cz2zEcuCB0G2ZFcUEmJkY6Zd2QfPHiAqxmZyCu8Iwc6IEoqhu7OFuQXFiDv9h1hi62oKi9B2tVrKJABuXo9R668G9DS2IBcaVxZZQ0i4QjK7xUjPy8fN2/eFDJxG3fv3kVGVi4aGhvR2lyDm7eyUVRyH+FQAOGADBgfZKy8j4gwqgphoVnCOnNzi2Wfh6aGWhFhS4VFaAmSH7MHJBdc6hKfd5wZ/lxgGhSH9VI42fSBVxE1CHKSdcnBuZ5xTR/cDEcjaJSxy8vJwf0HNbo60dTQhIKcAplIjQhK+liEx8ictGEhGFG9cear8CVHWlqanFhlOkZEfKVH4DeYg4WBVipeNLBNbKeFJUKFhYVyxZMVJ0gWjlw4PDNw3olwxnGGxi99GEz9xfvsEt8bDaGztQn5uTlIvXgF98oeIBSM4UGl2Jwr6WhublUOYssIBMOoq6tHIBAUu9OB0pJStU/hcAhVVRXo7GhHTMhFIBTGnYJCFObkoa2jW/VkLBRFo9ilQEQuUriyred4j9HFbNtjg720YkrilqL8yRZubSvtqkiT2L2i4ntCLLql/b1q4xqbakXvVSAvtxDtbZ0SHsBdsZVcqWltDYielzEVctLb2yl2swbJZy/jTnEl2ru6hFgVoa62VmxtD8or7svYNQrRqMCN62n6Rg7vQoXCURmzcpSX30dQ3DlSz9Gjx4V48cFN3qIP4n5VJYqLitHdHdBbUtXiv19dhTuFt9EdCOlKT0d7F4oLbuPOnWK0dXWjVo7B5fMpqH5Qi4B0eGBy4Ym+caEkwyhWPcAielB4lcy3Q4SF8apZ7/VLGNOQpfLBT9VjEsfB4HMaquSYxlOAfHOEV9s86LrSQDIjbdDbP2JctXwaTUmrCpT1SDLaUPXyNkAsgICUz3t6BKeytFh7oBsp67mBdfvqt14KJ7M+5Swd4hhYA2ANBcdBXzOV/rMbYXFH9bFeSSP+gBgNJRcSzgeZeL+Rb+4MpWcueNVN40hwXKyxt2GDBTs/dY7qJJZj5vlfNNg22rbRTeGzFnbVwt92uyccuXAYXHCuqSbzXCZEIQ7qLtoRXs33ilJX3U5hIio5cXO6SjK1CWoHGGznM9MxUsToTVMD46gP1ccCJXNYdKXaIHH3RGhjRHjeSDzfuKP9Ma18XLCxiTb4QR/FtFFcqqeN6DMfbK9EMU2P2DRaUJ6/qvulbTG9wI/Inn6OEfvIsgISFkJzU7ucy21624i90L6YakSYTvL2BCRG6hSf5mdaliVlkry1tLSatMyrx4LHxYwlV8cJ9dP2i5dBuvLE8RQPx7NNymhpaJQL46g+9fKd5MJKXDF5IXrwORN460T+GKYxeoCkPhGm0VyyYUNMHgYwtTpkx4FgfpYiYZ6bQ8CB1d4LaF5VyXtlsDlGGC9KVCrgIdE4Scvh1Jxeem/z7BGvvy9sMPtqJR4mHTNu2fKfB1T8Op4mQvsWsrNRxJ5IzGsChx70+HuwBGywwPken/Pe/kVF//b9kHY7cuEwuOAc5HnrzUmfKGgvxIipLaGekwjaCo1PZNMdbYraFc+voEPFJu5bF33WQTcJCh1KMCRC9aUmt6nV85hgfisDl5PQYYw3QhtmdT1BEmF6KuHSPiPstTX2TEWwLJOW3dchFB9Tai1MpwF00KLykX9DLrTbXjks0wR6wo0mYGZTv0U8mG670WTsgThYluzo5su934tcWDDWik3LYo3fpKXbTgANl43f3b9Mwhxqk5BupQfaExOrDVcwTPxm54G3QGyJJm2fAfbKeC6I198XNvi7hT2gy0BdXiR3/v6x1/xzcPghcOTCYXDhaaq4Ljc74+SWep6iAb44QdxhnNTpcb1O2MSajqFWEtAoLw13Guv56VOdqW4bq57HhL8NP6QcpvWnZy8NuUjA1754Ujq8EaFThCk8WmLCGKDZ2FMuBHjkwpPEJh7ibQm64gX4UgjUIRubRI2xOOLHmTY42p9c/BCYAhNmzTbEK9/Cqy8RZtL40Zdc8I8N1Yh+YAJTX6I2D5qe5STIhcluU7940Cb3kwQSPeDejo/ZmX5af9+0Dg7fD45cOAw2VCup0TH6iVsj1Fly5e2RC0ZTb8dTGYeCzr46XUBHf0nsFP3d6o87vNLigc9Lh9q6LehWeuATm4Z7b+cXL5wpdNWfLgaZorzoAcgFtzr+cUoSPwamTvrMehFj6VNoZhYs0MQmh3EzkLtH/LbId4OlxFsu8Cp7LNiy/DIAdJKym2Zq2oHQ9BwgFR1ajTOlME/C9yKBbe8vCfjb6/VI+08/+8ODLlA/4/vmdnB4FBy5cBhMUCupFlO9ZXQXtZTR24zxbgFIoKfhxMltgnQQ3NmyNIib/tLX+RKBLdZR6gPbFyPW5aFPJDe0BdbucWQ5huJjVHzQDD2wQaZG8Q1ALkwW62PcQOTi0XgCcmFhm+tHf//3AfOYThpw368cnaAcoH7kQgeIE5IT9eUhF98Nf3vpZt/YF/rZH46VQP2MV4eDw/eGIxcOgwlqJdVi1Fv6zFzCZBlT5X2zk9EiiXDvE9leCdT2zGeljyceaJ3c+vWh9VuYMp82TN2JWr834pmkTb7MNjgeTajDaz/ddCq58D1PoVvPPui4i5OimwRJ0CC1J0xnxpo5aVUoxseUhgDSz3CGDoj+EeJ/quTClG97QzFdTaQxvm9Bg73m2ydG1G/dHrzBsNzMDALDxdcrE1UJRoJc6GBonvhwvkTwt5dujg37Qr/tncAbO8/h4PC94ciFw2CCWkmNFHV6P3IRU6MVEKHOlmgRhhsT1i3Cb9mYErxS4tLHowFmZ7Q8Xcwje42jO6E77bMHFqZFmvCJYEv5wSXFM3F8uDewwfFoBV3emFin9IuPT9IimnTcWvsgbi+5savfQS4k3uaiGCtK13eTC/o1jEX53JTHIBfxIjwk/Imt6QjdfcOs3yDuZie1+TZdv7TW4Q2Gn1xwb8gFv3r2YpELNjveBz9sxHcJ2+t360nohdmDHo9n/3QkHBy+Nxy5cBhMGD0sepx6S9/+Mzrd6G1ugyK86jZhqq91S9LRn1wYUb/qdHFa8XZGy9PFdLLXOLqlTC9PH3Khfvv3ZGB+r9a4fC/EE8vGl8kE928bXZ4to1Mr5KiERdgvwqQxKxnijqfjxpALjjB9Oib6Qa+E3SSVoCR8PA4kLwORC1/7vKqsm9mfArkYCDaNTZfw2xAi4bbxhN/tIR4lDhkEDqcZKi9KyQUnkOk+w+LxXh6GP2uwxgFrtRHfJdzE3X16K6CbIojHUxwcvj8cuXAYTFA1qVZSIyYiexuWMF7mittqMEMgeKFoTZkR+6d+1elelAc6TRk2wkYylPZB/PpvDK8f/tSPC1uGX74XHpLJeBO9NvAl5E4HjPFcWTA9txHxfNyoJMLNOHthtI168W3SW8uSsLA8DoaUxPPFYWoxZZk466Y8hdsizxg6SKZD2hGF9X07xLd5iWF7Y/vhdxP9/Q4Oj4YjFw6DDdVK/dRTwvsw17fN2PdBogw/+ocOnOqlRLwbcRPvYYD+aZAJ92XzNvGQuC9hYa2vbw3fBy8fuXBwcHgqcOTCwcFhsODIhYPDMIUjFw4ODoMFRy4cHIYpHLlwcHAYLDhy4eAwTOHIhYODw2DBkQsHh2EKRy4cHBwGC45cODgMUzhy4eDgMFhw5MLBYZjCkQsHB4fBgiMXDg7DFI5cODg4DBYcuXBwGKZw5MLBwWGw4MiFg8MwhSMXDg4OgwVHLhwchikcuXBwcBgsOHLh4DBM4ciFg4PDYOEpkgv/D50k8EN/7MTh++Db4+zg8EPhyIXDywWr977jR7S8H7Z8uZDo1+PB5NXc8WJsWP/w+G7Q8YqvTh8Ywl+msyIhetAMbB5N1dOD3h7706xGemIRDWdO+/Ot5mfS5U9/3tUgxjRSSI/+HC/rML+G1yN1sWyDRBv80PJFLFhWIk8/PDRisMGKbfvNGBjxYqSftq92fBN73WkfYzGOq+kvx6iHv7+vY00/08iG/16e5wG227SvF9FoVPcWNu5Z43nU+SKB/bdj4B8L63bkwmFwQR0gc426YADdpLE+vaHz0kuncfSKbZEYtRP68+A91C3ip1fDRBOKSdFskqhXdSVtjOSKsUyjX8PRcELXUliU1ivCwlngk8AW7HOyNrY9xjbrXupiuGysMFVPL+PFbvZGjC01mU2bmE7ax77Q3eP139hKguHmJ9ejGi9B2v2o1BcUp+yZlvlZjrjZCo5FLCZjq+XQxng/fc/iTKne1jSCrkjUHActwx4HzZ9IxzE1+qXnu8lFrxRgfutdCo5Ix70G2WMRjReuPtmFpBNh9XslaD8pdIcjAekw4+Vgh82eYGNYroWdBBwU1hkKhTSNnYBmUCSNCKFu7j3pgwEDnxVYsR0fjoAVG2ParXuvLxZROZAExyISjUifDZkwQrdMKB4fH/oV8czgPxaEdfMY2+Nqj99A6QYDti6drzrZTRv6E5/hgIHOF46FIxcOgwvONzn3OO8GOOUY1D84FAwhJucoz9iIRoqNEd1n9KHoErExNMBhsaQxMZi9Mdogntsyp8M0zqIroyG1VzFaW4GkEluSICmhsJSjUdzQxrGN9D8BmN8rwzpZr9Yp7eZe7RnDbTrZGwMt7QYvGE07ejy2REIRi7DPTCgtjVDnx6TfJi37HA5zPHgxLySCod4wsV9iOWUbQUhscq+MXzTEetgeKUxg9AEzMB/L698+6mwTr3pUIpjCy61bk09rjodZPfO9Vi54oPxgJVF2XCvz0ikRERFDSD9ZGiUqBz8skyMs8RzkSDQg+U0T2bCIRzJsO6wxoBEw9bA+TRJvNJlcLGIG18ZZ2HI0OO54TnhI/TaYomOhBM6MIwmdNYCWYDCdWeVhXFhOrIiySAPmN5Vw5zmfG2xbiP7zpj/8aZ82/HWzHivDDVZpWLd/DBy5cBhccK7J3OOcG+DUi4ltoL6PRMT4UefrnhdMtCuejRSYOSthovti4YDGMp7BNMQaK4YgIhehEEOthIF6URJFwsYgM09YSAfthUlvzoeYkBWSFy3wSWCa2Ac2yB+l5yIbIaIrJhJjeisuL5E5X006mgZdzFA7YRKYXEZMOsaJLZV9hIRLgmJiI3rlQj4S6zbls0jNQD2YKIuER3zGLcdCE4qX8Qyl2IsTQnWI7CO+i7SoHIOISFjInRlTLiTEHk0uYnJApRQNNYZfmipeKyQPahw5IFTocqDYmaiMiDIdppe8YekEl6aYlqWxcZpHGyPGkpNMItiwXsbJ1GLH6QpxI3EcFGWrLJB+TWVgV0IY5kWbjTqeEx5Svw3m4eNtIksuzEoEx9MQMV3OkoQ6zjqWMr5y8pDUab8lnHkNK2eJzxc6Ib25opNQ3B0dHQMaesKmGQwhuLdkVSe9uK2/f/qhKLaf7HNnZ2d8DBhGOHLhMLjgPKMOM/OtP+wcNfHci1YTIdmIiNKjjmMM00XFWJIEkHxwFdfaFmalftQ5zX+NF5JBPeoZAqbnrQnq1GCIdonpJU4ie7lqwIRe2scG8/bLb4OkJdpeDdN2sl45D6VN7KVeOEr90m0PzEGiJWl0EIzuZx7aW7ZfSYH4e+R8DgdJJLzz3SQ3FbOcXq4ek3TJP7upOsCMI/sdFnvKlRyWqYOgNsYQsqgESrQZL1sAdwxjFeyHpOOFbojtkoS8+OUdDVqy7yYX2rMetLS0oLi4WJVRd3e3DgavqsmoWIl2iaOjyznSeB5IDgiJgNTCi2wZKg03xpBuScrVCSEFvCKneSS5YDGxoLBTGZDO7k5U1jaZcBYiZTO+q70b94ru4UFtPUISoIMp4doM2RkTnQhj9IsGHlhLJlTkgHNAI8LMqytLEYp0o6urEyX3KlBSWon2QFCGV8YqGkTl/SZ0BGRCyJjI4ZSxi+rWTuBnDZ1knlhwEpNUHDlyBG1tbV6ogT/dYMHfnmdR34sI9pvHobq6GhcuXEAgEPBizPFx5MLhWYNnYlw4P0kUVPeJbRDD1CP6r+ZBFQrvFKGuqUW0muhz0XO8FWCuuCVAQJJMo2YuSI3fixFVGkLN/fu4W1SCjrZOjWtuacKd4tuoflCDQJB5aYN4pU+9SmNKfeEV8VjwjM1DwKt7Ey3pqPfF5vX2hNDa1oLSiko0NXXpor90UdoRkTZ1qK1tqGtDUHR/KNSO8ooy3H9QJ3G0odL2KG1xBO1dQbS3d6Grsw3VFRVoqG/SlQO2KCr96+howZ3CYjyoblCb3NzYgLzsG8jKykJ1bZ0Sg4iaImlAJIBosAv1dTWoqH4gdiekJEOPj9ifhppa3C0uQ1tHQMZVuEFTE25l5+L2vTI0NTdLGzoQkOMSlOIe+cxFKNiNvXv2YMGCBThz5gxu3coW9kdWJalkvPQhEmbh4JFBScdtmUxDS8+DHxBPVA4maVBY0mge2ZBgRMVgSk6EJFMwIB2orkI40CqT4Q52JCVD5oKkZV6OAFBaVIovP/gCW7ftRnNXl3SSbZHMXltIAOnVmck6ZPeiwRg/aSDZKQ+cTrgYKkuKMXfWNFQ9KEPalcuYOH4qZs1dhis3cuRECKGtqQ5zFq5Dwd1W0zeZpGGyU/Eow3wOnTV9MRX73XxWZvr06aitre0Trwzb8w8GWHZdXR0KCgpQVFSEmpqaPvUPJ7C/+fn52LRpk5I8jr2FIxcOzxI88/xi9ACVtGgv0W28cGoV/bZk0XyMnTAJazZuR1dYLpsksV6UiqLXq2nRmbyy5upGUKYzV7tZopIP0aPB7g4cStqPEZ99hcyMLCEbUWzfvhVTp03GsuVrUH1fDKqUSyMtZlX0Jst7EnLBjJ6xUfe3wfJNx6nzeTcgJMSnAadOHcO8hcvkIixNLuL5/IRES1wk2oqcnFxs3XRILjArUdNQhkVLFmLp0rVobm33yguKQW9CSkY2buXfQUbaBaxbvgx7d+wV0tCk9pQrF7fzczDy89HYuHabkJBunDl5Er9//df4q7/8X9i8cx/auoVQ6GGQdkU7UVddjm2bN2Hx8rW4mpWPzgBXjSJoqanGisWLMWfOQhw9flaIUReST5zAr/75t5g2bzlu3szG1UsXcb++GR1S9yNvi7QLsxo58mvs378fubm5KCgsVHLR3dUt7KcA6ZlZaBKl1RvpQVnBHVw8e16utEuRk5uPlLMXcf3ydaSmXkaZGJiA5CvML8Clq1fR3N6ORmFhKWdO42rGJaTfuIH7jW24mZWDpXPn4lLqKRw6chDrt52QtDGUlZYh5dxZZAtLelD2AJNHTsR2GZiGTpILaa9pru64KKbP8igbG6h/LwKkVTLR9OlmXQIStiqs/UrKOfz8n/5R2GwRDh46gFFfjcXyVVtx5lK6jHsXcm5k4NVfvYeM7Fqdz1wuC/QEhFCZ1aLnZTtpxPoLmffkyZNx584dNWytra1xob9ZmK4/7GkJy12zZg1++tOf4le/+hVWrVqlq2+Ms/vhJFflfON4tMs55yd2jlw4DDY40wYUmYNcjeAyOi+Q+HwAV6tL7xZi5FefY/3GLZg+ezHauvjcQC8a62px/nwKsm7lIl8uGm5kZeLk2RTcLilXkkBlaG75iVvKy75xE1MnTEN6WoY+yzFx4nisXLkcixavQJFceQeCckFGktJryIXejvfOix8OWh0aG7bDV0afDosoIaC+J7kISF/zsXzZYuzedxiTJq/EvXvNmiTa2y0GvQYHDhzAyBEzJLwS9c0VWLF6BSZNmYe6hmbpaw9ikU5k59zC6l0HkF10F1s3rMZ+IQVL5iySi9ECtMm4RYVcdLY0YePyDVg8dwVa2jpxR2z4GbGtc2fPRVpWNrpI2ti+qJCbYCtyr13CwnnzsG7zLqzfvh+1TWLfpd3XL6Xg43ffxeFDx/HFVxNw+/Y9bBS9MnHSDCRfvqHtOn74EE6eu4ymcOR7PHMhE+CwZPj0008xY8YMXLp8GZ1dAWRcvYbx30zEex99jAtXrqCmrAqLJ0/Hjk1bMHrMGCxevByfvP8Z5kyeg88//xonUlJwMzsbE8eOw9vvvofTZ8+h+FYe3v3dbzFl2gSMmTwVJ85fw9bNu/GH11/H0YM7ZMDH491PpqD8fhCnjp/ChLFjMGH8ZFy7lIlJX0/E5q270CgkhysjlkjQ2Z9cMOzbfXzOoAH2VitIV3vlwLbU1yi5+PHf/whVD0px7XoGPv3wS4wYORmXrucIU2xExpUU/OQX7+J6bqPMZZYRFmIRlj7zJHl0L63h7y9PCluONV4Ukotx48apYUtKSsLevXt1v2/fPuzZs0eFYfQ/Tdm9ezd+9rOf4V/8i3+Bf/Wv/hV+8pOfaLity7aFbn87BqMtz1NsvxYtWoT58+crueBxsUvI9fX1OHjwIDIzMzXcwu8eCrD94d6u3NA91Pr5KNj+c8+Hxi3sWNjx6L9/ErCEhwk1s94a1ocwueodRHtLHRbOn423334XC+UqPSRtCEZ6UV5yDzOmzxADuwHnU1KxSojCpOmzkXLlOsLSFxo/0ydDLnJu3sK0idNxTewU9euOHdvwxRef4euRY1FVXWuMOMmIGAkZFWP3tU2PA84p1k3xWRvuPOGKBCuhnocYfPR0I/fGVUyZNB7bd+zH+x9MxI0bNXJuykhIXH3TXezctROffTwJpSVVaGqtxtqN6/Dp52PkwrNOj02wvRFHjh3Bmn2HcLuiAotmT8OuNasxedR4saVXUM/VGRnb7s42bFq6Hsvmr0IgLEQiGkGr2JqUcymorm8Eb5ZG2L5IEDEhF2mnj2CC2PBVG7Zj6rzluFdRLccmgrzMq3j/7bexbu1mfCLtyMy8hZlTpuDdP34sJOQg6htbkCkXMrMXrkSlkJjvvi0ihq+rqwOVlZW4LKSCt0bmzJ2L8ooqbBZm+fEHn2HBkmXIvHULqSfOYMQ77+NuwW381Y9+hHnzF+Orz0dh6ZylGDFiNA6eOiVkYCveeettLFu5CucvXkJ1cSnee+N3mDNvOkZNmIQdSaewSwZ60uhRqCq/gyVLF+M3b32FsuouHDl4BEsXLcQnH3+Oo0nHMVGY05Ztu9EkREfJBfWl7Ol8qVYudNVCxrm1GYf27cbEUV/jP//Zn+Ly1RSkXDiPdas3Y8z4mdi0az+OHT+EaZPH4j/+57/FvqNiEKSTPUIuuHIRkQF4VD+tAvErD8P2n3yE+pdNJcbbIhMmTMDp06fVgF27dk33lPT09D7+pyks+6OPPsK//tf/Gv/m3/wbfPjhh1pXRkaGxjGNrZv7gdxDQWxfdu3ahRUrVujDtfbYUHjriM/E8N6rnQdPaz68SPDPS+u2Rna4wPbb9t0STDsGNtz6nxZY2sOEypk2Rlcu+GBlTwh37+Ri7+7tovtX4r0PR6ChpUsfOuzu7MDBA3K1vWAJ7hQV68rF5u27kHwxHQHRM11d7Wo0/SsXUyZOQ/qVa/rs2saN62WuH8JvXnsTN+WiljZDRkNa4F+50EY9Bmh1PGLj9Uzh7yyTsA4x4OaTDV24U3AD8+bOxPad+/HV13NQUFAv52hIiESt2LZlorfexy9/9h4y0m+gO9SEe6X3MGbcDNwurpK29iIg5GLPnl3YeuQk7t1/gDVLF2L3unVYMH0uLqRnozYgtiHSpeRiw5J1Qi5WoztobsFXlRQj81oWmjo60RrsQXsX2xQW3tOOrItnMV1Iw/qte7Bs/Q65uK9Hd3sbOpvrcWjvHkyScV2wZC1qaxuFIN3A7j0HsXrzXpRX3pdxz8KkGfNR3tLxaHLR0tyoxuHSpUt633bHjh1oam5F8plz+PKLkdi+aw/Kq6pReCMHf/z173BwXxL+51/8BVYLw5wizHHkZ6Pwxlt/wCa5mjx77hz++Id3sXXHTlRW30fBzRz87le/xJixo/DWu3/ECunI/qQj+EKMQWb6BYwcPRI/+eW7yMopw4yp0zF54nh8+MHH2LZxBz599xPMnDUPNc0tclJIa8km5J/H8GV55oJLgnxliCQjHAzg7u0C7NqyEf/zv/8X3MzJRPLZ0zL5FmPm7CU4djYVRcWFMr678Nd//yucvVigfebzKvaZix/STyoXa2SsUnkSseVZMIzkYtq0afFnHqzY+MECy+YDyJy3Z8+e1dsy/ftq3Ta9P3yowI5xTk6Orh7xFokF+2lXLkhCmJbiNzpDRfz9Idh3S6KGi7DPdm77+27d9vX3/mLnw9MAR7+PcMWW5ELfUKCEUXwnDxvWr8b8RUswbfZCdIiBJBGIRkK4eOECZs2Zj5s3byIvLxdrN2zC3kPHUFNbjyVLFuP+/ftqOANiTI8IEfntb97A9q070djYgMWLF2K9XPmPGTsJBYXFCXLh3RaRrj4BmNkzNur+NnTlQjstJERXLoJobriP3bt3YMnyNdiy5Rjuy0X0pk07cDP7GrJzrmDhwoV463efia1Nxa69m7Bv/14k7T+GhuY2LSoc7sD5lHNYtWU3ahpbcC75FNYuW4rN67Yg/04ZdssF+YVL52RM8/HlxyPw1RdjUFn5QJoQRlFeNgoLbqMzFMb5y5lYuGQlgjJuiHWj4t4drF21Sp+5OHNBLsZu5CFp9y4hEtfkAngfFixYioKiMi1rz/btOHT4BK7n3UVLa7uQuTSsXr8FdZ3dj74twgc6+bQ5FRSv+hobG8HXYerrGpF2OQNZt3LQ3tmJcEcXrpxJwYVz5/Gjv/5r7Es6KOwyR/yXcfzkGVzPzdWnSTOupiPj2nW0S/o6YVvHDh6QK/RzOH5G0twqRFVVLTIuX0Z5aZEM3HkcOJqKB3UduHY1QwhHOi5fuorsrFycPXEOly6no6WL7/FKi72Dx51dnLLH+tv9exHAk5eTWialijRWpKWhFqdOHEFbZzPq6utw6cIVpGfcQl1Lm5wEUbQ01eFU8mXUNJABy1zoCSMU45fYeKJKEY/oLJUF3+Kg4vAr2SeFVUaEVWJ8/ZEPdJJcsJ7+9dFv8z1tYdl+8Ydz74eNs7D+l11sX/Ly8rB58+b4bRGOAcFzmc9ccEWHYdbA2PihBjsuVoYjbN/teWjHgXsed4b7YeOfFliaFUK/9aC6T/RDNIRQdztu3sjE2ZQLKCwu9dYC5E9IQ2NjvVzdF+ozVU1NjbiVk4+7ZZXoEEOWmpqqt2Fp5MPBLuTdysaBfYeRdf2mzPs23Cm6jXMpZ3HjZh66AyGvDaIbeDtGDcWTgmXYXn0bek5ppbLXW0F8SyYoBroc6dduoKKiAV2dPUi/moV6IR2xni6Ul5eLvcxHzYMGXM9Kw+W0S6gQg85vSuinHnpCKCsvxZ6kwygtr0JTYx1uZmXhblEpurpDyLqZjfKKe6i+X4HjR0/i5InzuF8lF3pyQdsuaTvaOxCM9uBm3h2sXLUOgQ65+JCL1VB3B4oKC3H9Zi7qmjvwoLYJBbk5KL97B7lC7KqkjJDka2trR5bojmw5Ds0dASEXzTi4Pwk5BXfQLfPoe5ELDgxfY+O3JFQBSYz5UEYUIZEwjZVUFg0Kuzyfgj/90z/Fps1bxYhJXCiiD3IGJB/fFgkEutDZ1SWGUiY48weDCIYD6OI+wodyehEJ8yttYjSlPj6pymUxLnnxwRyWGQ1LuUGJl7L5/QfCfkvBtlxDuTHRzwcPqd8Gm3eVzTjb5y/I4sPhoEygsJC2Dv0wSVjvnVERMD4s4xXRe2Q8FnwmhmWQ8OnrTt8Ba0C418ku8CuXx4UtzyooWxbny9GjR+PL8cTTVlYPg1WSrI99plg/xcbbPdvdX7G+7LDHoqqqCmlpaZ7yNWA4Vy740Bgf6KSf6YciBjKY/nk6XMD+ciz8/bZ+Ox79x+XJzgmWI3PKV97AkHheYIkOpB7khxW7RL+HRacxp9FZ1H2i70Qv6jcYJI62gIaWtoS6JiJ2xhjtkNidILrE4IWkHPPNhgg6xWgyPctkk/QDhkIupGD+azMeG1qocVrYIH+Uji/HXPqiX9UUof3UzzZIG9gn3iIicYhJW8MB0a20rVyhFruoel7SsuVyNHWsKsqqcLf4HoLSZ9rBcIjlS1mSXl9XlfEIdIu95EOs7D9fvRVbyrbQjpRWVAsJqZZ6RUfKOPGVU35rhM+y0M7zDR2urHP1KNQd0LFjfzS/V2coSj1TjdKSu+gKSX3ifyS54EG3E85OOh4gkgolnRoi4FsPMmgPKkWRXbqM0tJyaZgEsZOSMCJ5WSLL9NfHMvW9XUlD4URhfRrniZ3f8TbIP7/Qqe8/sw7fCWDzUBKO54SH1G+DlWDpO9Y0fOyzEfaR72Dr90RkIvGdZXMSkdjJ2Av5YF5z0hmjSZgv3pmxexiCQuJoVPh6KO+5082VKRogrjA8jjx48CAu9NvyeYVB9s3yGc5lS6bhntI/79MW9ol720/bXraN4XxbgnFsC8Os+Mt4mYX9sv3mcbDHhXE8JnxFdcuWLXrriGFMZ4/VUBM793i87Z7Pkg3V/g4kdn7bseDe9t/OC75NFde/1LVPBNVyLMg4+8G8/mmkR/QWPwhFexMUQ8avTXbLRZW9aFSCoM8rmOcq9C44yxQRU+SRAwbSI2kkva1TP+zEfNIW2iyqSE2vCbzMXtrHBvP3K8MGGSJgwH7Sw8+Wq6GXutkuQyqM7eOFNNvENJqW9lPJgLFztkx+lFJdtCG0BeILh1muuUDna6gkT/pNJbGVTGBuRdFOGLvOPPxeCG2JOd5enV5bNIR78dsLNII2O3HBJmlEbJnMQ3kkudArY69wCr+saZiTVMBO0+iJXweDRISTwSuQwfzICZtAvhiRQYjx4AvsFzXZIEsObOP0il7S6xcqxUUDGu8seyJxCbfJZ0LjVScwYOCzAis2faBw1IwYH5e2zOqFGVuOSWIsJKUkTDTfEBG9jSIjGgx1yp7lGpBUPGrlgigsLMTUqVMxfvx4jBkzRvd8XfTP//zP1c0HMH+oTJo0CRMnTlQ3yxg7dqyWTWFdjKfYtNwz/bMStse2y4bZfrONv/jFz/Hmm29o+LNu22CKHWvKlClTNIz95X7yZON/7bXXtP8cDwqPl80zVIR9Z9/45hL3DOOx//u//3u8995730o/VMV/Hv7DP/wj3nnnHR0PzgM7NvzkAC8KqI9Ur3o69vFgNJ0UYpVYHzCIwnrieo8GVxQfNVtIdKCu1qqOlADqPu+KnraSxUb5yWm2lX6xCUosRMxXKI1e5BeM+VwFP/9t60xsxB5pPvqfAPGCE05SCvaENo/7hPaXOJuWfRPiw3aYN2ekL8qWJEg6bW4byb8OgElv9D6F/WNaycv+SRodRppYKTPWGxBnBEG+oSLJSd64Im7bwDEnkaMt1QtVqZukgTbdXLiasbdzgFt/Hxhijp1pu01rb7t/N7mId8Q0hI0gNFY6YpmnKcAQEZNP/iWcqc1HTzjIJpkJZX7TRBWm1bLN3ixXmTrNYJqJp3VpGtMWLUPDWKupY0A8NGKwwYrZfiPsuxETo7HSfv4wmel/X8iwmXR60Oz48ETh7DEH1ObjMHhD8UhwzOy4Wfcf//jHPsz0h8IeD+smWB7Lpn+gOq1/MJAYF1M/wb1ti8TIHnrL5vChg7h86YL4Oc8kXLcWzGvyv4ywffZ8ibFQxQ2cPn0KSUm7vb6b9L7OvyRgg9mvRMMH6oJ/3lG38A0afrtneID9luPPvotv7bqN+paQGmzqJB0Tc4Fizg+DxNx5HHjHheUNcEAYpFFenJ2rtCveRbveCqcdYrvjX/IUP1fDzYekJI10QduvRpke9snE2+kc0dvH5txmNjpMP6XvDHiSbhJemX4na5MWxIV2TV1SH8fa9JsrAvxhTo9g0IZ6/dI2eYVF+cVNHRvTf9tg4zbkRXvN9OLg8yv66W+Jk5zGhOoFK4kZQ5iQYHuo983Fv1YrG+5Ztinf9ETDRLiizvqNLfLiZW/sNVMwqAevGNfgwavqCfF0Shk6sIf58cFJwMmqJ6VM6A8++KAvudBJYiaRrat/SCLUuF5k+FtpV4D4cZ7O7m4cSNqDKxdTpGOeImMaEU2vyorjwtCXHewH+yM7ER7iM2dOIGn/NvFyJZGB8i/j8nKBR8vrm3SArU/MWg/SWfbXzHmjqJcuW6FfQdQID3RZMaDLznqDvvEvA9haM0ai/hEU78q1G5B5LVOi5Lhz3kt4vF/xTd9+P3/YFpq2Dgg9lg+NfUGR6NfjweTV3PFibFj/8Phu0DHo5MLhxYIlFYQlF1QgXLnQH5MjdCLKRlkpxUxHkzIRkgg1rhcZfVrp9YtXP21dXdi/bxcyLgu5iAY0jmqYwlSGXHgrci89eHxFvMHgFdvJU0exL2mLeHmlw/kgPX3JyQWPlHEZ4UavemXPpXP9QSj5W7J0ObKzcyRB4tjaPFZ0a88DE+CLe1nA1vKqks8e9CAs3hWr1uFG5nWJ4nMMAemdGTftl3aQGxLtxNg4OPwQOHIxzEBCkSAVxk/32rVrdVlLYZULlaqXjtDgfvIywt7HZW+7QyGkX72Eu7dz0SvkguHWTKlaJbngE+VDQsl+m1zcyr6OjGsp4uVPDcncEGIR4w3tlwo8Rg8nFyQU5hc1OZ/NfOcS+YmTp1FeXikpEv2N5/FEt0OAXPTK+OgyuYwBD+/ZMymoKCmVOD6HEJLx8pEL7S7z8Bwh7XBw+OFw5GIYgUrVTyoo9rkIvkmgWqSPyIZ7H/pEM+BlhNdwPnHOKzn+fk4w0Cbh/J2DmFIJmirq2MRtEW958aVGP3Ih0tXdhvaOOgkwS+NyUW/iXyrwSLHhZkXC615CeAOfRpLPKAnJUAIlxrOltU1fz/OOtILp6bN5E5u+aTT4pQHP+7DwBemrHHQe47bmdoQDQRmTkPQszHcKdAS1m8rTSC1ItB25cHg8OHIxzEBCYR+8sUKCoa98Wa3pl354RPRLAfMKmPRbOkA9qoaJn+TVh6B6lFzE1yri5OLl7W8C/cgFr075Tn1vl+yN4ZF/fZXt5QLba8kFjSH/4t3UfvJnuO0rilyI4PcC9Ps8yqYMcbDp6bPuxMakIeJxLw3YWtIHfqdIzn8lDxQSjaD0LKLUUmc5k+qQOHLh8GRw5GLIg0qxr9CAEvGnqcWikHSoFmGc7jWJ3zkgHhX/YoAtNH03BtQYn7BoU2NHSSBEvfLb+mJshja58Egkh0I7SIMcEFsS0at5+Vd5ueB1SPrChXxzdE2o7YohT2ZlinzCzH3msZJIT58/bzzUC+gb9zKAreWM5uqFOefjneTKhYjlGySXJk7SyY7hL1dfHV4UOHIx5GE1CUkFr9jNe8n2+QoqWSoU2lBDLCgapTsrD8Oj4p8/2LrEGJhxMEaUxEK7zZWcaFAcfD87sXJhlK1shwS5YN+9nnlDwkNtXkMLCrEwhodzga/2vXRg2+WI8U/JhflXMcRZiEW0S/aSQrwU85sS7L+IP723pxh4ob7ARNzLAGktH0ru5S0QPsgs/bd90XCuapj5zr6bzhmKpk4Hh8eAIxdDHlQXRvSqTYwJv/ZWUVGB/PwCtLa26z1oahEa2aba+8jPycH9B7X64JcqItU4FonyiOengFgr29C3dtseEgj1s8/8kh3fH6chEX9jQyMyr99EbVOH9lESSVFhtDTX40r6VZy5cBmVtQ36Nomu8lAEvLJ/GcEPsrEf4VAnCgtykHYpA/W1zTp8fL++pyegv79wKzsfJWU14Bf7XjrwEMpfVP702Jv/+FyISN8bH5Qg9dw5FN+tUmLJ78Xw08j8ZeHsm7dw6sxp5BXc0Q//6bRguQq6OA885wsOsyJj9noRIfvu1ibk37iG20XFaOfPMUg/lGSHA3hQek/6n42Gplaln0F+RMnLa88jB4cfCkcuhjyoaBJCclFaWoJt27ZhwoSJOHDgENrbutR+BrrasWH1SsybPRsbNm5BbWOzXs3Er2gU/vL8rmcNT+H30/b0qVBxxu+ny16JRRShrg7s3LYTK1eux+Rp81Hf0okIf6sl1IVzp4/j7/7ub/Hf/uJ/4dT5CwjpsxmSP8bfJnn57j2bMTArNRyHaFT6ePYk/vav/xGH9x9HNMRx4Vf62pC0fx/mL1yOsRNmoaK6/uXqq3fQeVMkYsmFHDYGcwbQG4t0I/d6Kt59+23MW7QaId4Wkb5zTjyoLMNr//xr/B//57/D4qUrEYjEwKEhuVToTjbce0EvIiyp6I9wKIDkIwfxk//1F/jZL3+JK7kF6NT+9+L+3WKsmDUbS+cuwt6kI2gNRhCQPFzP4aqmJHqh++zw4sKRiyEPKhwK1UUMkUgIR48ewYIFC7B3bxKmTpmJygq5kgvHcC8/Fx++8xYupqRg+ozZuJSeqQ966ZVcXMHYsowis6U/e7BBrNk0jNs+IorTfBSMaTxyEQujUq7SRnz+Fa5cuYH3P5J95i3N0dXejNMnjmDN2rVIv5mjv7bLKzj+sJBZ8eGXVJ9PT58UhmRwLEJobWnA67/6HU4fO0deoX2rqLqLiZMm4tiJs/jsi3E4cjxF+v0S9dU76CQXfO9BvxroNZ/kQj+L3xtEfXUBpk+ejAWLN6ErJHG8HdATxrUrlzBn9iykpF5E1f1a86CvSHwEWL5uGPLijstA5ILHnj861VFfg7z0NIwaOwZnr11HGx9ojcWQduoUvnn/I6QeP4tJk2ehsLwK/Hk7rmDwh8Ds71s4OPxQOHIxpGGVoapY3YfkKmb37l36ewu7du7B1199g9uF93TlIvd6Bl7/xas4d+YMxk+aguPJKQhIuDXRuvVWAHwhnutZwyp7o/m49Qthrtpj0jfvlogYkrxbN/DeH/6Ia9dy8fN/fsAhiJMAABQOSURBVBsnklNVATfWPcDyxfPxTz97FR9+8TWuZGXrygXJGD/Jqw/C2YJfEhhSwdUqHjeOVRjNTTV44zdv4sj+43I13wt+nbXwTg4+++JzHDxyGh9/Pha79hzT3xh4aeAd9IeRCxkG2QTlGN/BnBkzMG/RRnQEhXzylkgsgCMH9uHVf/oJfv/Ou0g6cASBcE+cXOghj28Y4hX8AsOSDHv8lUWGu1FXdg8nT59BWUMT2qU7gUgUh3fuxGdvvI3TB05i9DdTcOP2XV25EFphxo2EWvvv4PDD4MjFkIVVhpZY8Ao8Cv6c+8mTJ7B48WIhGfswd85CFBeVofReKcoK8/Hxu28ruZg5Zz6u3sjWe7MhEaOuqGheDnJBMQ8oCsEguVAJo6KkGKNGjMaVtFt478OvkXE9D9VVD1D7oBrlEpeZlYUlq9cj+eIVdIf5oJvpYTjyct4W4X3zKH9xUV+RCKKjtR6v/+o1nDx6GsHuMOrqaoVc5GLylKk4dCQZX38zDafOXBkaKxcaJjtd2g+goaYAM6dOxTyuXIR7UVNbhcaG+6govSvnwG3s2ZuEVXLsOwMRCL8weUVs+abQF39ceNz94KpVa2MN0pJP4ujx4yi+X4fyugbcr6nF1eSzGPPxZ0g+moxpMxag5EG9fk6NK5Z6W8SRC4fHhCMXQxbUCFSEhlhYcsEH+MrLy4RY7MbKlWtw8kQyKsofYN2qdWiqqsD29auxaf167N53EFUNLQhJzhAVrVWuSiy4EkDVa2qgPHvY/hnNx21/UQNpLr8kqajLnhCCXW1I2r0fGzfuwep1u1BW1YDDh47hQso5vYLdsWuXkKocPGhq1V8ZVHIifeUvAZsev1wguTA/ZS3EMtiGC+dP4uc/+TmWLVwhZKoS58+dRfq1yzh2/ATWrt+JBYs3oKyyTonZSwPvgPObDCFLLjxmoDvxRkJtyLl+Gh+9/0d8PXYhbt97gPOpZ5B+5TxOHz+CpUsWISc3H0XFpQhFe5VccPVCR8Er/3nO9u8DP6nwu0PBblxKPoGvPnoX77zzB6SmX8eJcxdxJvkcGioqsW7RMmxcvRmHj55BSzCivz2iKzdy/hhi5hXk4PAD4MjFkAU1AhUh1SsJAfd8QFEMZTSCsrIyXLuWiYb6RnS0dyMrMwuRzjbUVJUh4+pVVMjVfECyBKUIKlqjX+jwyIWnZLk1LgumfJg2MnH8+xbiQbbEh5VBMO7b6ayLe00hCpZKVq/a2W5+KEtIRl1tHS5elD5W16MrGMXtwmJUVpSiIC8baVeu4L6MSYBkQgrR1xX53IWU1/etmRcfahyk/yQXPO6RcCcyhUgcPXAEqecvoLGuESX37uL+g3I0NjXjSnoW8m+X6bMmdixfCngHfKCVC93JJhpqR9ndTBw5lITjyVdQWlWHkrIiVFXelfA7OHH8GCoqqxCMyPkh+Sg8/vJvoA6WJhIPfDwwuxaR2HgwMTbeyqORSElOYYmFHnuZA9FwCHcLc3D80D593qq0ugbFJeVy7EsR6w6g4l4JMtIzUceLCclqn7Fi3peKZDq8UHDkYkiDioGi128iRuP6r2qIuJcP/XFFQgJsaipYigEdhqTEy/JCTRITz2t8E+MFqZMb3lrg9SX34rdxJkr2DOXdXl2UTcRZqJ8blk+D7/WrTzpttXjNDQ2ThT6mY/+46mIS24syGh9Tn2eMxWdHTMfKS+/tXhpovz0xvfGOnfZXoP0x4dpvcSqhYvDLBmk3j7F+54L9Zbc8aPeVYJv3IOzs5VbnkI+MRMWtx55FaDHmT8F0ZrL44MUzSWL3nX6WoNVpBVqbF8nVRZ4d5kjF04nE08Rh89BtctiW6htOfrfOezmnOPclNMoVOXEp9CQwPm5tfSoSbmIcHH44HLkYFvi+KsKqle+CTUM1ZFWRf2sNP+O8II00cfwSAQ0A1boG2WK0KIYGRfhjShJg4y00DQPNp4zjJIZBViTMxLOWvsWbBF5onzzDBQ/r8FAahIf1xfY9YTCtT/3eJCH15azSQJ00nIleGiUD6jJ+BeM4n2y4TeuJ3Xl+7ryqxCNzUVcCGUq3zGkJYwiFM5Wi+RO5PHh1ar0mh63bbPUMU5+N75vfwWFw4ciFw1OBKjKj2eTfU7BxUKmZkL5xVJBUqtyLVxRlrxIDcxvChNHB/DYN/VS5hkBoaTZcr9goRpnyGtAqac0Wj2OIw3BHfNrQw6khDs4MnR3xCEaRPvjnH3d2rlnxIry9L+m3EA/XeW9IgJnHXLkwpFjTMMi6PcTdSiqYUuaznkMmxqaPp7NpEqU6ODwTOHLh8ISgwqLi8hRcX80moOLlcizjZRePo4NKj7cpqCC9IEkfJyDxtDad7FS4SSwD60b1u1X0TG9WT7yWmXTxOIY4OHjTyefgzDDmXuaKZ7Dp17U2L5joTy76zEUR7nSW+fyUuEOFdfhnJMuy5TCOMcbfXxQ633lemHJMO0zrTRrG29LjuRwcngkcuXB4QlBpUXmJ+MmF6jKr3BJK0mwIOhjOX6uUfTyPQcLLLZ/B4HsrgnhEQunGHephWxKrH/SxFRqlLnPf2cGBiM8Ej5ia+cJQzkkJEyf9Si5MEgXTGYIhCfTf/PGfwniK9Xs738YURhdnN2elgT1PWD/nfOIZDIZbMQ7GeORCYW9Jemk0J88xm9vB4dnBkQuHpwAqLipKTzFSp8UdVG5G+TFIr/40jhvGUbVSkXpBHqzXlEjVm1C/Jl3i2tFL6IFlRkSdeg/m+cSkduTCIYH4TNBVAmPszVZmj0cuOI90LsUnnDXX9EgC/ecf04tHs3H+qcOLN5LYmILo4oxkeUQ8ph+5YHh/MRWZdhtwn1itM6nosiU4ODw7OHLh8HD01WR98K0ocRj1qg5P3xmVy3+GU03qE/Kq65jIqsG4mjbhIvRbtWi2Rl0q9NVSVd0m3mQx+T3Cwms4zcFAL96kNuTCC+4jDsMYPnJhRLbepOI80lmjEYmwxCwivDkan4hmxiu8IJvSD4YxlSlLHyU1ZZPJ6KfnDVmwJdh4U7L44oyHbg3UeJNHoI324h0cniEcuXCIQw2/BXVVTy/qamuRfvUqioqK0N3djZs3buLmrWxEY0YRq5KjQ/KaRVkJt/qOwRSJY2q+5hcOhfCgogqtLc0wPxxl0lG185cYuzpaUV1VgYamJtzIyUNFdQ1i+jUjKUN2/EZHUUE2Us6eQsqFC7gpado6OlWHmqKEwvSEZasL2eKWENXGTMBaDLlQr7q8KLq5cRh2sK9rNjU14OLFC0g+exbXrt9AfV0dSoqLcCs3H63dAZ3H4DdDJI95PZvzSOabujnheUvCEIBgN78pko76xqZ4Wv7ZU8MKP7Oek30T55NP4mJKMnLycqWuoOSRTFI2azPERiaxzGsWxdOBP6oW44dXdPIaImN/B4TfqYiTC1aiuSgODs8Ojlw4xMHP/VKB8ge/SCx6ojEUF93BpInjMXrUKNzMuoEd23fqZ5LDEbNyoIqTFjzGV0yFPFDZ8ouQEkGdTd3Hr4I2tbWg/H4d2ls6cPXseZTeLUJYiALT8HelIlIv/dXlRUhJPoGC27cxafo87D+cjGBASIH8R0T4tcFTB3bi7dd/hklTp+CbiTNwNjVdSIsUImVQsUakLb3RIFqaG1FeXYtQuAcND2rQ0lgnafi6nyht2zYRfn2TZEk/uqUj4TB8IPOcKwQiFeWlGPn1CLz73vuYMm0Otm3ejM1rV2DilFm4XVot81omYCysX8Q2fJfzKCbzTeaOzF1+Yt6umLXW1+HzD/6I1MtX9EuvnOj8lV6dnxJvP1YViUSwfeMqvP7q32PxnOmYOGkyzqdnyXlk5ib3lN5IEM33y9DQ0ITuUBQP6pvR0tImiaRGXcXj+Srtk3ORX9QVl0TxHDRz2s1sh2cNRy4c4uCnokkuqPC4QsAvW3Z2tOH0ieP48P33MWfWbKRfzUBlZTVa2zpw8Uo60q9dR6CzHUX5N3HufCrOX8rEg6r7KM4vwK4dSbrK0dZxH/sO7sXMuauQmnwFe9ZvQt6tTNzMvYl9+w7i7Nk0pN/IRlegExmXT2PPzg0oLrmHCTPmYdrs5Th44DTamrqUw/B3Qu7mXsGIj9/C/oP7MXLCTOzYf0oISASFudk4eiYF9xtbEGipxc4tGzFj/gpkZGZj7ZIl2LNtE6qrynD+/HmkpV9DMBxFufQlaf8haWcO7pWUxldkHIYJyG5Jk8VAB7o7sGrFUkyaPAULl6zG+HFjsHb5Aoz8ZjJyiyrQUFeDowf34dTpFJnTATHuLbhw6SKSU1LRUFuDvOvXcDHtCupb2hFua8Wn776DJavW4uS5c2hvbUZlRTmOJ59FZt5ttATD+rQRCUr2lXP4+I1XcSX5GEaP/gY7D59CRziGG9m5OJ1yWcrrQFfDA6xdMAML5y9C2rVbmD1/Oc4mn0NddQVSUy/gVm6hEO8AbudnY/+Rk7h2Kw8VFRXSPRIgRy0cnj0cuXCIQ39BUUCSEeNVmijdjrYWFBXkI/n0abz/3h8xb94CFBffEyJxEZ9++TWmTp+FW1npSD6+DxMmTcf6rUdQfLsEZ48cw+yZizFqzGiUVmZi8aqFGDNhMdLO38D8CVOReva4kJMU/OY3b2L5ii0YMW4S2jpbcf5kEqZPHo1bebkYP30uZi9ch+lTl+BwkijcLlHHQi7u3EzFa//0I3zxxef4bPRUHD9/HVVllZgzeQI++HIMth04jo7GSsycNBYTZi3B5auZmDJqJHZtWosjh/ZjzNhx+ONHn6Cs6gHybhfjnT+8jyNHTyI9I9Mp4mEHHm1DMDo7WrB04Tz84ue/wqx5y4SEnsW+nRvx9WghF8XluJ6Zjg1rluL99z9HxvV8XL58GXPmzcPB4ydxRgj4/CkT8cWIr5F84TK6Gxrw8e/fxrI1GzB3yTJs3rgeu3ftxMKVq7BgzSbcKipDl5xikWgUBenn8fO/+jNMHf2F1PUNkq9eR07RPUybORfvfz4ap1KuoKPhPj5545dCflYJWbmMdz/8CpcupiH52EGMGvkNvhk3DUW3C3A59Qze+MMnOJ2agezsW/qrvvwiZ1QuGhwcniUcuXD4Fnp49c5VjGgE3R3tuHfntv5q6KEDB/HrX7+mRnj5ijX4/XsfIenQUZTdLcSF0wcxY9Z8pF2/g46WbhzcsQebNuzCT372E9wpScOaLauxcOl2lBZUY/7YKTh38hCysjPwm9fewM7dx/C6GPhmubq7ev4Upk/4BjdycjBu2lxs3nUUC+atwdwZi9EZCCIWCaL41kV8+OYvsGPnDkyYuQTL1+9D6pnz+ESU+bzl63Eu/QY6Wu9jwcwpWL15H/IKizF30kScE0W8bPFCjBw1GkuWr8aDuiYUl1Ti9Td+L1d+Bboa81BywUCnn4ce5JiGQnyeIorurjYsX7wA48ZNRJHMi86uDhzcsxUjvp6Em4UVuHXzBpJ2bcHPfv5b7Dt4Clu2bBVyMRf1zS3Yv3sXRn74PpYuX4nrt/IQbm3BJ+/8HnsOHsXydRvx2acfY+asmVi1aTNGTp6B05evoTPaq89WZF9Oxgev/X9IPrIXU2fMwtJNu/SHxb748itMn7cUaVn5CLc3YcS7v8OJ4ydw/nIWPh85GcVFxVizdL6U/QU2bd2H++X3kCmE/Ze/fRfVDZ1ob2+T+Rwxz2C4uevwjOHIhUMcvLgJhSLGiHrPUZTeLcaeHdtRcrdIruzasWHDJr2FcOLUOSUX5y6koanuAY7u24qPPv0cV24IEalswIdvvIvlS1bj1V++itzCy0Iu1mLG3HW4lpqLkW9/iL3bN+LY6UP40d/8HRYsWYe/+vHPcLvoLo7u2YkPhCSkyFXZotWbMEfiJk2ag0spaQgL4QkHu3D+0A78+sc/wuy5c/HlmOnYsT8Zd/KKMOKjj7Fm804UlFagq70Wq5YuwLwl65GTexfzJk/G4d3bcPjAXnz55QgcO5mMxpZOZOfdwY/+7h9x+WqG6bZsBtTDDBwwwuGlhkx6PnPBJyHKSovwlczhLz7/GpW1jQgL6di5cQ0++HgkLl4vxqJFSzBn6iS8SnJx4BROnz6DEV99jbPnL+By6nmM/fIz7NixG9U1zQi2NGLqmFFYunKdzMEVOHHyKDZv24wxU6Zg5sKlyL5zDwGZT4FIDElb1+Onf/n/YP3KRRg3cQq2JB1D5o1sjBk9Euu27MK96kZEhfiM+/wDbNm6A1dvFOLTrybiRtZNHN6zDV9JG06fu4yu1iaknDmGv/p7OZfKa/UWJ1cg+QyIWZN0cHh2cOTCoQ8iouxoRLlyEQsFUVNVKYb9PCpK7gnXCOsDZS2t7Whr78KVazeRf6cE0WAQ5bdzkXLpAu7VNKKjOShXYzeQfTMH125eQ3tnA+5VVeBadjFK8ipw5fAZ5GVdQ15RDg4cOoxzF9Ox89AJ3Je8JbkFSDl1BiUVNSirb8O1/LtIu5KJzvZO84Q8Vy6uXcSRnVtw8MgxXEzPRn1LNwLdERTk3sbFtHS0dXchGGhDeVkJMjJz0dLUheK8fJTdzkNL4wNcvpyGm1JPKBpFTX2Lrr7cK6vSh1QfyiEeGuHwUkOOKR/U7OnpRm1tBc4ePY0zp1NQ9qBW53tR9g0cP3VJ5nU7bhfeRsGN60J8M1FW2YiWllZk3biB/MIitDbWIzsjDTcyb6GjI4jeSACVdwtxLSsX17Pz0RXowP26+zifdgU382+jMxjWz8JxVeHa5fM4smczThw5iLSMLDR0hGQ+dyI36yquCclo6AxKG2V+30gXYp+PhvYgrufdRamQ6Kb7Vbhy5SrulFQgEuhCWVEhdh44gWqZ83ybhGSZD586cuHwbAH8/w5RzEQOM2vBAAAAAElFTkSuQmCC" /></p><p>&nbsp;</p><p><em>Note: Patients (n = 30) who had an unknown nodal status are not shown because the HR could not be estimated</em></p><p>In patients that were hormone receptor negative, regardless of time from trastuzumab therapy, the hazard ratio for iDFS at 2 years was 0.94, with 95% CI (0.61, 1.46). In this population, efficacy has not been demonstrated.</p><p>Approximately 75% of patients were re-consented for extended follow-up beyond 24 months. Observations with missing data were censored at the last date of assessment. While the treatment benefit of neratinib over placebo was maintained at five years, the effect size cannot be reliably estimated.</p><p>The median OS follow-up time for the ITT population was 8.06 years, 8.03 years in the neratinib arm and 8.10 years in the placebo arm, with a total of 1542 (54.3%) patients followed up for survival for 8 or more years, 746 (52.5%) in the neratinib arm and 796 (56.1%) in the placebo arm. The number of deaths was 264 (9.3%), with 127 (8.9%) in the patients treated with neratinib and 137 (9.6%) in the patients treated with placebo.</p><p>There was no statistically significant difference in overall survival between the neratinib and the placebo arm [HR 0.96 (95% CI: 0.75, 1.22)] in the ITT population at a median follow-up of 8.06 years.</p><p>In the hormone receptor positive population who were less than one year from completion of trastuzumab therapy, the median follow-up was 8.0 years in the neratinib arm and 8.1 years in the placebo arm, with a total of 1339 (47.1%) patients followed up for survival for 8 or more years, 671 (23.6%) in the neratinib arm and 668 (23.5%) in the placebo arm. In this subpopulation the number of deaths was 55 (8.2%) in the patients treated with neratinib and 68 (10.2%) in the patients treated with placebo [HR 0.83 (95% CI, 0.58, 1.18)].</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The mass balance after administration of a single oral dose of 200 mg of neratinib was studied in six healthy subjects.</p><p><strong>Absorption</strong><br />Following oral administration of 240 mg neratinib, absorption was slow and peak plasma concentrations of neratinib occurred around 7 hours after administration. A single dose of 240 mg neratinib taken with food increased C<sub>max&nbsp;</sub>and AUC by approximately 17% and 13%, respectively, compared with administration in the fasting state. A single oral dose of 240 mg neratinib taken with a meal high in fat increased both C<sub>max</sub>&nbsp;and AUC by approximately 100%. In a mass balance study, the total recovery (urinary and fecal excretion) of intact neratinib and metabolites demonstrates that the fraction absorbed for neratinib is at least 10% and likely more than 20%. Moreover, model-based predictions suggested an overall absorbed fraction from the gut (fa) of 26%.</p><p><em>In vitro</em>&nbsp;neratinib solubility is pH-dependent. Treatments that increase gastrointestinal pH may lower the absorption of neratinib, thus decreasing systemic exposure.</p><p><strong>Distribution</strong><br />Binding of neratinib to human plasma proteins, including covalent binding to human serum albumin (HSA), was greater than 98% and independent of the tested neratinib concentration. Neratinib bound predominantly to HSA and human alpha-1 acid glycoprotein (AAG). Binding of M6 main metabolite (M6) to human plasma proteins was greater than 99% and independent of the tested M6 concentrations.</p><p><em>In vitro</em>&nbsp;studies demonstrated that neratinib is a substrate for P-glycoprotein (P-gp) (see Section 4.2, Section 4.3, Section 4.4 and Section 4.5) and BCRP.&nbsp;In vitro&nbsp;studies demonstrated that neratinib and its main metabolite M6 are not substrates of hepatic uptake transporters OATP1B1*1a and OATP1B3 at relevant clinical concentration.</p><p><strong>Biotransformation</strong><br />Neratinib is metabolised primarily in liver microsomes by CYP3A4 and to a lesser extent by flavin-containing monooxygenase (FMO).</p><p>Preliminary metabolite profiling in human plasma indicates that after oral administration, neratinib undergoes oxidative metabolism through CYP3A4. Circulating metabolites include neratinib pyridine N-oxide (M3), N-desmethyl neratinib (M6), neratinib dimethylamine N-oxide (M7) and traces of hydroxyl neratinib N-oxide and neratinib bis-N-oxide (M11). Neratinib represents the most prominent component in plasma and amongst circulating metabolites (M2, M3, M6, M7 and M11) none is above 8% of neratinib plus metabolite total exposure after oral administration of neratinib. The neratinib metabolites M3, M6, M7 and M11 were shown to have similar potencies to neratinib in either&nbsp;<em>in vitro</em>&nbsp;enzyme (binding assays) or cell based assays against cells expressing ERBB1, ERBB2 (HER2) and ERBB4.</p><p>Based on steady state exposures, neratinib provides the majority of pharmacological activity (73%), with 20% provided by exposure to M6, 6% provided by M3, and negligible contribution (&lt;1%) from M7 and M11 AUC.</p><p><strong>Elimination</strong><br />Following single doses of neratinib, the mean apparent plasma half-life of neratinib was 17 hours in patients.</p><p><strong>Excretion of neratinib is primarily via the faeces</strong><br />Following the administration of a single radiolabelled dose of 240 mg neratinib oral solution, 95.5% and 0.96% of the administered dose was recovered in the faeces and urine, respectively.</p><p>The excretion was rapid and complete, with most of the dose recovered in faeces within 48 hours and 96.5% of total radioactivity recovered in excreta after 8 days.</p><p>Unchanged neratinib was the most abundant species in excreta accounting for 62.1% of total dose recovered in excreta. The most abundant metabolites in faeces were M6 (19.7% of administered dose), followed by M2, M3 and M7, all below 10% of administered dose.</p><p><strong>Medicinal product interactions</strong><br /><u>Effect of CYP3A4/P-gp inducer on neratinib</u><br />Following concomitant administration of 240 mg neratinib with repeated doses of 600 mg rifampicin, a strong CYP3A4/P-gp inducer, neratinib exposures were significantly decreased by 76% and 87% for C<sub>max</sub> and AUC, respectively, compared with neratinib administration alone (see Section 4.3 and Section 4.5).</p><p><u>Effect of CYP3A4/P-gp inhibitor on neratinib</u><br />Co-administration of a single oral dose of 240 mg of neratinib in the presence of ketoconazole (400 mg once daily for 5 days), a strong CYP3A4/P-gp inhibitor, increased neratinib systemic exposure by 3.2- and 4.8-fold for C<sub>max</sub> and AUC, respectively, compared with neratinib administered alone.</p><p>Model-based predictions suggested that co-administration of a single oral dose of 240 mg of neratinib in the presence of fluconazole (200 mg once daily for 8 days), a moderate CYP3A4 inhibitor, increased neratinib systemic exposure by 1.3- and 1.7- fold for C<sub>max</sub> and AUC, compared with neratinib administered alone.</p><p>Model-based predictions suggested that co-administration of a single oral dose of 240 mg of neratinib in the presence of verapamil (120 mg twice daily for 8 days), a moderate CYP3A4/strong P-gp inhibitor, increased neratinib systemic exposure by 3.0- and 4.0-fold for C<sub>max</sub> and AUC, compared with neratinib administered alone (see Section 4.2, Section 4.4 and Section 4.5).</p><p><u>Effect of gastric pH modifiers on neratinib</u><br />Co-administration of lansoprazole or ranitidine (1x300 mg) with a 240 mg single dose of neratinib in healthy volunteers resulted in a decreased neratinib exposure by around 70% or 50%, respectively. The magnitude of ranitidine interaction on neratinib AUC was reduced by around 25%, by staggering the administration of ranitidine (2x150 mg) 2 hours after neratinib administration (see Section 4.2, Section 4.4 and Section 4.5).</p><p><u>Effect of other treatment on neratinib</u><br />There were no apparent clinically relevant drug-drug interactions observed for neratinib when administered concomitantly with capecitabine, paclitaxel, trastuzumab, vinorelbine, or antidiarrhoeals (loperamide) (see Section 4.5).</p><p><u>Effect of neratinib on CYP substrates</u><br />Neratinib and metabolite M6 were not potent direct inhibitors of CYP1A2, 2A6, 2B6, 2C8, 2C9, 2D6, or 3A4 and no time-dependent inhibition is expected.</p><p>Neratinib did not induce CYP1A2, 2B6, 2C9, or 3A4.</p><p><u>Effect of neratinib on transporters</u><br />There was no clinically relevant inhibition of human BSEP efflux transporter activity&nbsp;<em>in vitro</em>, with a reported IC50 value of &gt; 10 &micro;M. Neratinib at 10 &micro;M appeared to inhibit the BCRP efflux transporter which could be clinically relevant at intestinal level (see Section 4.5).</p><p>In&nbsp;<em>in vitro</em>&nbsp;studies, neratinib was an inhibitor of P-glycoprotein (P-gp) efflux transporters, which was further confirmed in a clinical study. Multiple oral doses of neratinib 240 mg increased digoxin exposures (54 and 32% increase in C<sub>max&nbsp;</sub>and AUC, respectively) with no impact on its renal clearance level (see Section 4.4 and Section 4.5).</p><p>Neratinib produced no inhibitory activity towards the uptake transporters, OATP1B1*1a, OATP1B3, OAT1, OAT3 and OCT2, with reported IC50 values were &gt; 10&micro;M. Neratinib produced inhibitory activity in OCT1 uptake transporter, with an IC50 of 2.9 &micro;M.</p><p><strong>Special populations</strong><br /><u>Renal impairment</u><br />Pharmacokinetic studies in patients with renal impairment or undergoing dialysis have not been carried out. Population pharmacokinetic modelling revealed that creatinine clearance did not explain the variability between patients, hence, no dose modifications are recommended for patients with mild to moderate renal impairment (see Section 4.2 and Section 4.4).</p><p><u>Hepatic impairment</u><br />Neratinib is extensively metabolised in the liver. In subjects with severe pre-existing hepatic impairment (Child-Pugh Class C) without cancer, the clearance of neratinib was decreased by 36% and exposure to neratinib increased by about 3-fold as compared to healthy volunteers (see Section 4.2 and Section 4.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse reactions not observed in clinical studies, but seen in animals at exposure levels similar to clinical exposure levels and with possible relevance to clinical use were as follows:</p><p><strong>Carcinogenesis, mutagenesis</strong><br />Neratinib was neither clastogenic nor mutagenic in the standard battery of genotoxicity studies.</p><p>Neratinib metabolites M3, M6, M7 and M11 are negative in the standard battery of<em>&nbsp;in vitro&nbsp;</em>genotoxicity studies.</p><p>A 6-month carcinogenicity study in Tg.rasH2 transgenic mice and the rat 2-year data showed no signs of carcinogenic potential.</p><p><strong>Reproductive toxicity</strong><br />In rabbits, there were no effects on mating or the ability of animals to become pregnant, but embryo-foetal lethality and foetal morphologic anomalies (e.g. domed head, dilation of brain ventricles and misshapen anterior fontanelles and enlarged anterior and/or posterior fontanelles) were observed at doses that may be considered to be clinically relevant.</p><p><strong>Environmental Risk Assessment (ERA)</strong><br />Environmental risk assessment studies have shown that neratinib has an evident potential to be persistent, bioaccumulative, and toxic to the environment (see Section 6.6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mannitol</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Microcrystalline cellulose</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Colloidal anhydrous silica</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Povidone</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Crospovidone</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Magnesium stearate</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Opadry red</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p><p>Store in the original package in order to protect from moisture.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>HDPE round bottles with desiccant bags and child resistant caps. Do not swallow the desiccant bag.</p><p>Pack size: 180 Film-coated Tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product may pose a risk to the environment (see Section 5.3).</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jazeera Pharmaceutical Industries
Al-Kharj Road 
P.O. Box 106229
Riyadh 11666, Saudi Arabia
Tel: + (966-11) 8107023, + (966-11) 2142472
Fax: + (966-11) 2078170
e-mail: SAPV@hikma.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                14 May 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>